TWO ESSAYS ON HEALTH CARE COSTS AND ASSET RETURNS by Payne, Brian C.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Dissertations, Theses, and Student Research 
from the College of Business Business, College of 
5-2010 
TWO ESSAYS ON HEALTH CARE COSTS AND ASSET RETURNS 
Brian C. Payne 
University of Nebraska - Lincoln 
Follow this and additional works at: https://digitalcommons.unl.edu/businessdiss 
 Part of the Business Commons 
Payne, Brian C., "TWO ESSAYS ON HEALTH CARE COSTS AND ASSET RETURNS" (2010). Dissertations, 
Theses, and Student Research from the College of Business. 9. 
https://digitalcommons.unl.edu/businessdiss/9 
This Article is brought to you for free and open access by the Business, College of at DigitalCommons@University of 
Nebraska - Lincoln. It has been accepted for inclusion in Dissertations, Theses, and Student Research from the 
College of Business by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
 
 
TWO ESSAYS ON HEALTH CARE COSTS 
AND ASSET RETURNS 
 
by 
 
Brian C. Payne 
   
   
A DISSERTATION 
   
     
   
Presented to the Faculty of 
The Graduate College at the University of Nebraska 
In Partial Fulfillment of Requirements 
For the Degree of Doctor of Philosophy 
   
   
Major: Business 
   
   
Under the Supervision of Professor John M. Geppert 
   
   
Lincoln, Nebraska 
   
   
May, 2010 
 
 
TWO ESSAYS ON HEALTH CARE COSTS 
AND ASSET RETURNS 
 
Brian C. Payne, Ph.D. 
University of Nebraska, 2010 
  
Adviser: John M. Geppert 
  
The first essay investigates whether health care is a priced factor in asset returns.  
Specifically, in the search for empirical relationships between macroeconomic factors 
and asset returns, health care appears to be a significant US economic force receiving less 
attention than others such as (aggregate) inflation, production, or consumption measures.  
We use the medical care component of the Consumer Price Index to measure medical 
inflation shocks as a candidate macroeconomic factor whose riskiness the market 
rewards.  Incorporating multiple model specifications during the period 1967-2009, we 
find this inflationary component to be a relatively robust source of priced risk in US stock 
returns. 
The second essay demonstrates how a genetic algorithm (GA) technique with 
standard parameters and the appropriate fitness function can generate five-asset portfolios 
that effectively hedge macroeconomic risks, including health care cost inflation.  
Investigating 40 macroeconomic series-year combinations, the GA generates 36 (11) 
hedging portfolios that are weakly (unambiguously) preferred to unmitigated risk 
exposure in an out-of-sample analysis between 2005 and 2008.  This same technique can 
 
 
create parsimonious mimicking or tracking portfolios for investable assets such as mutual 
funds and exchange-traded funds (ETFs), particularly in the down market of 2008. 
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Essay #1: Health Care as a Priced Factor in Asset Returns 
 
Introduction 
Health care represents a significant²and growing²portion of the US economy.  
Nationally, in 2009 health care spending is expected to reach $2.5 trillion, which 
represents over 17 percent of the gross domestic product (GDP).  In other words, 
currently one of every six dollars spent in this country is health care related.  This 
percentage has doubled over the past 30 years, and the Congressional Budget Office 
predicts it will double again over the next 25 years.1  The impact of such health care costs 
can be catastrophic to individuals, as documented by Himmelstein et al (2009).  They 
find 62 percent of personal bankruptcies filed in 2007 were linked to medical expenses 
even though nearly 80 percent of those filing for bankruptcy had health insurance.  This 
rate of medical-cost-induced personal bankruptcies has increased by almost 50 percent 
since 2001. 
Extrapolating this result from individual agents to the firms that compose the US 
financial market would indicate that firms with greater exposure to health care expenses 
should face higher risk of financial distress.  One software CFO summarizes the risk of 
health care costs VXFFLQFWO\ZKHQKHVWDWHV³+HDOWK-care costs are increasing faster than 
SUHWW\PXFKDQ\RWKHUFRPSRQHQWRIRXUFRVWVWUXFWXUH«WKH\KDYHWKHSRWHQWLDOWRFURZG
RXWLQYHVWPHQWLQRWKHUDUHDVDQGXOWLPDWHO\PDNHXVOHVVFRPSHWLWLYH´2  According to 
portfolio theory, unless this risk is diversifiable across firms, investors should price this 
firm-specific risk and demand greater firm-specific returns for bearing it.  The purpose of 
                                                          
1 http://www.forbes.com/2009/07/02/health-care-costs-opinions-columnists-reform.html 
2 K͛^ƵůůŝǀĂŶ͕<ĂƚĞ͕͞ůůǇĞƐŽŶZĞĨŽƌŵWƵďůŝĐ^ƵƉƉŽƌƚĨŽƌ,ĞĂůƚŚ-Care Reform is High, but Some CEOs Take  
ŝĨĨĞƌĞŶƚsŝĞǁ͘͟CFO December 2009, pp. 38-43.  This magazine is published by a subsidiary of The 
Economist. 
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this research is to determine the impact of health care costs on asset prices in the US 
market and to assess the degree to which medical costs are a priced risk in the US 
economy. 
 
Why Medical Inflation? 
The cost of medical care clearly affects firms in a non-trivial way.  First, medical 
care appears to be a major component of labor compensation.  According to the Kaiser 
)DPLO\)RXQGDWLRQ¶V(PSOR\HU+HDOWK%HQHILWV6XUYH\HPSOR\HU-sponsored 
insurance covers 159 million nonelderly people, with the employer contribution 
averaging $9,860 per year.3  This amount represents almost 74 percent of the $13,375 
total average annual health care insurance premiums for family coverage, with workers 
themselves contributing the $3,515 balance.  Also, data indicate medical care is a benefit 
provided by most publicly-traded firms.  According to the same Kaiser report, 98 percent 
of firms with over 200 workers compensated employees by paying for some level of 
health insurance premiums in 2009.  Over the past decade, rates have remained relatively 
constant in terms of the fraction of premiums paid by firms versus individuals and the 
percentage of individuals covered by large firms.  Assuming competitive labor markets, 
these trends indicate a labor market demand for such coverage in these large firms, 
signifying firms have limited ability or desire to discontinue providing them.  In fact, one 
&)2LQDUHFHQWSRSXODUSUHVVDUWLFOHVWDWHGKLVILUPPXVW³FRQWLQXHWRRIIHUDFRPSHWLWLYH
>KHDOWKFDUHFRPSHQVDWLRQ@SROLF\«:HVHHKHDOWKFDUHDVDQLQFUHGLEO\LPSRUWDQW
                                                          
3 http://ehbs.kff.org/ 
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recruitment and UHWHQWLRQEHQHILW´4  Consequently firms face medical care costs they 
cannot control yet must absorb due to their need to attract and keep high-quality labor.  
This trend appears valid for publicly-traded (i.e., larger) firms despite recent popular 
press reports that unaffordable premium increases for small businesses will likely 
decrease the amount they cover.5  Thus it appears escalating medical care costs represent 
a reasonable candidate as a systematic risk to stockholders who hold publicly-traded 
firms. 
 
Literature Review 
For decades now research has sought to establish an empirical connection 
between macroeconomic events and stock price movements that theoretically ought to 
exist.  This study extends the prior efforts that have documented a contemporaneous 
relationship between certain macroeconomic factors and returns.  As we describe in more 
detail later, our focus on medical inflation augments previous findings regarding 
aggregate inflation.  Studies show aggregate inflation surprises6 and returns tend to be 
negatively-related over time (see, for example, Chen, Roll, and Ross (1986), Flannery 
and Protopapadakis (2002) and Hong, Torous, and Valkanov (2007)).  Further, Chen, 
RROODQG5RVVSURYLGH³ZHDN´HYLGHQFHWKDWLQIODWLRQLVDSULFHGULVNIDFWRUZKLOH
the others do not investigate this result. 
                                                          
4 K͛^ƵůůŝǀĂŶ͕<ĂƚĞ͕͞ůůǇĞƐŽŶZĞĨŽƌŵWƵďůŝĐ^ƵƉƉŽƌƚĨŽƌ,ĞĂůƚŚ-Care Reform is High, but Some CEOs Take  
ŝĨĨĞƌĞŶƚsŝĞǁ͘͟CFO December 2009, pp. 38-43.  This magazine is published by a subsidiary of The 
Economist. 
5 http://www.gadsdentimes.com/article/20091025/ZNYT01/910253008?Title=Small-Business-Faces-
Sharp-Rise-in-Costs-of-Health-Care 
6 Expected aggregate inflation can also have a negative relationship with returns depending on the time 
period and specification under study (see CRR (1986)). 
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Before summarizing the foundation of literature upon which this study will build, 
it is important to understand the difference between a factor explaining stock returns and 
the factor serving as a priced source of risk.  While a macroeconomic factor, such as 
aggregate inflation, might exhibit high covariance with particular stock returns (i.e., have 
DKLJK³EHWD´LQDWLPHVHries regression), this relationship does not say whether the 
market views this factor as a risky one worthy of return premia.  In order for the factor to 
EHFRQVLGHUHGULVN\LWLVQHFHVVDU\IRUDQ\VHFXULW\¶V³EHWD´WRFRUUHODWHZLWKWKH
VHFXULW\¶VH[FHVV returns in the cross-section.  The Fama-MacBeth (1973) two-pass 
procedure represents the classical way to determine whether a factor is priced by the 
PDUNHW:HZLOOGHVFULEHWKLVSURFHGXUHLQPRUHGHWDLOXQGHUWKH³0HWKRGROJ\´VHFWLRQ 
The seminal study on the relationship between macroeconomic data and stock 
returns, Chen, Roll, and Ross (1986), investigates monthly stock returns between 1958 
and 1984 with a goal of bridging the gap that existed between the theoretical idea that 
macroeconomic events drive stock prices at some level and the fact that nobody had 
found empirical evidence of such a connection.  Specifically, the authors study whether 
industrial production, inflation (both expected and unexpected), a term risk premium 
(difference between return on long government bond and short Treasury bill), and a 
default risk premium (difference between return on portfolio of Bbb rated bonds and 
short Treasury bill) explain expected stock returns over time.  They admit these 
macroeconomic series are by no means exhaustive in their inclusion.  In briefly 
addressing other theoretical predictions and as a robustness test, the authors augment 
their model with the market risk premium, a measure of consumption, and an oil price 
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index (PPI for crude), ultimately concluding that the former has a negligible effect, and 
neither of the latter factors are priced. 
Methodologically, CRR (1986) form twenty size-based portfolios whose returns 
are used as the dependent variables in their models, since using portfolios helps to 
mitigate errors-in-variables problems.  They then implement a Fama-MacBeth (1973) 
two-pass methodology to assess whether the aforementioned macroeconomic factors are 
priced.  While the inclusion of the market return²either value- or equal-weighted²
performs well in the first-pass time series regressions, as we expect from the Sharpe 
(1964) and Lintner (1965) Capital Asset Pricing Model (CAPM), this factor is not priced 
in the presence of certain macroeconomic factors once the second-pass cross-sectional 
regressions are completed.  The authors indicate that relatively smooth macroeconomic 
measures will inherently fail to explain a substantial amount of the variance in noisy 
stock returns.  As a result, none of their models depict the coefficient of determination 
PHDVXUHLH³5-VTXDUHG´IRUDVVHVVPHQW:HDQWLFLSDWHVLPLODUO\XQLPSUHVVLYH5-
squared values for our first-pass regressions that include only macroeconomic factors. 
The consensus of this research is that industrial production, changes in the market 
risk premium, yield curve twists, and measures of unanticipated inflation and expected 
inflation changes are all significant in explaining expected stock returns.  The effect of 
these variables on stock returns is robust to the inclusion of the market return factor (per 
CAPM) as well as to the inclusion of consumption and oil robustness variables.  In sum, 
this study represents a hallmark effort in tying together the theory and empirical 
representation of macroeconomic events influencing stock returns. 
6 
 
 
 
 
In contrast to the study of macroeconomic factors, Fama and French (1993) study 
and find evidence of a parsimonious factor model that explains the variation in both stock 
and bond returns.  Specifically, they contend that the following five factors explain the 
returns: excess market return (value-weighted market return minus one-month Treasury 
bill), SMB (Small-minus-Big, calculated by subtracting the return of the decile of the 
largest stocks²by market capitalization²from the decile of smallest stocks), HML 
(High-minus-Low, calculated by subtracting the return of the stock decile having the 
lowest book-to-market equity ratio from the decile with the highest book-to-market 
equity ratio), DEF (default risk premium, calculated by subtracting the long government 
bond from a Baa-and-below portfolio of similar duration corporate bonds), and TERM 
(term risk premium, calculated by subtracting the one-month Treasury from the long 
government bond). 
These authors investigate monthly returns from 1963 to 1991 for 32 different 
portfolios of returns, which include 25 stock portfolios and 7 bond portfolios.  They form 
the stock portfolios by intersecting the quintiles of size and book-to-market equity ratio.  
Their bond portfolios include two government portfolios, short- and long-term, and five 
corporate portfolios ranging in grade from Aaa to low-grade (or junk) bonds. 
While their model is admittedly atheoretical and strictly empirically-founded, the 
Fama and French (1993) results are econometrically impressive.  Their model parameters 
are highly statistically significant, and the coefficient of determination values are 
extremely large across the 32 portfolios.  They do not price these particular factors in the 
traditional Fama-MacBeth (1973) two-pass manner, since they indicate adding bonds to 
the cross-VHFWLRQDOUHJUHVVLRQVZRXOGEHGLIILFXOWEHFDXVH³VL]HDQGERRN-to-market 
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HTXLW\KDYHQRREYLRXVPHDQLQJIRUJRYHUQPHQWDQGFRUSRUDWHERQGV´,QVWHDGRI
pricing their factors, the authors test for their cross-sectional effectiveness in the market 
by jointly-testing whether the intercept terms for all 32 portfolios are zero using the 
Gibbons, Ross, and Shanken (1989) methodology.  While this test does not unequivocally 
support their model²mainly due to the small/low book-to-market portfolio having a non-
zero intercept²their results indicate the factors explain stock and bond returns rather 
well.  Finally, they perform a variety of robustness tests, including examining the January 
effect and bisecting the sample, and find the results tend to hold. 
Since theory indicates macroeconomic factors should influence stock returns by 
serving as nondiversifiable risk factors (Ross (1976)), Flannery and Protopapadakis 
(2002) investigate the impact of 17 macroeconomic series on daily stock return mean and 
conditional volatility for the period between 1980 and 1996.  Ultimately the authors 
confirm that inflation (CPI), the Producer Price Index (PPI), and a monetary aggregate 
(M1 and M2) influence stock returns, as previous research has indicated.  Additonally, 
they make the novel discoveries that balance of trade (BOT), employment, and housing 
VWDUWVH[SODLQVWRFNUHWXUQV¶FRQGLWLRQDOYRODWLOLW\7KH\GHWHUPLQHQHZVIRUWKHVHVL[
variables is also associated with higher trading volume, an expected empirical result.  
Meanwhile, they fail to find influences from Industrial Production or GNP, as previous 
research has documented. 
Their data set of macroeconomic series is arguably the most comprehensive to 
date, and the authors utilize a cRQYLQFLQJPHDQVWRPHDVXUHWKH³VXUSULVH´FRPSRQHQWRI
the measures.  Their method is important, because it is the surprise, or unexpected 
component, of macroeconomic data that should theoretically induce stock price changes, 
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or returns.7  The authors measure surprise by using data from MMS International (now a 
VXEVLGLDU\RI6WDQGDUG	3RRU¶VRQDQDO\VWV¶H[SHFWDWLRQVRIPDFURHFRQRPLFGDWDYDOXHV
for a given date.  By comparing these expectations to the actual announced value, the 
authors quantify the surprise component.  In using daily returns and volatility, the authors 
argue they can quantify most precisely the effect the news has on the market. 
To mitigate criticism, Flannery and Protopapadakis (2002) employ various 
techniques.  To avoid allegations of model misspecification, they include a host of 
conditioning variables, including: lagged market return, lagged risk-free rate, lagged junk 
bond premium (AAA-BAA returns), lagged term risk premium, lagged dividend-to-price 
ratio, lagged firm size value, and a host of timing controls to account for post-holiday 
returns and the January effect.  Addtionally, they forestall the econometric problem of 
heteroskedasiticity by employing a generalized autoregressive conditional 
heteroskedasticity (GARCH) model to investigate returns. 
We aim to augment and extend Flannery and Protopapadakis (2002) since (1) 
their study looks at aggregate inflation (versus medical inflation) as one of the 
macroeconomic series and (2) their study identifies priced factor candidates, but they 
never determine whether these candidates are priced.  While we also confirm the negative 
relationship between contemporaneous inflation (and its surprise), we also investigate 
LQIODWLRQ¶VVXE-component related to medical costs.  Finally, whereas these authors 
determine which macroeconomic factors explain stock returns (and volatility) over time 
(i.e., they complete the Fama-MacBeth first-pass), our study investigates whether any 
                                                          
7 Theory tells us factors proxy for the stochastic discount factor (SDF), which is a ratio of the present and 
expected future marginal utilities of consumption.  Under the permanent income hypothesis, consumption 
is a random walk, which induces prices that necessarily deviate from expected levels and generate returns. 
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candidate factors we discover are indeed priced in equilibrium.  That is, we complete 
both the first- and second-pass for the relevant factor candidates. 
While prior studies have investigated contemporaneous macroeconomic 
YDULDEOHV¶DVVRFLDWLRQZLWKVWRFNUHWXUQV+RQJHWDOLQYHVWLJDWHWKHLQIRUPDWLon 
diffusion theory by determining that certain industry returns lead the broad market 
returns.  These authors determine that portfolios for retail, services, commercial real 
estate, metal, and petroleum forecast the stock market, in some cases by up to two 
months.  Their finding is generally robust to the eight-largest non-US stock markets.  
Additionally, they relate their results to economic theory by discovering that industries 
that forecast the market also generally forecast two macroeconomic series (Industrial 
Production Growth and the Stock and Watson (1989) coincident index of economic 
activity) that explain returns. 
Using monthly returns from 1946-2002, Hong et al (2007) investigate the ability 
of the Fama-French 38 industry sectors to explain broad market returns.  Their intent is to 
test the information diffusion hypothesis (see Merton (1987) and Stein (1999)), which 
assumes that news travels slowly across markets and due to limited information-
processing capacity, implying investors might not pay attention to or extract information 
from asset prices of industries they do not pay close attention to.  Excluding five 
industries for missing data and generating a commercial real estate industry portfolio, the 
authors ultimately determine 14 of the 34 industries lead the market by one month.  These 
industries are: commercial real estate, mines, apparel, print, petroleum, leather, metal, 
transportation, utilities, retail, money or financial, services, non-metallic minerals, and 
television.  They interpret this finding as evidence that information diffuses less-than-
10 
 
 
 
 
instantly across industry sectors to have an effect on the aggregate market and that 
information takes on the order of two months to be incorporated from industries into the 
broad market index.  With respect to international data, the authors study returns for 
Japan, Canada, Australia, UK, Netherlands, Switzerland, France, and Germany for the 
period 1973-2002 and find the results hold up remarkably well. 
These authors also control for similar factors as the other studies, specifically, 
lagged values for: excess market return, inflation, default spread (BAA-AAA), market 
GLYLGHQG\LHOGDQGPDUNHWYRODWLOLW\1RWDEO\WKHVHDXWKRUVKLJKOLJKWWKDW³IURPWKH
literature on stock market predictabilLW\WKDWEHLQJDEOHWRSUHGLFWQH[WPRQWK¶VUHWXUQLV
already quite an achievement, as it is notoriously difficult to predict the market at long 
KRUL]RQV´ 
The gaps in this research we intend to fill are that health care is not an explicit US 
sector these authors studied, so its leading ability in the US is not clear.  Notably, the 
other international stock markets studied have a health care sector, and its leading effect 
is unfortunately indeterminate based on the presented results.  Additionally, our health 
care measure is a macroeconomic series versus a composition of returns series, so we are 
bridging a gap between leading indicators and macroeconomic factors that is not 
addressed in previous literature.   
Another study, Lamont (2001), presents a purely atheoretical model to estimate, 
or track, non-investable macroeconomic series over time.  The author uses 13 base assets 
and their lagged returns to track these macroeconomic series.  The base asset series 
include four bond portfolios, eight industry-sorted stock portfolios, and the market 
portfolio for the stock market.  The key macroeconomic series estimated include: 
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industrial production growth, real-consumption growth, real labor income growth, 
inflation, excess stock returns, excess bond returns, and Treasury bill returns. 
To ensure he is not capturing the effect of other key variables known to predict 
stock and bond returns as well as the macroeconomy, he controls for nine lagged 
variables (with a constant term): Treasury bill returns, term premium for long-term 
government bonds (long bond yields minus Treasury bill), term premium for one-year 
government notes (one-year note yield minus Treasury bill yield), default premium on 
corporate bonds (BAA minus AAA yield), default premium on commercial paper (paper 
yield minus Treasury bill yield), the dividend yield on the CRSP value weight aggregate 
portfolio, 12-month production growth, CPI inflation, and excess stock returns.  
Ultimately, with partial R-squared values of between 0.04 and 0.23, Lamont (2001) 
concludes that, controlling for other known relationships, these investable portfolios do 
indeed track non-investable macroeconomic variables at some level. 
7KHUHOHYDQFHRI/DPRQW¶VVtudy to this research assumes we find that medical 
inflation is a priced factor in security returns.  If this result occurs, the natural next step 
will be to investigate ways firms can hedge the risk presented by medical inflation and its 
associated costs.  Specifically, whereas Lamont analyzes the ability of these investable 
assets to track aggregate inflation, we ORRNPRUHFORVHO\DWDQLQYHVWDEOHSRUWIROLR¶V
ability to track, or mimic, the behavior of medical inflation. 
Finally, as a caveat to our anticipated results, one must consider these conclusions 
cautiously since the contemporaneous relationships documented are based on ex post 
corrected macroeconomic data, an issue highlighted by Christoffersen, Ghysels, and 
Swanson (2001).  In their study, the authors demonstrate how markets adapt to 
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information as it is released, and unfortunately much macroeconomic data is initially 
released using preliminary, or estimated, values.  Conducting studies after the fact can 
chronologically misalign ex-post corrected macroeconomic data with market events at a 
specific point in time.  Thus while we price medical inflation using ex ante accurate data, 
the market might not have had these exact figures contemporaneously, so it is indeed 
possible that the relationships we demonstrate are perhaps skewed by the passage of time 
and the use of ex post data. 
 
Hypothesis Development 
Asset pricing theory (see Cochrane (2005) or Campbell, Lo, and Mackinlay 
JHQHUDWHVUHODWLRQVKLSVEHWZHHQH[SHFWHGVHFXULW\UHWXUQVDQGLQGLYLGXDOV¶
consumption as well as their investment opportunity set.  That is, changes in security 
SULFHVJHQHUDWHUHWXUQVDQGWKHVHFKDQJHVDUHLQGXFHGE\HYHQWVWKDWDOWHULQGLYLGXDOV¶
ability to consume or their opportunities to invest.  The most natural and intuitive events 
that alter these items are macroeconomic phenomena.  For instance, higher-than-expected 
LQIODWLRQDIIHFWVLQYHVWRUV¶DELOLW\WRFRQVXPHZKLFKVKRXOGLQWXUQDIIHFWWKHGHPDQGIRU
stocks and influence their prices.  As another macroeconomic example, a spike in 
unemployment would likely affHFWLQGLYLGXDOV¶DJJUHJDWHFRQVXPSWLRQDQGWKHUHIRUH
WKHRUHWLFDOO\DIIHFWVWRFNUHWXUQV,W¶VWKLVWKHRUHWLFDOUHODWLRQVKLSEHWZHHQ
macroeconomic phenomena and stock returns that forms the basis for this study. 
Specifically, this study analyzes the macroeconomic phenomenon of medical 
inflation and its effect on security returns.  Based on the relevance of medical care costs 
to the US economy, the fact that all firms with human capital appear to be exposed to this 
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cost, and the devastating effect these costs have had on some individuals (see 
Introduction for these details), this study proposes that medical care costs affect financial 
markets in a material manner, since they affect the riskiness of firm cashflows to the 
extent firms are exposed to medical inflation.  Specifically, we hypothesize that the 
PDUNHWSULFHVILUPV¶H[SRVXUHWRPHGLFDOFDUHFRVWVDVDVRXUFHRIV\VWHPDWLFULVN7KXV
those securities whose returns covary positively with medical inflation should earn excess 
returns.  We anticipate medical inflation surprises price negatively since those assets that 
covary positively with medical inflation shocks serve as hedging instruments against 
unanticipated spikes in health care costs. 
 
Methodology 
Is medical inflation different from aggregate inflation? 
We first establish that although the Medical Care Consumer Price Index (CPI) is a 
component of aggregate CPI, its (unexpected) behavior is sufficiently different from the 
aggregate measure to warrant its consideration as a separate priced factor.  Figure 1 plots 
the monthly time series from January 1967 to August 2009 of CPI for All Urban 
Consumers (CPIAUCSL), which we call aggregate CPI for brevity, and some of its major 
components.  For future reference, Appendix A includes all figures, and Appendix B 
includes all tables.  All levels in this study are seasonally-adjusted whenever possible.  
Specifically, series include Medical Care CPI (CPIMEDSL), Housing CPI (CPIHOSSL), 
Food and Beverage CPI (CPIUFDSL), and Transportation CPI (CFDTRNSL).  These 
components currently represent almost 80 percent of the aggregate CPI, with the Medical 
component representing 6.39 percent, Housing 43.42 percent, Food 15.76 percent, and 
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Transportation 15.31 percent.8  While the composition of aggregate CPI has certainly 
changed over time, these composition changes are not material for our purposes since our 
focus is on inflation in the medical component over time. 
Our data sample begins in January 1967 since it represents the time when Medical 
CPI begins a trend of over 40 years of month-to-month variation.  While data exist 
beginning in 1947, data for two key factors, DEF and TERM, only becomes available 
beginning in April 1953 when the 10-year government bond data originated.  More 
importantly, Medical Care CPI exhibits 108 months of zero changes in those first 238 
months of measurement, which is almost 50 percent of the time and clearly deviant 
behavior considering the more recent pattern of consistent upward monthly variation.  
The sample ends in August 2009, for a total of 512 months of data. 
While a visual analysis of all panels of Figure 1 shows that medical CPI levels 
clearly diverges from the other displayed CPI components beginning in approximately 
1985, statistical tests of the relation between aggregate and medical CPI further confirms 
this observation.  Dickey-Fuller tests for unit roots indicate all subject CPI series are 
integrated of order 1, or I(1), for all time periods shown, yet none of them are 
cointegrated either pairwise or as a group.  Therefore, to work with stationary series, 
from here we will use the monthly percent changes in these series.  We use the term 
³LQIODWLRQ´WRUHIHUWRSHUFHQWFKDQJHVLQDSDUWLFXODU&3,PHDVXUHHJPRQWKO\Pedical 
inflation represents the monthly percent change in medical CPI).  To calculate per period 
percent changes we difference the natural log of the levels.  For internal consistency, we 
also convert any discrete returns to their continuous values throughout this study.  All 
                                                          
8 For data availability and relevance reasons, we omit data on Apparel (3.69 percent), Recreation (5.74 
percent), Education and Communication (6.30 percent), and Other goods and services (3.39 percent). 
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monthly and quarterly percent changes are stationary according to Dickey-Fuller tests, 
with the exceptions coming in annual sampling where Food and Transportation inflation 
maintains a unit root.   
 
Estimate of the joint distribution 
Our first test of statistical independence or difference between aggregate (and 
other types of) inflation and medical inflation involves an estimate of their joint 
distribution using a one-thousand iteration bootstrap simulation.  In this simulation, our 
goal is to determine whether the actual joint distribution of the monthly time series of 
medical inflation and aggregate inflation differs from a joint distribution created if these 
series were independent.  The procedure for the simulation involves first placing medical 
inflation values into quartiles.  Next, the values for a second time series are placed into 
quartiles.  We create a 4 x 4 grid that contains the counts of each quartile intersection.  
For instance, if the lowest values of medical inflation (i.e., quartile 1) intersected with the 
lowest values of aggregate (i.e., quartile 1) 54 times, then the count in cell (1, 1) equals 
54, as we see in Figure 2.  Next we randomly reorder monthly aggregate inflation values 
and match these random values with the quartile of the corresponding monthly medical 
inflation value.  To determine whether the actual correspondence occurs more or less 
frequently than if the series were independent, we average the count of the random 
pairings over the 1000-iteration bootstrap simulation.  It is then possible to determine 
whether the actual pairing count is in the tails of the random pairing count. 
Figure 2 depicts the quartile-by-quartile average results for one-thousand 
iterations comparing monthly medical inflation to others.  All monthly pairings are 
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represented, and thus the sum of all cells equals our 512-month dataset.  Shaded cells 
differ from a ³UDQGRP´value by occurring with extremely high (bold and shaded) or low 
(underlined and shaded) frequency.  We use Į = 0.10 on each side to determine the non-
random pairings. 
Figure 2 indicates that monthly medical inflation is positively related to monthly 
aggregate inflation, especially at the extreme values (quartiles 1,1 and 4,4), which makes 
sense since (a) medical inflation is a component of aggregate inflation, and even with its 
low weighting within aggregate inflation, extreme values will magnify its affect on 
aggregate inflation and (b) it is also positively-related²albeit to a lesser extent²to 
Housing inflation, Food inflation, and Transportation inflation, which are obviously also 
components of the aggregate inflation measure.  The bold (underlined) cells indicate 
where the cell values are above (below) the 90th percentile values for that cell across the 
one-thousand bootstrapped iterations.   
This positive relationship is also shown using Table 1, which shows the various 
monthly inflation correlations on the upper triangle.  Variances (covariances) are on the 
diagonal (lower triangle).  For example, Panel A indicates a correlation of 0.405 between 
aggregate inflation and medical inflation.  Monthly medical inflation is less correlated 
with aggregate inflation than it is with housing inflation.  While the correlation with food 
and transportation inflation is still positive, these values are lower yet.  As one would 
expect, the correlations all grow monotonically as the measurement frequency decreases, 
or time horizon increases, to quarterly and annual data.  Interestingly, across all sampling 
frequencies, medical inflation has the lowest variance, with the variance measures located 
on the diagonal.  Coupled with the time series level plots in Figure 1, this result indicates 
17 
 
 
 
 
medical inflation appears to be moving upward at a relatively constant rate relative to the 
other inflation measures.  On the contrary, transportation inflation exhibits much higher 
volatility than the other measures across all sampling frequencies. 
While monthly medical inflation is contemporaneously positively related to 
aggregate inflation and its major components, contemporaneous medical and aggregate 
inflation are not ultimately our primary variables of concern.  Since theory argues the 
market imputes any expected information into returns, it is the surprises in these variables 
that should truly impact stock returns.  Therefore it is the correlation between these 
surprises, or shocks, that matter most.  While we explicitly address this relationship next, 
to foreshadow, the respective correlations are much lower among surprises irrespective of 
the measurement method we use. 
 
VAR decomposition  
Given the inherent and exhibited contemporaneous relationship between medical 
inflation and aggregate inflation coupled with our inability to create a compelling 
rationale for one exogenously determining the other, we believe each to have an 
autoregressive component as well as an explanatory component that includes lagged 
values of the other inflation factor.  Additionally, since we are ultimately interested in 
WKHVHLQIODWLRQIDFWRUV¶DIIHFWRQWKHVWRFNPDUNHWone method to get surprises involves 
using a vector autoregression model (VAR) that incorporates these three variables.  
Specifically, we estimate the VAR model in equations (1) to (3) to determine how similar 
or different the relationships between medical and aggregate inflation are with respect to 
the market. 
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ܥܲܫܯܧܦܯܱݐ = ߙ0 + ߙ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߙ2,݅ܥܲܫܣܷܥܯܱݐെ݅ + ߙ3,݅ܯܭܴܶܨݐെ݅ + ݑݐ        (1) 
ܥܲܫܣܷܥܯܱݐ = ߚ0 + ߚ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߚ2,݅ܥܲܫܣܷܥܯܱݐെ݅ + ߚ3,݅ܯܭܴܶܨݐെ݅ + ݒݐ       (2) 
ܯܭܴܶܨݐ = ߜ0 + ߜ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߜ2,݅ܥܲܫܣܷܥܯܱݐെ݅ + ߜ3,݅ܯܭܴܶܨݐെ݅ +ݓݐ      (3) 
 
where CPIMEDMOt (CPIAUCMOt) represents monthly medical (aggregate) inflation for 
month t, MKTRFt is the market risk premium9, and ut, vt, and wt represent the residuals, 
which we WUHDWDVWKH³QHZV´or surprise component of each series. 
Medical inflation represents its own niche of products and services that are 
uniquely influenced by their industry- or market-specific cost changes.  But the medical 
care industry also utilizes products and services common across industries, and the cost 
inflation these items experience is best represented by the lagged cost changes of the 
entire market basket of goods.  We easily could have proxied the aggregate inflation 
component with its non-medical subcomponents (e.g., Food, Housing, Transportation, 
etc.), but doing so should yield analogous results with perhaps less precision due to the 
loss in degrees of freedom.  Similar logic holds for explaining aggregate inflation.  We do 
not necessarily anticipate the market risk premium will affect our inflation measures, 
however, we include this variable in the VAR to allow for discerning differences between 
lagged medical and aggregate inflation measures on stock market returns.   
Table 2 summarizes the outputs from this VAR model, which uses the Schwarz 
criterion to determine the appropriate lag length of 2.  From Column 3, labeled 
³&3,$8&02´the market risk premium significantly leads aggregate inflation by one 
                                                          
9 dĂŬĞŶĨƌŽŵ<ĞŶ&ƌĞŶĐŚ͛ƐĚĂƚĂůŝďƌĂƌǇ͗
http://mba.tuck.dartmouth.edu/pages/faculty/ken.french/data_library.html 
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month.  On the other hand, it does not have a relationship with medical inflation.  Instead, 
both one- and two-month lagged medical and aggregate inflation explain current medical 
inflation.  Medical inflation leads aggregate inflation by two months, while aggregate 
inflation is DXWRFRUUHODWHGDWRQHPRQWKFRQWUROOLQJIRUWKHRWKHUYDULDEOHV¶LQIOXHQFHV
Finally, only the one-month lagged market risk premium has any explanatory power for 
the current market excess return. 
 
Impulse response 
The plots in Figure 3 show the univariate impulse response functions among these 
variables.  Specifically, these plots demonstrate the 18-month effect of a one standard 
deviation shock to each variable along with the asymptotic standard error confidence 
bands.  Plots (1,2) and (2,1) are of primary interest, as they indicate that a univariate 
shock to medical or aggregate inflation has a two- to three-month upward effect on its 
counterpart.  But this upward effect reverses and eventually dies out over the ensuing 15 
months.  Thus a shock to medical (aggregate) inflation has no permanent effect on 
aggregate (medical) inflation according to the results from this model.  So despite the 
relationship between aggregate and medical inflation that occurs by-construction, this 
result provides some of the strongest evidence to this point that medical and aggregate 
inflation can be considered different macroeconomic phenomena. 
 
Variance decomposition 
While the impulse response functions demonstrate the results of a unilateral shock 
to a particular variable on another variable, for example, the timing and magnitude of a 
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shock to aggregate inflation on medical inflation, it is also constructive to view the 
variance decomposition.  Using the Choleski variance decomposition method and 
ordering by medical inflation, aggregate inflation, and market risk premium, we can 
determine the composition of mHGLFDOLQIODWLRQ¶VYDULDQFH over time attributable to 
shocks to itself, shocks to aggregate inflation, and shocks to the market risk premium.  
Table 3 depicts this decomposition. 
These results further support the relationship between aggregate and medical 
inflation found in the VAR outcome and impulse response functions.  Specifically, by 18 
months after a shock to medical inflation, fully 86 percent of the variance in medical 
inflation is driven by its own behavior.  Alternatively, 13.6 percent is driven by the 
variance in aggregate inflation, and less than 1 percent by the variance in the market risk 
premium.  These resultVDUHQRWVHQVLWLYHWRWKHYDULDEOHV¶RUGHULQJThus it appears that 
aJJUHJDWHLQIODWLRQ¶VYDULDQFHis not the major force driving medical inflation¶VYDULDQFH, 
and we have more evidence that these two series are separate phenomena despite their 
inherent relationship.  It becomes apparent later that the market perceives the associated 
risk differently as well. 
 
Is Medical Inflation Different from Rm-Rf, SMB, HML, MOM, DEF, and TERM? 
To explore whether medical inflation is a priced risk factor in stock returns, it is 
also worthwhile ensuring it does not simply proxy for factors already known to perform 
well in explaining stock returns.  Specifically, Fama and French (1993) demonstrate the 
efficacy of their well-known SMB and HML factors to explain the time series of stock 
returns.  Additionally, they echo the CRR (1986) findings that DEF and TERM have 
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important relationships with stock returns.  While CRR (1986) find DEF and TERM are 
priced risk factors in stock returns, Fama and French (1993) find these two factors help 
generate a more unifying model to explain time series returns of both stocks and bonds, 
not solely stocks as approached in CRR (1986).  Finally, we look at the relationship 
between medical inflation and Momentum (MOM), initiated by Jegadeesh and Titman 
(1993) and implemented by Carhart (1996 and 1997) to help explain stock returns. 
For this section, we collect SMB, HML, and MOM values IURP.HQ)UHQFK¶V
data library.  We calculate the default risk premium, DEF, as the difference between the 
monthly 0RRG\¶VVHDVRQHG%DDFRUSRUDWHERQG\LHOGand the 10-year Treasury constant 
maturity rate.   TERM represents the term risk premium, or by-month difference between 
the 10-year Treasury constant maturity rate and the three-month Treasury bill.  For these 
measures we obtain the Baa portfolio, long government bond, and three-month Treasuries 
after January 1995 from the Federal Reserve Statistical Release H.15, Selected Interest 
Rates.  We are gratefully acknowledge Jeffrey Pontiff for providing pre-1995 data on the 
three-month Treasuries. 
 
Joint distribution 
Analogous to the bootstrapping method employed above, Figure 4 shows the 
quartile joint distributions between medical inflation and various factors.  The only real 
potential for a relationship between medical inflation and known factors occurs with the 
term risk premium (TERM).  While a clear negative pattern fails to emerge, the 
abundance of abnormally high and low contemporaneous relationships (10 of 16 cells) is 
concerning.  Although the relationship is not as pronounced as we anticipated, this 
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indication of some relationship is not surprising given that TERM effectively represents 
the difference between the limits of the yield curve, which many interpret as an indicator 
of future inflation.  To the extent the market interprets current high inflation as 
unsustainable going forward, one would expect the somewhat negative relationship we 
observe.  A consistent result occurs in the final grid, which indicates that medical 
LQIODWLRQ¶Vnegative relationship with TERM is similar to the relationship between 
aggregate inflation and TERM.  This result becomes evident by comparing the bottom 
two results in Figure 4. 
Figure 4 indicates the relationship of SMB, HML, MOM, and DEF with medical 
inflation is virtually no different than a random pairing of the monthly values.  While 
DEF shows some slight evidence of a positive relationship with medical inflation, a 
confounding result is that DEF is also high when medical inflation is low an abnormal 
amount of time (see sector 1,4). 
The correlations in Table 4, which again contain the correlations in the upper 
triangle and covariances on the diagonal and lower triangle, show medical inflation is not 
very correlated with any of the other previously-demonstrated factors using monthly 
sampling.  Again, the absolute values of the correlations generally grow monotonically as 
the sampling frequency decreases.  Medical inflation once again has the lowest variance 
of all factors studied in this section.  The other notable facts from Table 4 are that once 
again medical inflation is much less volatile than the other measures, and also the excess 
market return, MKTRF, has a variance is generally larger than the other factors.  Thus 
even though medical inflation might be related to other factors, as CRR (1986) highlight, 
we must consider the relative volatility of various macroeconomic series.  Specifically, at 
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the monthly frequency, the next least volatile factor, DEF, has a variance (0.548), which 
is over seven times that of medical inflation (0.073).  The other factors have variance 
values greater than medical inflation by two orders of magnitude.  Thus if the visual, 
bootstrapping simulation, and correlation results are not enough to separate medical 
inflation as its own factor, then its relative smoothness over time should suffice.  This 
smoothness could prove detrimental, as prior authors have pointed out the consequent 
FKDOOHQJHRIVXFKUHODWLYHO\³VPRRWK´PDFURHFRQRPLFVHULHVKDYLQg much explanatory 
power considering the highly-varying nature of asset returns. 
 
VAR analysis 
Akin to our earlier VAR analysis that includes inflation and the market risk 
premium, in this analysis we expand the VAR model to include the factors considered in 
this section that may explain and influence medical inflation.  In addition to aggregate 
inflation and the market risk premium, we augment the VAR with SMB, HML, MOM, 
DEF, and TERM.  Thus our system is represented by the following: 
 
ܼݐ = ߁ܼݐെ1 + ݑݐ  
 
where ܼݐ  is an (8 x 1) state vector that includes medical inflation, aggregate inflation, 
market risk premium, SMB, HML, MOM, DEF, and TERM, ߁ represents the (8 x 8) 
matrix of parameters, assuming we use one lagged value as explanatory variables, and ݑݐ  
is the (8 x 1) vector of error terms for each respective variable in the state vector.  In our 
case, the time series of ݑ1is the variable of interest: unexpected medical inflation.  To 
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clarify the above description, equation (4) illustrates the first equation (of 8) represented 
by the entire VAR system. 
 
ܥܲܫܯܧܦܯܱݐ = ߙ0 + ߙ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߙ2,݅ܥܲܫܣܷܥܯܱݐെ݅
+ ߙ3,݅ܯܭܴܶܨݐെ݅ + ߙ4,݅ܵܯܤݐെ݅ + ߙ5,݅ܪܯܮݐെ݅ + ߙ6,݅ܯܱܯݐെ݅ + ߙ7,݅ܦܧܨݐെ݅
+ ߙ8,݅ܶܧܴܯݐെ݅ + ݑݐ   (4) 
 
Using the Schwarz criterion to determine the appropriate lag length of 1, Table 5 depicts 
the VAR parameter estimates for this specification. 
These results indicate that besides medical inflation itself, only aggregate inflation 
leads medical inflation by one month, controlling for the other lagged factors.  We 
anticipated this result based on the earlier three-variable VAR, which showed the 
relationship to aggregate inflation.  Lagged medical inflation does not have explanatory 
power for any of these other factors except for aggregate inflation and TERM, both of 
which it significantly leads by one month. 
The variance decomposition reported in Table 6 shows the major source of 
variance over time for medical inflation stems from its own volatility (88.7 percent).  The 
next major source of variance is aggregate inflation (9.1 percent), followed by MKTRF, 
HML, and TERM, which change slightly depending on the variable ordering, however, 
not substantially enough to warrant further comment.  While the low self-values for DEF 
and TERM might initially cause concern, these values are order-sensitive and change 
dramatically when moved forward within the system.  In general for all these variables, 
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order matters, and shocks to their own values persist over time.  In untabulated results, 
the volatility in the market risk premium plays the major secondary role for these factors. 
 
Estimates for Unexpected Medical Inflation 
While medical inflation itself is noteworthy due to its markedly different behavior 
than aJJUHJDWHLQIODWLRQDQGDUJXDEO\GLUHFWLQIOXHQFHRQILUPV¶ILQDQFLDOSHUIRUPDQFH, 
theory predicts that the market has already imputed the expected medical inflation level 
into prices.  Thus if the only medical inflation that occurs is at the expected level, then 
prices (i.e., returns) will not change based on this information.  However, if medical 
inflation rises or falls in an unexpected manner, then to the extent this information affects 
either cash flows or their riskiness, prices ought to react accordingly and generate the 
commensurate returns.  Since we know stock prices do indeed change often, and we 
suspect medical inflation plays a role in these changes, we are critically concerned with 
the effect of unexpected medical inflation on stock prices. 
There exist multiple methods to disaggregate medical inflation into its expected 
and unexpected components, each with its own advantages and drawbacks.  One 
alternative, along the lines of Fama and Gibbons (1982), is to decompose medical 
inflation into its expected and unexpected components using a time-varying parameter 
model.  They implement this technique through a Kalman Filter econometric method 
based on a procedure originally described by Ansley (1980).  Although Fama and 
Gibbons (1982) disentangle expected and unexpected aggregate inflation, we extend their 
implementation and apply it to medical inflation.  The criticism with this method is 
clearly that aggregate inflation differs from medical inflation (as we argued in an earlier 
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section), and as a result, the Fisher (1930) relationship between aggregate inflation and 
interest rates does not necessarily hold for its components, such as medical inflation.  The 
advantage of its straightforwardness is evident.  For completeness, Figure 5 shows the 
plot of actual aggregate inflation (CPIAUCMO) and expected aggregate inflation 
(EXPINF) using this Kalman Filter method.  Expected aggregate inflation (EXPINF) is 
clearly a smoothed version of the more volatile actual inflation (CPIAUCMO) series. 
The other readily-available alternative we analyze is to estimate the VAR model 
along the lines of those we have created in earlier sections and use the residual from 
equations (1) and (4), ݑݐ , as the unexpected component of medical inflation. 
 
State space estimate 
The first method we investigate here is the state space estimate, in which we use 
the same time-varying parameter Kalman filter model as Fama and Gibbons (1982) to 
generate expected and unexpected medical inflation.  Please see Appendix C for a 
description of this method based largely on the presentation in Hamilton (1994a).  For 
visual analysis, Figure 6 depicts the resulting time series plot of actual (CPIMEDMO) 
and expected (EXPMEDINF) using this technique. 
Visual inspection indicates the estimate of expected medical inflation is a 
smoothed version of the more volatile actual medical inflation values, analogous to the 
more theoretically-based results for aggregate inflation in Figure 5.  Given the lack of 
available alternatives for disaggregating expected and unexpected medical inflation, this 
similarity encourages us that while our decomposition of medical inflation into its 
components is not strictly based on the Fisher (1930) relationship like aggregate inflation, 
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WKHVLPLODULW\RIPHGLFDOLQIODWLRQ¶Vbehavior WRDJJUHJDWHLQIODWLRQ¶VXVLQJWKLVWHFKQLTXH
encourages us this method is not entirely inappropriate. 
 
VAR estimate 
Using the earlier VAR models, which we will refer to as the Inflation VAR (3 
variables: CPIMEDMO, CPIAUCMO, and MKTRF) and the Factor VAR (8 variables: 
CPIMEDMO, CPIAUCMO, MKTRF, SMB, HML, MOM, DEF, and TERM), we create 
two series of unexpected medical inflation using the residuals from the first equation in 
each VAR specification.  Figure 7 shows, respectively, a time series plot of the expected 
medical inflation values from the Inflation VAR (EXPMED3VAR) and Factor VAR 
(EXPMED8VAR) juxtaposed with the actual medical inflation (CPIMEDMO) time 
series.  These results indicate the expected medical inflation tracks actual medical 
inflation quite closely, with the exception of a few deviations in the early-1980s and late-
1990s. 
Table 7 summarizes the relationships between our various measures of 
unexpected medical inflation and other key variables of interest by quantifying the 
correlations between these various measures and some of the key variables we are 
concerned might demonstrate redundancy with medical inflation. 
Whereas previous results indicate a possibility that medical inflation might simply 
pick up the effect of aggregate inflation or perhaps even the TERM risk premium, the 
correlations between our various measures for medical inflation surprises and these 
variables are nearly zero per Table 7.  The reason for the slight difference between some 
of these results and Table 1 is the loss of observations with the lagged terms in the VARs.  
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These results provide more compelling evidence that surprises in medical inflation, which 
might affect stock returns, do not simply reflect previously-documented factors that have 
been shown to explain returns.  Again, our measures of medical inflation surprises are the 
Kalman Filter series (UNEXPMEDKALMAN), the Inflation VAR residual series 
(UNEXPMED3VAR), and the Factor VAR residual series (UNEXPMED8VAR).  While 
aggregate inflation earlier proved to be our chief concern for redundancy with a positive 
correlation of 0.404, the correlations between the medical inflation surprises generated by 
the Kalman Filter and VAR models are much lower, ranging from 0.009 to 0.119.  
Further, none of the medical inflation shock measures are correlated with aggregate 
inflation shocks (correlations from -0.024 to 0.003).  Recall that CRR (1986) show 
aggregate inflation is (mildly) priced in returns.  Additionally, the relationships between 
medical inflation and TERM are effectively zero (ranging from -0.002 to 0.003).  Finally, 
it is encouraging that all measures of unexpected medical inflation are highly-positively 
correlated with one another (between 0.853 and 0.892).  In other words, the medical 
inflation surprises appear quite insensitive to the mechanism used to generate them, and 
they are not correlated with other factors that prior research has explored. 
Given these results in Table 7, we proceed using only the unexpected medical 
inflation from the state space model (UNEXPMEDKALMAN) time series.  This time 
series is most nearly orthogonal to both aggregate inflation and TERM, which to this 
point have been the factors of greatest concern in terms of redundancy. 
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Results 
Fama-MacBeth (1973) Two-Pass Method 
Having established unexpected medical inflation as a distinct factor from others 
that have shown an association with US stock returns in past studies, the next step is to 
determine whether it is priced in equilibrium.  To do so, we employ the Fama-MacBeth 
(1973) two-pass method of time series and cross-sectional regression models.  To 
minimize the errors-in-variables problems with individual stock returns, we use portfolios 
to measure returns.  Specifically, we use the 25 Fama-French portfolio returns, which are 
formed by independently-sorting all NYSE, AMEX, and NASDAQ stocks available on 
CRSP into quintiles based on size and book-to-market ratio.10  In the first pass, we use 60 
PRQWKV¶RIWLPHVeries returns to generate betas according to equation (5). 
 
ܴ݌ ,ݐ = ߙ0 +෍ߚ݌ ,݅ ܼ݅ ,ݐ
݇
݅=1
+ ݑݐ      (5) 
 
where ܴ݌ ,ݐ  is the month t excess return on portfolio p, p  «,25, t represents 60 
PRQWKV¶ZRUWKRIWLPHVHULHVGDWD, k represents the number of factors, and ܼ݅  represents a 
factor used to explain returns.  ߚ݌ ,݅  represents a portfolio-specific parameter estimated in 
the model and is calculated as the covariance of the factor and portfolio return normalized 
by the variance of the factor (i.e., ߚ݌ ,݅ = ܿ݋ݒ(ܴ݌ ,݅ ,ܼ݅)/ݒܽݎ(ܼ݅)). 
We then cross-sectionally price these betas monthly over the ensuing 12 months 
according to equation (6).   
                                                          
10 :HJUDWHIXOO\DFNQRZOHGJH.HQ)UHQFK¶VGDWDOLEUDU\IRUSURYLGLQJWKHVHUHWXUQV
http://mba.tuck.dartmouth.edu/pages/faculty/ken.french/data_library.html. 
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ܴ݌ ,ݐ = ߣ0 +෍ߣ݅,ݐߚ݌ ,݅
݇
݅=1
+ ݑݐ      (6) 
 
This analysis occurs on a rolling basis, beginning with 60-month beta estimation 
from January 1967 to December 1971, followed by cross-sectional regressions from 
January to December 1972.  We then increment the beta estimation period by 12 months, 
re-calculate the betas using equation (5), and re-price the factors using equation (6).  With 
data beginning in January 1967 and ending in August 2009, we ultimately have just under 
38 yHDUV¶ZRUWKRIPRQWKO\ULVNSULFHVߣ݅), or 452 monthly observations.  Calculating the 
statistics on these risk price series allows us to determine whether the price of risk for the 
respective factor differs significantly from zero.  In other words, for each unit of factor 
³ULVN´WKHDVVRFLDWHGFRHIILFLHQWTXDQWLILHVWKHH[Wra return required for bearing such risk. 
 We determine whether medical inflation is a priced risk factor using a variety of 
specifications.  First and most simply, we include medical inflation expected and 
unexpected components as the only factors and then add aggregate inflation components.  
Next, we augment the CRR (1986) model specifications to include medical inflation 
components.  Additionally, we extend the more recent results of Flannery and 
Protopapadakis (2002), explicitly pricing those macroeconomic series they indicate 
perform well in a first-pass scenario and further augmenting these measures with medical 
inflation.  Finally, in a sort of hybrid macroeconomic-characteristics model, we price the 
Fama and French (1993) five factors, include momentum, and augment these factors with 
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medical inflation.  Generally speaking, it appears medical inflation in some form loads as 
a priced risk factor across the model frameworks. 
 
Two-pass method with unexpected medical inflation (and unexpected aggregate inflation) 
Table 8, Panel A contains the results for the first set of second-pass regressions.  
Specifically, this table shows the second-pass results for 6 different model specifications 
having completed first-pass regressions for the period January 1967 to August 2009, or 
512 months. 
7RJHWDEDVHOLQHRQRXUPRGHO¶Vperformance for the subject period, the first 
specification includes only the market excess return (i.e., simple single-factor CAPM), 
both for the first-pass time series regressions and the second-pass.  To provide an 
example of the first-pass results from equation (5), we present Table 8, Panel B.  It shows 
first-pass results across the entire time period (512 months), while the rolling regression 
methodology used in Table 8, Panel A runs the first pass time series regression for sixty 
months at a time.  The results in Panel B, columns 4 through 6 indicate that the market 
risk premium explains each of the portfolio returns well across the entire time series (see 
the high t-statistics and coefficients of determination). 
Turning back to Table 8, Panel A, the second column shows that in our period of 
study, the market risk premium factor is indeed priced in equilibrium during this period.  
While contrary to theory, we find a well-known empirical result that covariance with the 
market statistically has a negative return premium, which is opposite of that predicted by 
the Sharpe-Lintner Capital Asset Pricing Model.  This result indicates the market risk 
premium is negative, or that this sample has a negatively-sloped Security Market Line.  
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As pointed out by Ahn, Gadarowski, and Perez (2009), this result could simply be an 
artifact of the relatively constant beta values (range from 0.81 to 1.45) across the 25 
portfolios.  Unfortunately such a negative-sloping Securities Market Line (SML) is a 
commonly-found but theoretically-discouraging result. 
The first novel two-pass test we complete involves only expected and unexpected 
medical inflation as the possible risk factors.  Table 8, Panel C, shows results from the 
associated first-pass regressions, which are analogous in format to those for the market 
factor shown in Table 8a. 
From the first-pass regressions, it is evident that while the market risk premium is 
contemporaneously highly-SRVLWLYHO\FRUUHODWHGZLWKHDFKSRUWIROLR¶VUHWXUQVWKHVDPH
cannot be said of the contemporaneous relationship between medical inflation (expected 
RUXQH[SHFWHGDQGWKHSRUWIROLRV¶UHWXUQV from the first-pass regressions.  Like the 
market risk premium, which is statistically priced (Table 8, Panel A, Column 2), the 
results for medical inflation indicate the contemporaneous expected and unexpected 
medical inflation are both priced at conventional statistical levels (Table 8, Panel A, 
Column 3).  Additionally, results for unexpected medical inflation (Column 4) are robust 
to the replacement of expected medical inflation with its first difference series, the analog 
to the change in expected aggregate inflation used in the CRR (1986) study.  The fourth 
specification (Column 5) in Table 8, Panel A, which substitutes aggregate inflation 
expected and unexpected components for medical inflation, demonstrates that neither 
expected nor unexpected aggregate inflation are priced when used alone in the model.  
Finally, and perhaps most notably, mHGLFDOLQIODWLRQ¶VORDGLQJDVDSULFHGULVNIDFWRULV
robust to including aggregate inflation components as factors in the fifth specification 
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(Columns 7 and 8).  While the economic price of medical inflation decreases 
substantially when including aggregate inflation as a factor (from 0.10 to 0.05), 
unexpected medical inflation is nonetheless priced at conventional significance levels 
whether one uses the time series of expected medical and aggregate inflation or their first 
differences.  Since Dickey-Fuller tests confirm that expected medical inflation 
(EXPMED) is a stationary time series, we proceed using it in future specifications versus 
the change in it. 
While concerns about multicollinearity clearly arise when including both 
aggregate and medical inflation in the same model, the robustness of mHGLFDOLQIODWLRQ¶V
pricing both alone and despite the potential multicollinearity is encouraging.  And we 
know the relationship between unexpected medical inflation, the variable of primary 
interest, is effectively uncorrelated with the other inflation measures.  Overall, these 
models that incorporate medical inflation in relatively simple specifications entice us to 
explore more comprehensive specifications for evidence of medical inflation as a priced 
risk factor. 
Although it is encouraging that the medical inflation factor prices in equilibrium 
during this period of study, one surprise result is that this factor prices positively.  As 
with aggregate inflation, it seems most plausible that as stock (or portfolio) returns 
covary positively with medical inflation, then these assets would represent hedges for the 
³EDG´VWDWHRIKLJKPHGLFDOLQIODWLRQ$VDUHVXOWLQYHVWRUVORRNLQJWRprotect their 
wealth against such a bad state would bid up the prices of these assets and consequently 
reduce returns to these assets.  Thus one would predict that a high covariance between 
returns and medical inflation shocks would lead to lower expected returns.  In other 
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words, we anticipate the medical inflation factor we have constructed should price 
negatively in equilibrium. 
To determine if this unexpected result occurs consistently over time, we now 
subdivide the period of study into two sub-periods.  The first period runs from January 
1967 to December 1984; the second period from January 1985 to August 2009.  Given 
the 60-month beta formation period at the beginning of our sample, these sub-periods 
FRQWDLQDQGPRQWKV¶RIUHWXUQGDWDUHVSHFWLYHO\7KH rationale for subdividing 
the entire period at this date comes from Figure 1.  The mid-1980s appears to be the time 
when medical inflation begins diverging from the other components of medical inflation 
and represents a reasonable basis for partitioning the sample.11 
Table 8, Panel D contains the results of the subdivided sample in columns 3 and 4 
for the specification 6 in Table 8, Panel A.  For our basic specifications, although medical 
inflation surprises are priced positively across the entire sample period, this result only 
occurs because of their positive pricing in the early sub-period.  In the more recent 
period, medical shocks price negatively and significantly, as we would predict.  
Additionally, while expected medical inflation prices (positively) in the earlier period, it 
fails to price in the latter period.  Unfortunately the positively-priced medical inflation 
result in the early period remains a mystery despite multiple robustness tests and 
explorations, as we describe later. 
 
 
 
                                                          
11 The pattern described in the following sub-period results also generally holds when we arbitrarily 
subdivide the sample into its 4 decades (1970s, 80s, 90s, and 2000s). 
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Two-pass method with other factors 
We now augment the CRR (1986) model to include medical inflation as a 
potential source of priced risk.  Like these authors, we leave the first-pass results 
untabulated, recognizing the challenge for our relatively smooth macroeconomic series to 
explain highly volatile security returns at a level with any meaningful significance.  
Instead, Table 9, Panel A presents the second-pass results from the CRR (1986) baseline 
and four model permutations. 
The first column represents the basic CRR (1986) model results.  The default risk 
premium (DEF) is priced, and the industrial production measure (INDPRO), while close, 
does not price at conventional statistical levels.  Notably, our definition for TERM differs 
slightly from CRR, who use the one-month Treasury bill versus the three-month Treasury 
bill.  While we are unable to replicate perfectly the CRR (1986) results essentially 
because we could not duplicate all of their data (e.g., they used 20 size portfolios versus 
the three, five, and ten currently available YLD.HQ)UHQFK¶V'DWD/LEUDU\), our results for 
overlapping sub-periods align qualitatively.  Model specifications that include medical 
LQIODWLRQ¶Vexpected and unexpected medical inflation, shown in column 2, indicate that 
unexpected medical inflation is priced at conventional statistical levels. 
 Comparable to CRR (1986), specifications 3 and 5 (columns 4 and 6) control for 
WKHPDUNHW¶VLQIOXHQFHE\LQFOXGLQJWhe value-weighted market return premium (MKTRF) 
as a priced factor candidate.  Once again, medical inflation surprises are priced 
(specification 3), and when we aggregate both expected and unexpected medical 
inflation, it prices significantly (specification 5).  The market prices significantly 
(negative) in both specifications, and specification 4 shows that the aggregated medical 
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inflation factor LVLQVHQVLWLYHWRWKHPDUNHW¶VLQFOXVLRQVLQFHLWprices significantly absent 
WKHPDUNHW¶VHIIHFWVAdditionally, unexpected aggregate inflation prices in the 
specification (3) that controls for the excess market return.  Overall, accounting for 
medical inflation in the CRR (1986) analysis strengthens the evidence that market 
participants demand return premia for exposure to medical inflation. 
 Again, while the medical inflation surprises price in equilibrium across the entire 
sample, the positive risk price is unexpected.  As with the earlier analysis, we present the 
subdivided sample results in Table 9, Panel B.  Since both specifications 2 and 3 from 
Table 9, Panel A are of interest, we conduct sub-sample analysis for both specifications 
in Table 9, Panel B.  The results once again clearly indicate the positively-priced medical 
inflation factor for the entire period results from the strongly positive values during the 
pre-1984, or pre-divergence, phase.  Medical inflation in both specifications prices 
negatively for the more recent time period.  Also, in support of CRR (1986), both the 
DEF and TERM factors price in more recent times.  Thus it appears again that the price 
of medical inflation as a source of risk has a time-dependent sign. 
 The next step in this analysis stems from the macroeconomic factor work 
presented in Flannery and Protopapadakis (2002).  By investigating the returns to 
surprises in 17 macroeconomic series, these authors identify multiple novel series that 
appear to explain returns and thus could serve as candidates for priced risk factors.  
Health care, or medical inflation, is not one of the series they explicitly investigate, so our 
evidence about its pricing is new.  Further, a positive externality of our efforts to price 
only the medical inflation macroeconomic factor is to extend their work by 
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³LQYHVWLJDW>LQJ@ZKHWKHULQYHVWRUVHDUn excess returns for bearing the risks associated 
with any of [their] factor candidates.´ 
 Table 10, Panel A depicts the results using a subset of those macroeconomic 
variables deemed relevant by Flannery and Protopapadakis (2002).  A few caveats are in 
order.  First and foremost, we do noWKDYHWKHGDLO\³VXUSULVH´GDWDIRUHDFK
macroeconomic series that Flannery and Protopapadakis (2002) have available for their 
study.  We have used only publicly-available information for our time series.  
Additionally, we have incorporated neither Unemployment nor Balance of Trade data.  
We have not located monthly values for the former variable at this time.  The latter 
exhibits somewhat odd behavior across our period of study.  While initially positive, it 
began a trend of decline around 1980, interrupted by a brief uptick in the late 1980s. 
 Due to these caveats, our analysis certainly has room for extension.  For now, 
Table 10, Panel A presents evidence that even accounting for those candidate factors 
presented by Flannery and Protopapadakis (2002), medical inflation, both expected and 
unexpected, hold their own as priced macroeconomic risk factors across the entire time 
period.  This general result holds across a variety of model specifications, and their 
economic relevance remains at approximately the same levels as those shown in prior 
tables.  The risk premium is on the order of 0.04 to 0.06 percent per month, or 
approximately 48 to 72 basis points per year, for a one-unit-change in medical inflation 
beta. 
 Since a positively-priced medical inflation factor again emerges, we again 
conduct the sub-period analysis.  As seen in earlier results, Table 10, Panel B indicates 
that medical inflation prices negatively, as expected, over the last 25 years.  The positive 
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loading for the entire period is driven strictly by the highly-positive pricing during the 
period when medical inflation and other inflation components exhibited similar trends in 
their levels (see Figure 1). 
The next, and final, analysis involves augmenting three model specifications 
based on the well-known Fama-French factors with medical inflation.  Table 11, Panel A 
depicts the results on these second-pass regressions.  Specifications 1, 4, and 7 (columns 
2, 5, and 8) are the baseline specifications for a 3-factor, 5-factor, and 6-factor (i.e., 5-
factor plus Momentum) analysis.  Each respective subsequent specification (i.e., 2, 5, and 
8) includes expected and unexpected medical inflation.  The final specifications in each 
progression, 3, 6, and 9, replace disaggregated medical inflation with the composite 
value. 
Regarding our variables of interest, contrary to our prior results, in no case is 
unexpected medical inflation priced when we incorporate it across the entire period.  
Furthermore, the composite medical inflation value is not priced in these specifications.  
Expected medical inflation is positively priced, albeit at a substantially lower economic 
value than we have seen in the prior tables.  These results clearly do not support our 
hypothesis, per se, and as before, it is concerning that expected medical inflation carries 
some return premia here.  As for the other factors, MKTRF (negative) and  HML 
(positive) price in all specifications, TERM (positive) prices in all specifications save 
one, and MOM (negative) fails to price.  SMB (positive) never prices, and DEF 
(negative) only prices at conventional levels in the final specification. 
Once again, the results support our hypothesis when we subdivide the sample.  
Table 11, Panel B summarizes the subdivided second-pass of the final specification from 
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Table 11, Panel A, which includes all factors.  While medical inflation surprise does not 
price across the entire period, the early sub-period again drives this insignificant result.  
In the more recent sub-period, medical inflation surprises price negatively, consistent 
with the results in our prior specifications.  Additionally, the level of concern diminishes 
about expected medical inflation pricing across the entire time period.  The subdivided 
results indicate expected medical inflation fails to price in the last 25 years.  Finally, in 
more recent times, these data indicate MKTRF (negative), HML (positive), DEF 
(negative), and TERM (positive) all price significantly. 
 In an attempt to explain the counterintuitive finding that medical inflation prices 
positively from 1972 to 1984, we consider a couple possibilities.  Given the Jensen, 
Mercer, and Johnson (1996) finding regarding the relationship between asset returns and 
WKH)HGHUDO5HVHUYH¶VPRQHWDU\ policy stance, we posit that perhaps medical inflation 
pricing is conditioned upon the same monetary policy phenomenon.  We divide the 
sample into contractionary and expansionary monetary policy periods according to the 
method described in Jensen, Mercer, and Johnson (1996), using their data augmented 
with data from the Federal Reserve Statistical Release H.15, Selected Interest Rates for 
more recent months.  We then explore medical inflation pricing using two methods.  In 
the first method, we simply test the means of medical inflation factor prices (i.e., ߣ from 
equation (6)) for any difference across the two monetary policy environments.  While the 
evidence is not statistically convincing, perhaps this area is one for further future 
exploration since we find contractionary periods tend to load higher than expansionary 
periods with p-values ranging from 0.110 to 0.436 depending on the specification (results 
not tabulated). 
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In the next method, we test for a time-series difference in the relationship between 
asset returns and medical inflation surprise by interacting the medical inflation surprise 
with an indicator variable for whether each month occurs during a contractionary or 
expansionary timeframe.  This method involves running the time series regressions of 
equation (5) for the whole period with an additional interaction term.  Again, these 
untabulated results show no significant difference between the covariance between 
medical inflation shocks and asset returns associated with different monetary policy 
periods. 
 
Robustness Test: Characteristics-Based Medical Care Factor 
 One possible criticism of the previous specification (see Table 11) is that there 
exists a mix of characteristics-based, zero investment factors such as SMB and HML 
alongside the macroeconomic medical inflation factor.  Thus the next task we undertake 
is to form a zero investment portfolio medical factor and determine whether it is priced in 
equilibrium. 
 To create a medical high-beta minus low-beta (MedHML) factor, we form 
portfolios of securities based on their covariance with medical inflation shocks.  
Specifically, we pull from &563DOOVWRFNVWKDWKDYHDWOHDVWPRQWKV¶RIUHWXUQV
between January 1967 and December 2008, resulting in 16,093 firms.  From these we 
draw a random sample of 3,000 firms.  Beginning in January 1967, we perform time-
series regressions of individual firm returns on medical inflation shocks, expected 
medical inflation, SMB, HML, DEF, TERM, and MOM for sixty months.  We then order 
the firms based on the resulting beta associated with unexpected medical inflation and 
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use this ordering for the ensuing 12 months.  We create quintiles of these stocks ordered 
by medical inflation news beta and calculate an equally-weighted monthly average of 
firm returns each quintile.  Differencing the average returns of the high-beta quintile and 
low-beta quintile forms our MedHML factor.  We roll the beta estimation period forward 
by 12 months and repeat the process.  In the end we generate 444 MedHML returns for 
the period ranging from January 1972 to December 2008.  Across the whole period there 
exists no statistical difference between the average returns of the high- and low-beta 
quintiles (i.e., MedHML is statistically no different than zero), which is not problematic 
(see Cochrane (2005)). 
 Given this MedHML series, we incorporate it as a factor and proceed with the 
Fama-MacBeth (1973) two-pass procedure using equations (5) and (6) to determine 
whether it is priced.  We present the first-pass results for the entire period in Table 12, 
Panel A.  Contrary to the less-than-impressive first-pass results in Table 8, Panel C, these 
results indicate that across the entire time period MedHML covaries significantly with the 
Fama-French 25 portfolio returns for 14 of the 25 portfolios at conventional significance 
levels.  Additionally, the covariance is positive for small firms and then changes sign as 
firms grow in size.  All else equal, small firms correlate better over time with medical 
inflation than do larger firms.  We do not discern a pattern with the book-to-market 
measure. 
 The second-pass results are located in Table 12, Panel B.  The result found in 
earlier specifications persists here.  The medical inflation surprise factor²in this case 
MedHML²prices negatively in the most recent time period (see column 4).  Because we 
ORVHDQH[WUDPRQWKV¶RIGDWDPRYLQJIURPWKHSUHYLRXVVSHFLILFDWLRQVWRWKLVRQHWKH
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more recent sub-period is substantially larger than the earlier sub-period, and thus this 
negative pricing in the recent sub-period appears to dominate across the whole timeframe 
(column 2).  Interpreted, this negative price on the MedHML zero investment portfolio 
indicates that as the difference between the medical inflation surprise betas (or returns) 
grows, expected returns decrease.  In the end the market prices a risk factor formed by 
simultaneously taking a long (short) position in stocks exhibiting high (low) covariance 
with medical inflation surprises similarly to how it prices the macroeconomic medical 
inflation measure.  Thus it appears that our finding of the market pricing the risk 
associated with health care costs is robust to creating a firm characteristics-based factor 
in addition to the macroeconomic factor analyzed earlier. 
 
Discussion 
While it appears at the aggregate level the risk to firms of health-care related costs 
are priced, one might wonder whether it would be more appropriate to partition the 
sample of firms into those who are large enough to self-insure versus those who purchase 
coverage from external agencies.  Such an indicator variable would capture the 
incremental relationship between returns and self-insuring firms, but we believe the firm 
(i.e., portfolio) betas already capture these differences.  Whether a firm self-insures or 
opts for an externally-managed plan, it will ultimately bear the cost of medical care for 
insured employees.  Perhaps a delay in this cost recognition could occur if an external 
insurance company has to recoup an unexpected rise in costs (i.e., higher medical 
inflation) in a future period, but the firm will ultimately bear the expense.  To the extent 
the market incorporates this information, it should be imputed into returns and allow the 
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ILUPV¶EHWDVWRFDSWXUHWKHHIIHFWV6HSDUDWHO\EXWUHODWHGLWLVQRWLPPHGLDWHO\FOHDUWKDW
that by-firm self insurance data is available. 
Another item of possible concern is whether medical inflation represents only the 
costs of medical care but is independent of the actual expenditures firms incur to 
purchase the care, which is a more accurate indicator of the risk posed by unexpected cost 
escalation in this area.  As discussed, earlier, medical care inflation represents the cost 
index for a basket of medical care commodities and services.  This component represents 
6.39 percent of the aggregate inflation measure quantified by the Consumer Price Index 
(CPI).  On the other hand, expenditures on medical care are generally tracked as a 
fraction of GDP.  According to the Congressional Budget Office, spending on health care 
has grown from approximately 5 percent of GDP in 1960 to 17 percent today.12  So while 
it is conceivable that costs increase but expenditures do not, which would argue against 
the use of medical inflation as a proxy for firm exposure to health care cost growth, the 
growth in medical care costs as a fraction of GDP indicates that expenditures are rising in 
addition to costs.  Addtionally, results from the Kaiser Family Foundation 2009 Survey 
of Employer Health Benefits indicates that firms have increased their payment of medical 
benefits by 132 percent between 1999 and 2009.  In the same period, the cost of medical 
care as measured by medical CPI has risen by 52 percent.  Thus it appears using this cost-
EDVHGPHDVXUHRIILUPV¶H[SRVXUHWRPHGLFDOFDUHLQIODWLRQFRXOGEHPRUHFRQVHUYDWLYH
than looking DWILUPV¶DFWXDOH[SHQGLWXUHV 
Perhaps the cost versus expenditure question loses some relevance when we 
consider the medical inflation surprise beta could account for it.  Once again, the medical 
                                                          
12 http://www.cbo.gov/ftpdocs/87xx/doc8758/MainText.3.1.shtml 
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inflation surprise beta captures the by-firm (i.e., portfolio) relationship between firm 
returns and medical inflation shocks and should account for the unique effect of price 
changes versus expenditure changes.  For instance, if medical care costs (i.e., inflation) 
rise 10 percent but a firm implements a wellness program designed to decrease medical 
care needs for employees that exacts a 10 percent decrease in medical care services used, 
then these effects offset each other.  Firm earnings experience no medical care induced 
shock, leading to no return difference due to this shock and exacting a zero beta (i.e., 
covariance) between the return and medical care shock.  One might argue that firms who 
pay health insurance premiums are relatively-penalized since they pay these premiums 
regardless of medical care services used, but we assume the insurers act in an actuarially-
neutral fashion and adjust premia in the subsequent time periods to reflect cost and 
expenditure changes.  In other words, if there is a positive shock to medical inflation 
(cost) and health care usage (expenditures), then for an externally-insured firm the insurer 
will adjust future premiums to offset the unexpected loss.  Conversely, these insurers will 
also adjust to offset an unexpected gain.  This assumption makes the cost versus 
expenditure question moot, because ultimately firm earnings bear the brunt of any 
changes in medical care costs. 
Finally, a clear contemporary policy question involves financing expanded health 
care in this country.  Since the results of this study indicate investors in firms that are 
more exposed to medical inflation demand lower returns due to the hedging effect of such 
DVVHWVDJRYHUQPHQWLQWHUYHQWLRQWKDWUHGXFHVILUPV¶ULVNRIPHGLFDOLQIODWLRQZRXOG
drive down prices of hedging assets and drive up prices of their risky counterparts.  While 
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this wealth transfer from hedge-portfolio holders to those holding risky assets would 
occur, it is not apparent the government needs to correct it with a redistribution scheme. 
 
Conclusion 
Health care represents a major component of the US economy.  In the past 
quarter-century its costs have risen much faster than price in the balance of the economy 
as measured by the Consumer Price Index.  Despite these escalating costs, firms have 
shown resilience in their commitment to provide medical care as an employee benefit.  
To the extent firms are exposed to medical costs differently (i.e., more or less employees, 
better or worse health care plans, more or less leverage when negotiating rates with 
providers), their ultimate cash flows change as this component of their cost structure 
changes.  To the extent the investors cannot diversify away this risk across firms, they 
will demand excess returns for bearing the risk of escalating medical expenses that firms 
evidently will not or cannot trim. 
 This study is an attempt to determine whether the market does indeed consider 
medical care costs a source of undiversifiable and hence priced risk.  By separating the 
medical inflation component from the other basket of goods that composes aggregate 
inflation, one can generate a macroeconomic factor to test this question.  Looking at 
monthly returns for the time period between January 1967 and August 2009, we lean on 
earlier factor models, specifically those generated by CRR (1986) and Fama and French 
(1993) as a baseline.  Additionally, we incorporate the novel findings regarding 
macroeconomic factors from Flannery and Protopapadakis (2002).  We augment these 
models to include an expected and unexpected medical inflation component, which we 
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generate based on Fama and Gibbons (1982) and Ansley (1980).  At the top-level our 
findings generally support the contention that (unexpected) medical inflation does 
represent a priced risk factor, particularly in the last 25 years.  Work still needs to be 
done for the earlier period of this study, 1967 to 1984, to determine why medical inflation 
surprises price in the opposite direction as one would anticipate. 
 Given these findings that suggest medical inflation surprises are priced in the 
market recently, they are by definition non-diversifiable.  Since many large entities are 
liable for current and future medical care costs and must decide where to invest today to 
offset these future liabilities, our results indicate these entities cannot simply invest in the 
market and expect to fully fund health care expenses.  Furthermore, Jennings, Fraser, and 
Payne (2009) highlight that more targeted and seemingly natural hedging investments 
such as health care mutual funds are not effective instruments to offset medical inflation.  
Faced with non-diversifiable medical care cost risk that is not naturally hedged, future 
work could determine what investable assets would serve as a mechanism to best hedge 
the risks associated with unanticipated health care cost changes.  
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Figure 1 
 
Panel A: Monthly Consumer Price Index (CPI) Levels 
 
 
Panel B: Quarterly CPI Levels 
 
 
Panel C: Annual CPI Levels 
 
CPIAUCSL: Aggregate Inflation 
CPIMEDSL: Medical Component 
CPIHOSSL: Housing Component 
CPIUFDSL: Food Component 
CPITRNSL: Transportation Component  
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Figure 2 
Monthly Joint Distributions of Inflation Components, Sorted into Quartiles 
 
CPIMEDMO vs. CPIAUCMO                CPIMEDMO vs. 
CPIHOSMO 
1 2 3 4 
1 54 34 22 17 
2 34 45 28 15 
3 24 29 43 31 
4 13 16 33 64 
 
 
CPIMEDMO vs. CPIUFDMO               CPIMEDMO vs. 
CPITRNMO 
1 2 3 4 
1 32 40 30 25 
2 33 44 33 12 
3 33 26 32 36 
4 25 17 31 53 
 
 
These 4x4 grids represent the results of a 1000-iteration bootstrapping simulation in which the 
first time series, monthly medical inflation (CPIMEDMO), values are placed into quartiles.  Next, 
the values for the time series listed second (e.g., CPIAUCMO in the first example) are also placed 
into quartiles.  The numbers in each quartile intersection represents the number of times the 
quartile values match for the period January 1967 to August 2009.  For example, monthly 
medical inflation (CPIMEDMO) and monthly aggregate inflation (CPIAUCMO) are both in their 
lowest quartile range (i.e., 1,1) 54 times during the period of study.  To determine whether this 
value is statistically higher (or lower) than it would be if the series were independent, we 
randomly reorder the second time series 1000 times.  Generally, at the 10 percent level, the values 
for all quartile combinations fall between 27 and 32 for these random pairings.  The bold font 
(underlined font) and shaded cells represent quartile intersections that are statistically higher 
(lower) than these 10 percent cutoffs.  Variables are defined in Figure 1. 
1 2 3 4 
1 42 52 23 10 
2 39 38 37 8 
3 23 28 37 39 
4 20 9 26 71 
1 2 3 4 
1 42 35 22 28 
2 37 29 23 33 
3 23 38 45 21 
4 25 21 34 46 
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Figure 3 
Impulse Response Functions for Three-Variable Vector Autoregression (VAR) Model 
 
These results depict the 18-month response of medical inflation (CPIMEDMO), aggregate 
inflation (CPIAUCMO), and WKHPDUNHW¶VUHWXUQH[FHVVRIWKHULVNIUHHUDWHMKTRF) in the 
following VAR model to a one-standard deviation shock to itself and the other variables in the 
system for the period January 1967 to August 2009. 
ܥܲܫܯܧܦܯܱݐ = ߙ0 + ߙ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߙ2,݅ܥܲܫܣܷܥܯܱݐെ݅ + ߙ3,݅ܯܭܴܶܨݐെ݅ + ݑݐ        
ܥܲܫܣܷܥܯܱݐ = ߚ0 + ߚ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߚ2,݅ܥܲܫܣܷܥܯܱݐെ݅ + ߚ3,݅ܯܭܴܶܨݐെ݅ + ݒݐ       
ܯܭܴܶܨݐ = ߜ0 + ߜ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߜ2,݅ܥܲܫܣܷܥܯܱݐെ݅ + ߜ3,݅ܯܭܴܶܨݐെ݅ +ݓݐ      
 
Note i = 1, 2 for a two-lag model using the Schwarz criterion for lag length.  Implicit causal 
ordering is shown above (CPIMEDMO, CPIAUCMO, and MKTRF), with the results insensitive 
to changes in this ordering.  These response functions use the Cholesky decomposition to 
orthogonalize the residuals, and dashed lines represent the two-standard-deviation confidence 
bands. 
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Figure 4 
Monthly Joint Distributions of Potential Risk Factors, Sorted into Quartiles 
 
CPIMEDMO vs. SMB       CPIMEDMO vs. HML 
 
1 2 3 4 
1 42 28 24 33 
2 30 31 30 31 
3 32 37 30 28 
4 23 31 39 33 
 
 
CPIMEDMO vs. MOM      CPIMEDMO vs. DEF 
1 2 3 4 
1 31 20 36 40 
2 36 32 27 27 
3 32 37 34 24 
4 26 36 28 36 
 
 
CPIMEDMO vs. TERM                             CPIAUCMO vs. TERM 
 
 
 
 
 
These 4x4 grids represent the results of a 1000-iteration bootstrapping simulation in which the 
first time series, monthly medical inflation (CPIMEDMO), values are placed into quartiles.  Next, 
the values for the time series listed second (e.g., SMB in the first example) are also placed into 
quartiles.  The numbers in each quartile intersection represents the number of times the quartile 
values match for the period January 1967 to August 2009.  For example, monthly medical 
inflation (CPIMEDMO) and the Fama-French (1992) SMB factor are both in their lowest quartile 
range (i.e., 1,1) 42 times during the period of study.  To determine whether this value is 
statistically higher (or lower) than it would be if the series were independent, we randomly 
reorder the second time series 1000 times.  Generally, at the 10 percent level, the values for all 
quartile combinations fall between 27 and 32 for these random pairings.  The pink (green) 
shading represent quartile intersections that are statistically higher (lower) than these 10 percent 
cutoffs.  Variables include the Fama and French (1993) factors SMB, HML, DEF, and TERM; 
the Carhart (1997) momentum (MOM) factor; and aggregate inflation (CPIAUCMO). 
  
1 2 3 4 
1 34 30 30 33 
2 29 31 30 32 
3 31 34 27 35 
4 30 31 38 27 
1 2 3 4 
1 27 35 22 43 
2 29 33 37 23 
3 28 26 49 24 
4 34 35 19 38 
1 2 3 4 
1 30 48 32 17 
2 29 23 27 43 
3 25 19 42 41 
4 40 34 25 27 
1 2 3 4 
1 32 28 26 39 
2 20 33 32 39 
3 16 29 43 38 
4 56 34 25 12 
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Table 1 
 
Panel A: Monthly Covariance/Correlation Table 
CPIMEDMO CPIAUCMO CPIHOSMO CPIUFDMO CPITRNMO 
CPIMEDMO 0.073 0.405 0.452 0.109 0.141 
CPIAUCMO 0.036 0.107 0.741 0.525 0.736 
CPIHOSMO 0.041 0.081 0.112 0.302 0.296 
CPIUFDMO 0.014 0.082 0.048 0.227 0.095 
CPITRNMO 0.040 0.253 0.104 0.047 1.103 
 
Panel B: Quarterly Covariance/Correlation Table 
CPIMEDQ CPIAUCQ CPIHOSQ CPIUFDQ CPITRNQ 
CPIMEDQ 0.462 0.580 0.632 0.261 0.275 
CPIAUCQ 0.327 0.690 0.878 0.628 0.768 
CPIHOSQ 0.372 0.631 0.748 0.499 0.484 
CPIUFDQ 0.182 0.537 0.444 1.057 0.218 
CPITRNQ 0.406 1.385 0.908 0.487 4.713 
 
Panel C: Annual Covariance/Correlation Table 
CPIMEDA CPIAUCA CPIHOSA CPIUFDA CPITRNA 
CPIMEDA 6.244 0.722 0.721 0.337 0.563 
CPIAUCA 5.108 8.010 0.966 0.727 0.817 
CPIHOSA 5.491 8.323 9.276 0.662 0.729 
CPIUFDA 2.774 6.785 6.642 10.863 0.341 
CPITRNA 7.458 12.243 11.769 5.952 28.060 
 
Table 1 shows the Pearson correlations among inflation variables at various sampling frequencies 
in the upper triangles.  Covariances are shown on the diagonal and lower triangles.  Variable 
definitions follow. 
 
CPIMEDxx: Medical Component 
CPIAUCxx: Aggregate Inflation 
CPIHOSxx: Housing Component 
CPIUFDxx: Food Component 
CPITRNxx: Transportation Component   
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Table 2 
Vector Autoregression (VAR) Estimates 
(January 1967-August 2009) 
 
 Included observations: 509 after adjustments 
 Standard errors in ( ) & t-statistics in [ ] 
  CPIMEDMO CPIAUCMO MKTRF 
CPIMEDMO(t-1) 0.235 0.065 -0.351 
   (0.040)  (0.051)  (0.944) 
  [ 5.802] [ 1.273] [-0.372] 
CPIMEDMO(t-2)  0.401  0.166 -0.619 
   (0.040)  (0.050)  (0.931) 
  [ 10.060] [ 3.298] [-0.665] 
CPIAUCMO(t-1)  0.0809  0.518 -0.556 
   (0.036)  (0.045)  (0.830) 
  [ 2.276] [ 11.565] [-0.671] 
CPIAUCMO(t-2)  0.107  0.065  0.410 
   (0.036)  (0.046)  (0.843) 
  [ 2.965] [ 1.429] [ 0.487] 
MKTRF(t-1) 0.002 0.006 0.096 
   (0.002)  (0.002)  (0.045) 
  [ 0.841] [ 2.621] [ 2.142] 
MKTRF(t-2) -0.001 0.000 -0.048 
   (0.002)  (0.002)  (0.045) 
  [-0.493] [-0.041] [-1.056] 
Constant  0.117  0.033  0.920 
   (0.021)  (0.027)  (0.492) 
  [ 5.563] [ 1.240] [ 1.869] 
 R-squared  0.473  0.425  0.016 
 Adj. R-squared  0.467  0.418  0.004 
 
 
Table 2 depicts the VAR parameters for the period January 1967 to August 2009 for the 
following model, which includes medical inflation (CPIMEDMO), aggregate inflation 
(CPIAUCMODQGWKHPDUNHW¶VUHWXUQH[FHVVRIWKHULVNIUHHUDWHMKTRF). 
ܥܲܫܯܧܦܯ ܱݐ = ߙ0 + ߙ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߙ2,݅ܥܲܫܣܷܥܯܱݐെ݅ + ߙ3,݅ܯܭܴܶܨݐെ݅ + ݑݐ        
ܥܲܫܣܷܥܯܱݐ = ߚ0 + ߚ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߚ2,݅ܥܲܫܣܷܥܯܱݐെ݅ + ߚ3,݅ܯܭܴܶܨݐെ݅ + ݒݐ       
ܯܭܴܶܨݐ = ߜ0 + ߜ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߜ2,݅ܥܲܫܣܷܥܯܱݐെ݅ + ߜ3,݅ܯܭܴܶܨݐെ݅ +ݓݐ      
 
Note i = 1, 2 for a two-lag model using the Schwarz criterion for lag length. 
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Table 3 
Variance Decomposition 
(January 1967-August 2009) 
 
Variance Decomposition of CPIMEDMO: 
Period S.E. CPIMEDMO CPIAUCMO MKTRF 
1 0.20 100.00 0.00 0.00 
2 0.21 98.98 0.88 0.13 
3 0.23 95.92 3.97 0.10 
4 0.24 93.59 6.23 0.18 
5 0.25 91.62 8.18 0.20 
6 0.25 90.16 9.60 0.25 
7 0.26 89.08 10.66 0.27 
8 0.26 88.28 11.44 0.29 
9 0.26 87.69 12.01 0.30 
10 0.27 87.25 12.44 0.31 
11 0.27 86.92 12.76 0.32 
12 0.27 86.68 13.00 0.32 
13 0.27 86.50 13.17 0.33 
14 0.27 86.36 13.31 0.33 
15 0.27 86.25 13.41 0.34 
16 0.27 86.17 13.49 0.34 
17 0.27 86.11 13.55 0.34 
18 0.27 86.07 13.59 0.34 
Variance Decomposition of CPIAUCMO: 
Period S.E. CPIMEDMO CPIAUCMO MKTRF 
1 0.25 0.74 99.26 0.00 
2 0.28 1.30 97.63 1.07 
3 0.30 3.89 94.79 1.32 
4 0.31 5.42 93.20 1.38 
5 0.31 7.05 91.57 1.38 
6 0.32 8.15 90.47 1.38 
7 0.32 9.07 89.55 1.38 
8 0.32 9.73 88.90 1.37 
9 0.32 10.24 88.39 1.37 
10 0.33 10.62 88.02 1.37 
11 0.33 10.91 87.73 1.36 
12 0.33 11.12 87.51 1.36 
13 0.33 11.29 87.35 1.36 
14 0.33 11.41 87.23 1.36 
15 0.33 11.51 87.13 1.36 
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16 0.33 11.58 87.06 1.36 
17 0.33 11.63 87.01 1.36 
18 0.33 11.67 86.97 1.36 
Variance Decomposition of MKTRF: 
Period S.E. CPIMEDMO CPIAUCMO MKTRF 
1 4.63 0.00 1.34 98.66 
2 4.65 0.03 1.49 98.48 
3 4.66 0.14 1.49 98.37 
4 4.66 0.18 1.49 98.33 
5 4.66 0.21 1.50 98.30 
6 4.66 0.22 1.50 98.27 
7 4.66 0.24 1.51 98.25 
8 4.66 0.25 1.52 98.24 
9 4.66 0.25 1.52 98.23 
10 4.66 0.26 1.53 98.22 
11 4.66 0.26 1.53 98.21 
12 4.66 0.27 1.53 98.20 
13 4.66 0.27 1.53 98.20 
14 4.66 0.27 1.53 98.20 
15 4.66 0.27 1.53 98.20 
16 4.66 0.27 1.53 98.19 
17 4.66 0.27 1.53 98.19 
18 4.66 0.27 1.54 98.19 
Cholesky Ordering: CPIMEDMO CPIAUCMO MKTRF 
 
Table 3 depicts the variance decomposition for the following VAR system for the period January 
1967 to August 2009. 
ܥܲܫܯܧܦܯܱݐ = ߙ0 + ߙ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߙ2,݅ܥܲܫܣܷܥܯܱݐെ݅ + ߙ3,݅ܯܭܴܶܨݐെ݅ + ݑݐ        
ܥܲܫܣܷܥܯܱݐ = ߚ0 + ߚ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߚ2,݅ܥܲܫܣܷܥܯܱݐെ݅ + ߚ3,݅ܯܭܴܶܨݐെ݅ + ݒݐ       
ܯܭܴܶܨݐ = ߜ0 + ߜ1,݅ܥܲܫܯܧܦܯܱݐെ݅ + ߜ2,݅ܥܲܫܣܷܥܯܱݐെ݅ + ߜ3,݅ܯܭܴܶܨݐെ݅ +ݓݐ      
 
Variables include medical inflation (CPIMEDMO), aggregate inflation (CPIAUCMO), and the 
PDUNHW¶VUHWXUQH[FHVVRIWKHULVNIUHHUDWHMKTRF).  Note i = 1, 2 for a two-lag model using the 
Schwarz criterion for lag length. 
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Table 4 
 
Panel A: Monthly Covariance/Correlation Table 
CPIMEDMO MKTRF SMB HML MOM DEF TERM 
CPIMEDMO 0.073 -0.039 0.031 0.033 0.030 -0.081 -0.080 
MKTRF -0.049 21.405 0.298 -0.340 -0.142 0.051 0.018 
SMB 0.027 4.427 10.342 -0.255 -0.027 0.070 0.061 
HML 0.027 -4.771 -2.487 9.193 -0.162 -0.042 -0.019 
MOM 0.037 -2.953 -0.387 -2.207 20.147 -0.158 -0.024 
DEF -0.016 0.175 0.166 -0.094 -0.523 0.548 0.306 
TERM -0.027 0.105 0.247 -0.074 -0.137 0.287 1.607 
 
Panel B: Quarterly Covariance/Correlation Table 
CPIMEDQ MKTRFQ SMBQ HMLQ MOMQ DEFQ TERMQ 
CPIMEDQ 0.462 -0.067 0.039 0.060 0.066 -0.098 -0.091 
MKTRFQ -0.352 59.047 0.421 -0.278 -0.134 0.039 0.057 
SMBQ 0.145 17.652 29.757 -0.249 -0.016 0.140 0.099 
HMLQ 0.211 -11.133 -7.066 27.084 -0.164 -0.073 0.037 
MOMQ 0.312 -7.155 -0.610 -5.903 48.026 -0.251 -0.081 
DEFQ -0.145 0.651 1.659 -0.828 -3.774 4.723 0.345 
TERMQ -0.224 1.577 1.947 0.692 -2.024 2.710 13.096 
 
Panel C: Annual Covariance/Correlation Table 
CPIMEDA MKTRFA SMBA HMLA MOMA DEFA TERMA 
CPIMEDA 6.244 -0.103 0.222 0.069 0.040 -0.083 -0.092 
MKTRFA -4.651 328.455 0.246 -0.272 -0.081 -0.189 0.185 
SMBA 7.093 56.794 162.802 0.085 -0.262 0.168 0.293 
HMLA 2.503 -71.086 15.697 208.432 -0.398 0.079 0.134 
MOMA 1.401 -20.567 -46.742 -80.212 195.279 -0.042 -0.257 
DEFA -1.457 -24.137 15.135 8.041 -4.184 49.665 0.330 
TERMA -3.087 45.176 50.295 26.077 -48.338 31.242 180.672 
 
Table 4 shows the Pearson correlation among various factors at various sampling frequencies in 
the upper triangles.  Covariances are shown on the diagonal and lower triangles.  Variable 
definitions follow. 
 
CPIMEDxx: Medical Component of inflation 
MKTRFxx: Value-weighted market return in excess of the risk-free rate 
SMBxx: SMB factor as described by Fama and French (1993) 
HMLxx: HML factor as described by Fama and French (1993) 
MOMxx: Momentum factor as described by Carhart (1997) 
DEFxx: Default risk premium as described by Chen, Roll, and Ross (CRR) (1986) 
TERMxx: Term risk premium as described by CRR (1986) 
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Table 5 
Vector Autoregression (VAR) Estimates 
(January 1967-August 2009) 
 
 Included observations: 509 after adjustments 
 Standard errors in ( ) & t-statistics in [ ] 
CPIMEDMO CPIAUCMO MKTRF SMB HML DEF TERM MOM 
CPIMEDMO 
(t-1) 0.447 0.174 -0.630 0.212 0.446 0.037 0.195 0.719 
-0.040 -0.044 -0.831 -0.564 -0.537 -0.034 -0.084 -0.788 
[ 11.273] [ 3.909] [-0.758] [ 0.375] [ 0.831] [ 1.080] [ 2.321] [ 0.912] 
CPIAUCMO 
(t-1) 0.199 0.502 -0.219 0.262 0.557 -0.027 -0.051 -0.410 
-0.036 -0.040 -0.750 -0.509 -0.484 -0.031 -0.076 -0.711 
[ 5.560] [ 12.530] [-0.291] [ 0.515] [ 1.151] [-0.858] [-0.671] [-0.577] 
MKTRF(t-1) 0.002 0.004 0.068 0.158 0.067 -0.014 0.018 -0.165 
-0.002 -0.003 -0.050 -0.034 -0.032 -0.002 -0.005 -0.047 
[ 0.829] [ 1.467] [ 1.359] [ 4.673] [ 2.100] [-7.009] [ 3.571] [-3.497] 
SMB(t-1) 0.004 0.006 0.088 -0.023 0.019 -0.006 0.014 0.113 
-0.003 -0.004 -0.068 -0.046 -0.044 -0.003 -0.007 -0.064 
[ 1.148] [ 1.782] [ 1.293] [-0.498] [ 0.438] [-2.010] [ 1.972] [ 1.758] 
HML(t-1) 0.006 -0.003 -0.026 0.016 0.185 -0.007 0.027 -0.145 
-0.004 -0.004 -0.076 -0.051 -0.049 -0.003 -0.008 -0.072 
[ 1.573] [-0.817] [-0.343] [ 0.316] [ 3.800] [-2.382] [ 3.548] [-2.028] 
DEF(t-1) 0.009 -0.056 0.221 0.433 -0.181 0.973 0.171 -1.139 
-0.015 -0.016 -0.307 -0.208 -0.198 -0.013 -0.031 -0.291 
[ 0.632] [-3.417] [ 0.719] [ 2.081] [-0.915] [ 76.957] [ 5.531] [-3.915] 
TERM(t-1) -0.002 -0.026 0.021 0.039 0.137 -0.009 0.888 0.105 
-0.008 -0.009 -0.174 -0.118 -0.113 -0.007 -0.018 -0.165 
[-0.240] [-2.747] [ 0.122] [ 0.327] [ 1.217] [-1.187] [ 50.462] [ 0.636] 
MOM(t-1) 0.000 -0.002 -0.004 -0.027 -0.023 0.007 -0.002 0.004 
-0.002 -0.003 -0.048 -0.033 -0.031 -0.002 -0.005 -0.046 
[ 0.090] [-0.910] [-0.077] [-0.839] [-0.732] [ 3.428] [-0.342] [ 0.097] 
Constant 0.191 0.252 0.276 -0.982 0.048 0.068 -0.261 2.760 
-0.040 -0.045 -0.839 -0.569 -0.542 -0.035 -0.085 -0.795 
[ 4.775] [ 5.614] [ 0.329] [-1.726] [ 0.088] [ 1.969] [-3.086] [ 3.470] 
R-squared 0.348 0.438 0.018 0.062 0.045 0.935 0.866 0.062 
Adj. R-
squared 0.338 0.429 0.002 0.047 0.030 0.934 0.864 0.047 
 
Table 5 depicts the VAR parameters for the period January 1967 to August 2009 for the 
following model. 
 
ܼݐ = ߁ܼݐെ1 + ݑݐ      
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ܼݐ  is a (8 x 1) state vector that includes medical inflation (CPIMEDMO), aggregate inflation 
(CPIAUCMO), market excess return over the risk-free rate (MKTRF), SMB, HML, MOM, DEF, 
and TERM, ߁ represents the (8 x 8) matrix of parameters, and ݑݐ  is the (8 x 1) vector of error 
terms for each respective variable in the state vector.  Note this model uses one-lag based on the 
Schwarz criterion for lag length. 
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Table 6 
Variance Decomposition 
(January 1967-August 2009) 
 
Variance Decomposition of CPIMEDMO: 
Period S.E. CPIMEDMO CPIAUCMO MKTRF SMB HML DEF TERM MOM 
1 0.221 100.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 0.250 95.776 3.657 0.068 0.100 0.389 0.007 0.001 0.001 
3 0.262 92.665 6.387 0.276 0.173 0.466 0.011 0.013 0.009 
4 0.267 90.976 7.845 0.422 0.212 0.474 0.012 0.043 0.016 
5 0.269 90.128 8.555 0.498 0.230 0.472 0.012 0.086 0.020 
6 0.271 89.696 8.889 0.535 0.237 0.470 0.013 0.137 0.023 
7 0.271 89.462 9.046 0.555 0.241 0.469 0.015 0.188 0.024 
8 0.271 89.321 9.119 0.567 0.242 0.468 0.022 0.235 0.026 
9 0.271 89.226 9.152 0.575 0.243 0.468 0.033 0.276 0.027 
10 0.272 89.153 9.167 0.581 0.243 0.468 0.049 0.311 0.028 
11 0.272 89.091 9.172 0.587 0.244 0.467 0.071 0.338 0.029 
12 0.272 89.035 9.173 0.593 0.244 0.467 0.097 0.360 0.031 
13 0.272 88.982 9.172 0.599 0.244 0.467 0.128 0.377 0.032 
14 0.272 88.930 9.169 0.605 0.244 0.467 0.163 0.389 0.033 
15 0.272 88.878 9.165 0.612 0.244 0.467 0.201 0.398 0.034 
16 0.272 88.827 9.161 0.619 0.244 0.467 0.242 0.405 0.036 
17 0.272 88.776 9.157 0.626 0.245 0.467 0.283 0.409 0.037 
18 0.272 88.726 9.152 0.633 0.245 0.467 0.326 0.412 0.038 
Variance Decomposition of CPIAUCMO: 
Period S.E. CPIMEDMO CPIAUCMO MKTRF SMB HML DEF TERM MOM 
1 0.248 2.529 97.471 0.000 0.000 0.000 0.000 0.000 0.000 
2 0.285 6.154 91.923 1.033 0.544 0.038 0.041 0.145 0.122 
3 0.299 7.885 89.131 1.639 0.652 0.035 0.109 0.387 0.163 
4 0.305 8.543 87.757 1.912 0.693 0.036 0.214 0.660 0.185 
5 0.308 8.732 86.963 2.068 0.709 0.039 0.362 0.925 0.202 
6 0.310 8.742 86.394 2.173 0.716 0.042 0.557 1.161 0.216 
7 0.311 8.695 85.905 2.255 0.719 0.044 0.796 1.357 0.229 
8 0.312 8.638 85.439 2.324 0.720 0.046 1.077 1.514 0.242 
9 0.313 8.585 84.978 2.388 0.721 0.049 1.392 1.634 0.254 
10 0.314 8.539 84.516 2.450 0.721 0.051 1.736 1.722 0.266 
11 0.315 8.499 84.054 2.510 0.721 0.054 2.101 1.784 0.277 
12 0.316 8.463 83.594 2.571 0.721 0.056 2.480 1.825 0.289 
13 0.317 8.429 83.141 2.632 0.721 0.059 2.867 1.851 0.301 
14 0.318 8.396 82.696 2.693 0.722 0.063 3.255 1.865 0.312 
67 
 
 
 
 
15 0.318 8.364 82.262 2.754 0.722 0.066 3.639 1.870 0.323 
16 0.319 8.333 81.843 2.814 0.723 0.069 4.015 1.870 0.333 
17 0.320 8.302 81.440 2.873 0.724 0.073 4.380 1.866 0.343 
18 0.321 8.271 81.055 2.930 0.725 0.076 4.731 1.860 0.353 
Variance Decomposition of MKTRF: 
Period S.E. CPIMEDMO CPIAUCMO MKTRF SMB HML DEF TERM MOM 
1 4.631 0.013 1.399 98.588 0.000 0.000 0.000 0.000 0.000 
18 4.670 0.150 1.488 97.797 0.354 0.025 0.176 0.003 0.007 
Variance Decomposition of SMB: 
Period S.E. CPIMEDMO CPIAUCMO MKTRF SMB HML DEF TERM MOM 
1 3.142 0.123 0.036 8.176 91.665 0.000 0.000 0.000 0.000 
18 3.241 0.157 0.054 12.536 86.264 0.057 0.777 0.008 0.146 
Variance Decomposition of HML: 
Period S.E. CPIMEDMO CPIAUCMO MKTRF SMB HML DEF TERM MOM 
1 2.989 0.096 0.190 11.858 3.581 84.276 0.000 0.000 0.000 
18 3.061 0.378 0.551 11.779 3.460 83.385 0.174 0.156 0.117 
Variance Decomposition of DEF: 
Period S.E. CPIMEDMO CPIAUCMO MKTRF SMB HML DEF TERM MOM 
1 0.191 0.081 1.864 0.036 0.281 0.415 97.323 0.000 0.000 
18 0.682 0.656 1.121 14.014 1.131 0.894 79.235 0.940 2.008 
Variance Decomposition of TERM: 
Period S.E. CPIMEDMO CPIAUCMO MKTRF SMB HML DEF TERM MOM 
1 0.468 0.001 0.192 0.296 0.071 2.851 16.687 79.903 0.000 
18 1.080 3.938 0.875 3.094 0.386 0.744 22.237 68.144 0.582 
Variance Decomposition of MOM: 
Period S.E. CPIMEDMO CPIAUCMO MKTRF SMB HML DEF TERM MOM 
1 4.390 0.004 0.208 1.684 0.360 4.435 0.005 0.022 93.283 
18 4.524 0.166 0.220 3.214 1.304 5.083 2.012 0.109 87.893 
Cholesky Ordering:  CPIMEDMO CPIAUCMO MKTRF SMB HML DEF TERM MOM 
 
Table 6 depicts the variance decomposition for the following VAR system for the period January 
1967 to August 2009. 
ܼݐ = ߁ܼݐെ1 + ݑݐ      
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ܼݐ  is a (8 x 1) state vector that includes medical inflation (CPIMEDMO), aggregate inflation 
(CPIAUCMO), market excess return over the risk-free rate (MKTRF), SMB, HML, MOM, DEF, 
and TERM, ߁ represents the (8 x 8) matrix of parameters, and ݑݐ  is the (8 x 1) vector of error 
terms for each respective variable in the state vector.  Note this model uses one-lag based on the 
Schwarz criterion for lag length.  
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Table 8 
Panel A 
Fama-MacBeth (1973) Second-Pass Cross-Sectional Results for Priced Factors 
 (January 1967-August 2009) 
 
  Parameter Parameter Parameter Parameter Parameter Parameter Parameter 
  P-value P-value P-value P-value P-value P-value P-value 
Constant 1.092 0.802 0.673 0.723 0.481 0.770 0.390 
  0.000 0.001 0.009 0.001 0.031 0.001 0.075 
MKTRF -0.577 
  0.097 
EXPMED 0.032 0.046 
  0.035 0.004 
¨EXPMED 0.009 0.038 
  0.648 0.028 
UNEXPMED 0.099 0.087 0.048 0.047 
  0.002 0.006 0.050 0.077 
EXPINF 0.009 -0.010 
  0.714 0.607 
¨EXPINF -0.010 -0.006 
  0.187 0.323 
UNEXPINF -0.007 0.025 -0.028 0.008 
  0.779 0.314 0.246 0.736 
N= 452 452 452 452 452 452 452 
 
 
Table 8, Panel A depicts results from the second-pass of the Fama-MacBeth (1973) rolling 
regression procedure to assess priced risk factors in stock returns for multiple model 
specifications.  Test assets are the 25 Fama-French quintile-sorted size and book-to-market 
portfolios.  Shading indicates a coefficient significant at the 10% level (or p-value < 0.10).  
MKTRF is the market return net of the risk-IUHHUDWHWDNHQIURP.HQ)UHQFK¶V'DWD/LEUDU\
EXPMED (UNEXPMED) is the expected (unexpected) component of medical inflation as 
determined by a state space model described in Fama and Gibbons (1982).  ¨(;30(D is the 
first-differenced series (i.e., time t minus time t-1) of medical inflation.  Definitions for aggregate 
inflation (EXPINF, ¨EXPINF, and UNEXPINF) are analogous to those of medical inflation.  
7KHVHGDWDVHULHVRFFXUVEHWZHHQ-DQXDU\DQG$XJXVWIRUPRQWKV¶ZRUWKRIGDWD
The second-pass results in 452 data points due to the initial 60-month beta formation period. 
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Table 8 
Panel B 
First-Pass Regression Results 
(January 1967-August 2009) 
 
Constant T-Stat ȕMKTRF T-Stat 
Adjusted 
R-Squared 
Size (Small) 
B/M (Low) -0.449 -2.022 1.445 30.243 0.641 
B/M 2 0.254 1.318 1.230 29.681 0.633 
B/M 3 0.341 2.131 1.084 31.543 0.660 
B/M 4 0.556 3.590 1.005 30.208 0.641 
B/M (High) 0.630 3.694 1.060 28.908 0.620 
Size 2 
B/M (Low) -0.228 -1.357 1.414 39.214 0.750 
B/M 2 0.147 1.092 1.167 40.482 0.762 
B/M 3 0.437 3.485 1.043 38.753 0.746 
B/M 4 0.493 3.933 0.993 36.887 0.727 
B/M (High) 0.506 3.262 1.086 32.570 0.675 
Size 3 
B/M (Low) -0.181 -1.300 1.348 45.075 0.799 
B/M 2 0.208 2.021 1.108 50.195 0.831 
B/M 3 0.298 2.841 0.985 43.660 0.789 
B/M 4 0.405 3.651 0.922 38.651 0.745 
B/M (High) 0.604 4.313 1.004 33.359 0.685 
Size 4 
B/M (Low) -0.029 -0.279 1.234 54.308 0.852 
B/M 2 0.017 0.199 1.082 57.438 0.866 
B/M 3 0.216 2.188 1.012 47.723 0.817 
B/M 4 0.355 3.444 0.936 42.254 0.777 
B/M (High) 0.362 2.706 1.021 35.492 0.711 
Size (Big) 
B/M (Low) -0.046 -0.597 0.991 59.417 0.874 
B/M 2 0.081 1.073 0.935 57.850 0.868 
B/M 3 0.031 0.340 0.871 43.827 0.790 
B/M 4 0.135 1.237 0.814 34.722 0.702 
B/M (High) 0.243 1.743 0.847 28.262 0.610 
 
Table 8, Panel B shows results for the Fama-MacBeth (1973) first-pass regression for the 
following model. 
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ܴ݌ ,ݐ = ߙ0 +෍ߚ݌ ,݅ ܼ݅ ,ݐ
݇
݅=1
+ ݑݐ      
 
where ܴ݌ ,ݐ  is the month t excess return on portfolio p, p  «t represents time, k represents 
the number of factors, and ܼ݅  represents a factor used to explain returns.  ߚ݌ ,݅  represents a 
portfolio-specific parameter estimated in the model and is calculated as the covariance of the 
factor and portfolio return normalized by the variance of the factor (i.e., ߚ݌ ,݅ = ܿ݋ݒ(ܴ݌ ,݅ , ܼ݅)/
ݒܽݎ( ܼ݅)).  For this specification, the portfolios p are the Fama and French size- and book-to-
market sorted quintiles, t represents the 512 months spanning from January 1967 to August 2009, 
and the only factor is the market return in excess of the risk-free rate (MKTRF).  Shading 
indicates parameters that are significant at conventional (90 percent) level. 
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Table 8 
Panel C 
First-Pass Regression Results 
(January 1967-August 2009) 
 
Constant T-Stat ȕEXPMED T-Stat 
ȕUNEXPMED 
KALMAN T-Stat 
Adjusted 
R-Squared 
Size (Small) 
B/M (Low) 0.767 0.617 -1.314 -0.568 -0.659 -0.295 -0.003 
B/M 2 1.439 1.354 -1.420 -0.718 -1.132 -0.594 -0.002 
B/M 3 1.087 1.186 -0.673 -0.394 -0.702 -0.427 -0.003 
B/M 4 1.172 1.361 -0.483 -0.301 -0.571 -0.369 -0.004 
B/M (High) 1.170 1.262 -0.283 -0.164 -0.032 -0.019 -0.004 
Size 2 
B/M (Low) 1.218 1.081 -1.757 -0.839 -1.182 -0.585 -0.002 
B/M 2 0.912 0.990 -0.620 -0.361 -1.252 -0.757 -0.003 
B/M 3 1.722 2.076 -1.739 -1.127 -0.639 -0.429 -0.001 
B/M 4 0.978 1.223 -0.222 -0.149 -1.341 -0.934 -0.002 
B/M (High) 0.787 0.866 0.247 0.146 -0.946 -0.581 -0.003 
Size 3 
B/M (Low) 1.488 1.432 -2.241 -1.159 -0.877 -0.470 -0.001 
B/M 2 1.165 1.389 -1.033 -0.662 -0.842 -0.560 -0.002 
B/M 3 1.226 1.604 -1.067 -0.750 -1.383 -1.008 -0.001 
B/M 4 0.926 1.259 -0.322 -0.236 -1.435 -1.088 -0.002 
B/M (High) 1.129 1.349 -0.268 -0.172 -0.513 -0.341 -0.004 
Size 4 
B/M (Low) 1.590 1.722 -2.210 -1.287 -1.476 -0.891 0.001 
B/M 2 1.206 1.501 -1.469 -0.982 -1.612 -1.118 0.000 
B/M 3 0.963 1.246 -0.680 -0.472 -1.345 -0.969 -0.002 
B/M 4 1.152 1.573 -0.842 -0.618 -1.348 -1.025 -0.001 
B/M (High) 0.365 0.437 0.767 0.494 -1.363 -0.909 -0.002 
Size (Big) 
B/M (Low) 1.600 2.187 -2.447 -1.798 -0.970 -0.739 0.003 
B/M 2 1.131 1.629 -1.323 -1.024 -0.667 -0.535 -0.001 
B/M 3 0.704 1.036 -0.625 -0.495 -0.370 -0.304 -0.003 
B/M 4 0.233 0.347 0.442 0.354 -1.237 -1.027 -0.002 
B/M (High) 1.231 1.648 -1.288 -0.927 -0.387 -0.289 -0.002 
 
Table 8, Panel C shows results for the Fama-MacBeth (1973) first-pass regression for the 
following model. 
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ܴ݌ ,ݐ = ߙ0 +෍ߚ݌ ,݅ ܼ݅ ,ݐ
݇
݅=1
+ ݑݐ      
 
where ܴ݌ ,ݐ  is the month t excess return on portfolio p, p  «t represents time, k represents 
the number of factors, and ܼ݅  represents a factor used to explain returns.  ߚ݌ ,݅  represents a 
portfolio-specific parameter estimated in the model and is calculated as the covariance of the 
factor and portfolio return normalized by the variance of the factor (i.e., ߚ݌ ,݅ = ܿ݋ݒ(ܴ݌ ,݅ , ܼ݅)/
ݒܽݎ( ܼ݅)).  For this specification, the portfolios p are the Fama and French size- and book-to-
market sorted quintiles, t represents the 512 months spanning from January 1967 to August 2009, 
and the factors k  are expected and unexpected medical inflation (EXPMED and 
UNEXPMEDKALMAN, respectively).  Shading indicates parameters that are significant at 
conventional (90 percent) level. 
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Table 8 
Panel D 
 
Jan 72-Aug 09 Jan 72-Dec 84 Jan 85-Aug 09 
Parameter Parameter Parameter 
Variable P-Value P-Value P-Value 
Constant 0.770 0.377 0.977 
  0.001 0.318 0.001 
EXPMED 0.046 0.100 0.018 
  0.004 0.008 0.206 
UNEXPMED 0.048 0.207 -0.035 
  0.050 0.001 0.031 
EXPINF -0.010 -0.085 0.030 
  0.607 0.067 0.073 
UNEXPINF -0.028 -0.133 0.027 
  0.246 0.003 0.355 
N= 452 156 296 
 
Table 8, Panel D depicts results from the second-pass of the Fama-MacBeth (1973) rolling 
regression procedure to assess priced risk factors in stock returns for multiple model 
specifications.  Test assets are the 25 Fama-French quintile-sorted size and book-to-market 
portfolios.  Coefficients significant at the 10% level (or p-value < 0.10) are shaded.  EXPMED 
(UNEXPMED) is the expected (unexpected) component of medical inflation as determined by a 
state space model described in Fama and Gibbons (1982).  Definitions for aggregate inflation 
(EXPINF and UNEXPINF) are analogous to those of medical inflation.  These data series occurs 
EHWZHHQ-DQXDU\DQG$XJXVWIRUPRQWKV¶ZRUWKRIGDWD7KHVHFRQG-pass results 
for the first specification containts 452 data points due to the initial 60-month beta formation 
period.  The second and third specifications depict results when the sample entire sample is split 
into two time periods. 
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Table 9 
Panel A 
Fama-MacBeth (1973) Second-Pass Cross-Sectional Results for Priced Factors-Chen, Roll, 
and Ross (1986) Mactoreconomic Factors 
(January 1967-August 2009) 
 
  Parameter Parameter Parameter Parameter Parameter 
  P-value P-value P-value P-value P-value 
Constant 0.802 0.769 1.391 0.865 1.435 
  0.002 0.001 0.000 0.001 0.000 
EXPMED 0.033 0.019 
  0.019 0.169 
UNEXPMED 0.054 0.052 
  0.028 0.021 
CPIMED 0.078 0.065 
  0.014 0.026 
MKTRF -1.033 -1.078 
  0.000 0.000 
INDPRO -0.154 -0.121 0.008 -0.102 -0.025 
  0.139 0.201 0.930 0.310 0.787 
¨EXPINF -0.003 -0.006 -0.007 -0.001 -0.004 
  0.612 0.181 0.155 0.791 0.463 
UNEXPINF 0.011 -0.008 -0.023 0.011 -0.013 
  0.606 0.678 0.312 0.565 0.554 
DEF -0.129 -0.083 -0.075 -0.106 -0.070 
  0.043 0.171 0.188 0.093 0.241 
TERM 0.080 0.239 0.351 0.084 0.182 
  0.585 0.090 0.007 0.549 0.147 
N= 452 452 452 452 452 
 
Table 9, Panel A depicts results from the second-pass of the Fama-MacBeth (1973) rolling 
regression procedure to assess priced risk factors in stock returns for multiple model 
specifications.  Test assets are the 25 Fama-French quintile-sorted size and book-to-market 
portfolios.  Coefficients significant at the 10% level (or p-value < 0.10) are shaded.  EXPMED 
(UNEXPMED) is the expected (unexpected) component of medical inflation as determined by a 
state space model described in Fama and Gibbons (1982).  MKTRF is the market return net of the 
risk-free rate (taken from Ken French¶V'DWD/LEUDU\,1'352LVWKHPRQWKO\FKDQJHLQ
Industrial Production.  ¨(;3INF is the first-differenced series (i.e., time t minus time t-1) of 
aggregate inflation.  UNEXPINF is analagous to UNEXPMEDINF but for aggregate inflation.  
DEF is the difference between the 10-year Treasury bond and a portfolio of Baa corporate bonds.  
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TERM is the difference between the 10-year Treasury bond and the 90-day Treasury bill.  These 
GDWDVHULHVRFFXUVEHWZHHQ-DQXDU\DQG$XJXVWIRUPRQWKV¶ZRUWKRIGDta.  The 
second-pass results in 452 data points due to the initial 60-month beta formation period. 
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Table 9 
Panel B 
Fama-MacBeth (1973) Second-Pass Cross-Sectional Results for Priced Factors-Chen, Roll, 
and Ross (1986) Mactoreconomic Factors, Divided Sample 
(January 1967-August 2009) 
 
Table 9, Panel A, Column 3 
(Specification 2) 
Table 9, Panel A, Column 4 
(Specification 3) 
Jan 72- 
Aug 09 
Jan 72- 
Dec 84 
Jan 85- 
Aug 09 
Jan 72- 
Aug 09 
Jan 72- 
Dec 84 
Jan 85- 
Aug 09 
  Parameter Parameter Parameter Parameter Parameter Parameter 
  P-Value P-Value P-Value P-Value P-Value P-Value 
Constant 0.769 0.107 1.118 1.391 0.778 1.715 
  0.001 0.794 0.000 0.000 0.080 0.000 
EXPMED 0.033 0.059 0.019 0.019 0.033 0.011 
  0.019 0.055 0.170 0.169 0.275 0.406 
UNEXPMED 0.054 0.216 -0.032 0.052 0.206 -0.029 
  0.028 0.001 0.045 0.021 0.000 0.072 
MKTRF -1.033 -0.672 -1.222 
  0.000 0.198 0.001 
INDPRO -0.121 -0.360 0.005 0.008 0.006 0.009 
  0.201 0.113 0.955 0.930 0.976 0.922 
¨EXPINF -0.006 -0.006 -0.006 -0.007 -0.007 -0.007 
  0.181 0.485 0.247 0.155 0.442 0.225 
UNEXPINF -0.008 -0.048 0.012 -0.023 -0.080 0.008 
  0.678 0.190 0.606 0.312 0.057 0.771 
DEF -0.083 0.033 -0.143 -0.075 0.027 -0.128 
  0.171 0.801 0.020 0.188 0.810 0.042 
TERM 0.239 -0.301 0.523 0.351 -0.024 0.549 
  0.090 0.194 0.003 0.007 0.906 0.001 
N= 452 156 296 452 156 296 
 
Table 9, Panel B depicts results from the second-pass of the Fama-MacBeth (1973) rolling 
regression procedure to assess priced risk factors in stock returns for multiple model 
specifications.  Test assets are the 25 Fama-French quintile-sorted size and book-to-market 
portfolios.  Coefficients significant at the 10% level (or p-value < 0.10) are shaded.  EXPMED 
(UNEXPMED) is the expected (unexpected) component of medical inflation as determined by a 
state space model described in Fama and Gibbons (1982).  MKTRF is the market return net of the 
risk-free rate (taken from Ken French¶V'DWD/LEUDU\,1'352LVWKHPRQWKO\FKDQJHLQ
Industrial Production.  ¨(;3INF is the first-differenced series (i.e., time t minus time t-1) of 
aggregate inflation.  UNEXPINF is analagous to UNEXPMEDINF but for aggregate inflation.  
DEF is the difference between the 10-year Treasury bond and a portfolio of Baa corporate bonds.  
TERM is the difference between the 10-year Treasury bond and the 90-day Treasury bill.  These 
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GDWDVHULHVRFFXUVEHWZHHQ-DQXDU\DQG$XJXVWIRUPRQWKV¶ZRUWKRIGDta.  The 
second-pass results in 452 data points due to the initial 60-month beta formation period.  The 
second, third, fifth, and sixth specifications depict results when the sample entire sample is split 
into two time periods.  
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Table 10 
Panel A 
Fama-MacBeth (1973) Second-Pass Cross-Sectional Results for Priced Factors-Flannery & 
Protopapadakis (2002) Mactoreconomic Factors 
(January 1967- August 2009) 
 
  Parameter Parameter Parameter Parameter Parameter 
  P-Value P-Value P-Value P-Value P-Value 
Constant 0.592 0.732 1.035 1.246 1.152 
  0.012 0.002 0.000 0.000 0.000 
EXPMED 0.036 0.039 
  0.008 0.005 
UNEXPMED 0.044 0.056 
  0.042 0.010 
CPIMED 0.083 0.077 
  0.011 0.009 
EXPINF 0.040 
  0.011 
¨EXPINF 0.002 -0.003 -0.001 0.003 
  0.765 0.614 0.793 0.624 
UNEXPINF 0.014 -0.003 0.007 -0.007 -0.009 
  0.541 0.908 0.764 0.769 0.708 
PPIAgg 0.123 0.105 0.118 0.062 0.052 
  0.118 0.243 0.166 0.473 0.575 
PPICrude -0.089 0.015 0.414 
  0.794 0.969 0.271 
M1 -0.081 -0.149 -0.076 -0.035 -0.022 
  0.162 0.016 0.187 0.535 0.703 
M2 -0.127 -0.156 -0.095 -0.088 -0.079 
  0.002 0.000 0.010 0.010 0.024 
HOUST -2.234 -1.906 -1.721 -1.977 -1.238 
  0.014 0.034 0.060 0.031 0.166 
MKTRF -0.716 -0.906 -0.797 
  0.011 0.002 0.008 
N= 452 452 452 452 452 
 
Table 10, Panel A depicts results from the second-pass of the Fama-MacBeth (1973) rolling 
regression procedure to assess priced risk factors in stock returns for multiple model 
specifications.  Test assets are the 25 Fama-French quintile-sorted size and book-to-market 
portfolios.  Coefficients significant at the 10% level (or p-value < 0.10) are shaded.  EXPMED 
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(UNEXPMED) is the expected (unexpected) component of medical inflation as determined by a 
state space model described in Fama and Gibbons (1982).  CPIMED is aggregate medical 
inflation, or the sum of expected and unexpected medical inflation.  ¨(;3,1)LVWKHILUVW-
differenced series (i.e., time t minus time t-1) of aggregate inflation.  UNEXPINF is analagous to 
UNEXPMEDINF for aggregate inflation.  PPIAgg (PPICrude) is the monthly change in Producer 
Price Index for all commodities (crude materials).  M1 (M2) is the monthly change in M1 (M2) 
Money Stock, seasonally adjusted.  HOUST is the monthly change in total new housing starts.  
The prior 5 series come from the St. Louis Federal Reserve Federal Reserve Economic Database 
(FRED).  MKTRF is the market return net of the risk-free rate IURP.HQ)UHQFK¶V'DWD/LEUDU\  
These data series occurs between January 1967 and $XJXVWIRUPRQWKV¶ZRUWKRIGDWD
The second-pass results in 452 data points due to the initial 60-month beta formation period. 
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Table 10 
Panel B 
Fama-MacBeth (1973) Second-Pass Cross-Sectional Results for Priced Factors-Flannery & 
Protopapadakis (2002) Macroeconomic Factors, Divided Sample 
(January 1967- August 2009) 
 
Table 10, Panel A, Specification 4 
Jan 72-Aug 09 Jan 72-Dec 84 Jan 85-Aug 09 
  Parameter Parameter Parameter 
  P-Value P-Value P-Value 
Constant 1.246 0.914 1.420 
  0.000 0.054 0.000 
EXPMED 0.036 0.080 0.013 
  0.008 0.012 0.287 
UNEXPMED 0.044 0.184 -0.030 
  0.042 0.001 0.035 
CPIMED 
  
EXPINF 
  
¨EXPINF -0.001 -0.003 0.000 
  0.793 0.741 0.966 
UNEXPINF -0.007 -0.069 0.026 
  0.769 0.090 0.358 
PPI (Agg) 0.062 -0.178 0.189 
  0.473 0.308 0.048 
PPI (Crude) 
  
M1 -0.035 0.007 -0.057 
  0.535 0.927 0.456 
M2 -0.088 -0.112 -0.075 
  0.010 0.081 0.060 
HOUST -1.977 -0.805 -2.594 
  0.031 0.625 0.018 
MKTRF -0.906 -0.794 -0.966 
  0.002 0.136 0.005 
N= 452 156 296 
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Table 10, Panel B depicts results from the second-pass of the Fama-MacBeth (1973) rolling 
regression procedure to assess priced risk factors in stock returns for multiple model 
specifications.  Test assets are the 25 Fama-French quintile-sorted size and book-to-market 
portfolios.  Coefficients significant at the 10% level (or p-value < 0.10) are shaded.  EXPMED 
(UNEXPMED) is the expected (unexpected) component of medical inflation as determined by a 
state space model described in Fama and Gibbons (1982).  CPIMED is aggregate medical 
inflation, or the sum of expected and unexpected medical inflation.  ¨(;3,1)LVWKHILUVW-
differenced series (i.e., time t minus time t-1) of aggregate inflation.  UNEXPINF is analagous to 
UNEXPMEDINF for aggregate inflation.  PPIAgg (PPICrude) is the monthly change in Producer 
Price Index for all commodities (crude materials).  M1 (M2) is the monthly change in M1 (M2) 
Money Stock, seasonally adjusted.  HOUST is the monthly change in total new housing starts.  
The prior 5 series come from the St. Louis Federal Reserve Federal Reserve Economic Database 
(FRED).  MKTRF is the market return net of the risk-free rate IURP.HQ)UHQFK¶V'DWD/LEUDU\  
These data series occur between January 1967 and $XJXVWIRUPRQWKV¶ZRUWKRIGDWD
The second-pass results in 452 data points due to the initial 60-month beta formation period.  The 
second and third specifications depict results when the sample entire sample is split into two time 
periods. 
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Table 11 
Panel B 
Fama-MacBeth (1973) Second-Pass Cross-Sectional Results for Priced Factors-Statistical 
Factors, Divided Sample 
(January 1967-August 2009) 
 
Table 11, Panel A, Specification 8 
Jan 72-Aug 09 Jan 72-Dec 84 Jan 85-Aug 09 
  Parameter Parameter Parameter 
  P-Value P-Value P-Value 
Constant 1.261 0.627 1.595 
  0.000 0.230 0.000 
EXPMED 0.039 0.078 0.018 
  0.002 0.003 0.152 
UNEXPMED 0.002 0.079 -0.039 
  0.918 0.105 0.008 
MKTRF -0.930 -0.538 -1.136 
  0.001 0.325 0.001 
SMB 0.097 0.258 0.013 
  0.511 0.277 0.946 
HML 0.488 0.798 0.324 
  0.001 0.001 0.085 
DEF -0.078 0.056 -0.149 
  0.151 0.566 0.021 
TERM 0.292 -0.076 0.486 
  0.021 0.720 0.002 
MOM -0.395 -0.263 -0.464 
  0.193 0.498 0.264 
N= 452 156 296 
 
Table 11, Panel B depicts results from the second-pass of the Fama-MacBeth (1973) rolling 
regression procedure to assess priced risk factors in stock returns for multiple model 
specifications.  Test assets are the 25 Fama-French quintile-sorted size and book-to-market 
portfolios.  Coefficients significant at the 10% level (or p-value < 0.10) are shaded.  EXPMED 
(UNEXPMED) is the expected (unexpected) component of medical inflation as determined by a 
state space model described in Fama and Gibbons (1982).  MKTRF is the market return net of the 
risk-free rate.  SMB is calculated by subtracting the return of the decile of the largest stocks²by 
market capitalization²from the decile of smallest stocks.  HML is calculated by subtracting the 
return of the stock decile having the lowest book-to-market equity ration from the decile with the 
highest book-to-market ratio.  See Fama and French (1993) for additional details regarding 
87 
 
 
 
 
MKTRF, SMB, and HML.  DEF is the difference between the 10-year Treasury bond and a 
portfolio of Baa corporate bonds.  TERM is the difference between the 10-year Treasury bond 
and the 90-day Treasury bill.  MOM is a momentum factor found by subtracting the returns of a 
stock portfolio having the lowest recent returns from a portfolio having the highest recent returns.  
0.75)60%+0/DQG020FRPHIURP.HQ)UHQFK¶V Data Library.  These data series 
RFFXUVEHWZHHQ-DQXDU\DQG$XJXVWIRUPRQWKV¶ZRUWKRIGDWD7KHVHFRQG-pass 
results in 452 data points due to the initial 60-month beta formation period.  The second and third 
specifications depict results when the sample entire sample is split into two time periods. 
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Table 12 
Panel B 
Fama-MacBeth (1973) Second-Pass Cross-Sectional Results for Priced Factors, 
with Divided Sample 
 (January 1967-December 2008) 
 
Jan 77-Dec 08 Jan 77-Dec 84 Jan 85-Dec 08 
Parameter Parameter Parameter 
P-value P-value P-value 
CONSTANT 1.442 0.124 1.882 
0.000 0.801 0.000 
MedHML -0.006 -0.006 -0.006 
0.039 0.180 0.096 
MKTRF -1.021 -0.225 -1.286 
0.002 0.757 0.000 
SMB 0.082 0.270 0.019 
0.642 0.449 0.926 
HML 0.539 0.709 0.483 
0.001 0.015 0.015 
DEF 0.108 0.121 0.103 
0.101 0.461 0.133 
TERM 0.103 0.047 0.122 
0.466 0.865 0.460 
MOM 1.393 0.569 1.667 
0.000 0.295 0.000 
N= 384 96 288 
 
Table 9, Panel B depicts results from the second-pass of the Fama-MacBeth (1973) rolling 
regression procedure to assess priced risk factors in stock returns for multiple model 
specifications.  Test assets are the 25 Fama-French quintile-sorted size and book-to-market 
portfolios.  Coefficients significant at the 10% level (or p-value < 0.10) are shaded.  MedHML is 
the return formed by subtracting the returns of a portfolio having a low beta with medical 
inflation from the returns of a portfolio having a high beta with medical inflation.  These 
portfolios are formed by sorting individual stocks into quintiles based on their medical inflation 
beta.  MKTRF is the market return net of the risk-free rate.  SMB is calculated by subtracting the 
return of the decile of the largest stocks²by market capitalization²from the decile of smallest 
stocks.  HML is calculated by subtracting the return of the stock decile having the lowest book-
to-market equity ration from the decile with the highest book-to-market ratio.  See Fama and 
French (1993) for additional details regarding MKTRF, SMB, and HML.  DEF is the difference 
between the 10-year Treasury bond and a portfolio of Baa corporate bonds.  TERM is the 
difference between the 10-year Treasury bond and the 90-day Treasury bill.  MOM is a 
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momentum factor found by subtracting the returns of a stock portfolio having the lowest recent 
returns from a portfolio having the highest recent returns.  MKTRF, SMB, HML, and MOM 
FRPHIURP.HQ)UHQFK¶V'DWD/LEUDU\These data series occur between January 1967 and 
December 2008, for 504 PRQWKV¶ZRUWKRIGDWDPRQWKV¶RIGDWDDUHXVHGWRJHQHUDWHWKH
medical inflation surprise beta coefficient to create deciles, leaving 444 months for the two-pass 
method.  The second-pass in this case results in 384 data points due to the initial 60-month beta 
formation period.  The second and third specifications depict results when the entire sample is 
split into two time periods. 
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Appendix C: 
Using State Space Models to Disentangle Expected and Unexpected Inflation 
 
The Kalman filter model is a state-space representation where model parameters are 
continually updated to reflect new information.  The model establishes dynamic parameter values 
and facilitates finite-sample forecasts.  This Appendix presents a brief summary of the topic, 
which follows Hamilton (1994a), to which the reader is referred for a more extensive treatment. 
 
The generic state-space representation of the dynamics of an observed variable y 
associated with an unobserved variable ɗ is given by the following system. 
 
ɗt+1 = Fɗt + vt+1  (1) 
 
yt = A
Ԣxt +  H
Ԣɗt + wt   (2) 
 
ZKHUH)$¶DQG+¶DUHPDWULFHVDQGxt  is a vector of exogenous variables, which could include 
lagged values of y if uncorrelated with ɗ and w at all leads and lags.  Equation (1) represents the 
state or transition equation; equation (2) the observation or measurement equation.  The two error 
series v and w are shocks to the respective transition process and measurement equation, 
respectively, and represent white noise.  Assumptions in this model are that the error terms are 
uncorrelated at all lags, x is uncorrelated with all lags of ɗ DQGZDQGWKHV\VWHP¶VREVHUYDWLRQV
are a finite series with the first unobservable state ɗ  uncorrelated with all subsequent shock (i.e., 
v and w) values. 
 
 Given this general setup, Fama and Gibbons (1982) investigate the unobservable ex ante 
real interest rate, ɗ, which is a function of the nominal interest rate (i.e., lagged Treasury bill), i, 
inflation, I, and the average ex ante real interest rate, r, according to Fisher (1930) and 
represented by equation (3).   
 
ɗt = it െ  E(I)t െ  r   (3) 
 
where E(*) is the expectations operator.  Assuming the expected real interest rate follows an 
AR(1) process, the state equation becomes (4) below. 
 
ɗt+1 = ɏɗt +  vt+1  (4) 
 
Since we have observations on the ex post real interest rate, which is the nominal interest rate 
minus actual inflation, we can write the measurement equation as follows. 
 
it െ It = ሺit െ EሺIሻtሻ+  ሺEሺIሻt  െ Itሻ   (5)  
 
or substituting from (3), 
 
it െ It = r +  ɗt +  ሺEሺIሻt  െ Itሻ =  r +  ɗt + ut    (6) 
 
where ut  equals ሺEሺIሻt  െ Itሻ, or the negative value of unexpected inflation.  This term represents 
error in the inflation forecast.  If these inflation forecasts are made in optimal fashion, then these 
errors, ut , should be uncorrelated with their lags and with the ex ante real interest rate, ɗt.  Thus 
the conditions of equation (2) are met, and one can see how the general Kalman filter model in 
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equations (1) and (2) apply when we let F = ɏ, yt =  it െ It , Ԣ = r, and HԢ = 1 to get the 
following system. 
 
ɗt+1 = ɏɗt + vt+1 
 
it െ It = r +  ɗt + ut = r +  ɗt +  ሺEሺIሻt  െ Itሻ 
 
Using the Dynamic Linear Model (DLM) capability in the RATS computer program and setting 
initial values of 0.1 for the coefficient on the nominal interest rate (i.e., lagged Treasury bill), i, 
and 1.0 for the variances of the error terms v and u, we iteratively solve this system to extract the 
time-varying constant parameter.  Doing so in turn allows us to separate aggregate inflation into 
its unexpected and expected components. 
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Essay #2: Using Genetic Algorithms for Hedging Health Care Costs, Managing 
Macroeconomic Risk, and Tracking Investments 
 
Introduction 
The intuition behind a natural hedge is straightforward enough, and can be easily 
illustrated through example.  If an individual is concerned about wealth decreases from 
rising gasoline and heating oil prices, then he or she could offset the wealth decreases by 
investing in oil companies (with fixed production factor costs).  Likewise, one would 
think it is possible to offset health care costs by investing in health care-related firms.  
Empirically, however, this natural hedge for health care does not exist according to the 
analysis in Jennings, Fraser, and Payne (2009).  By investigating the correlation between 
various investable health care mutual funds and health care inflation, they find these 
funds do a poor job of hedging health care costs that have outpaced general inflation 
since the mid-1980s.  Since hedging such non-investable macroeconomic factors has 
substantial practical relevance for health care and beyond, the purpose of this paper is to 
present an implementable technique to form a hedging or risk management strategy.  
Narrowly, this research demonstrates the ability of a genetic algorithm (GA) 
methodology to identify a portfolio of assets that offsets the risk posed by monthly 
medical inflation.  More broadly, the GA procedure implemented here could be used to 
find risk-managing portfolios for virtually any non-investable time series, representing a 
significant risk management tool.  Further, the technique translates directly into creating 
SRUWIROLRVWKDWPLPLFLQYHVWDEOHDVVHWV7KLVSDSHULOOXVWUDWHVWKHWRRO¶VIOH[LELOLW\E\
demonstrating its ability to find asset portfolios that track mutual funds and exchange-
traded funds (ETFs). 
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Literature Review 
We provide a brief summary of GAs here, referring the interested reader to Bauer 
(1994) for a more detailed description and Holland (1975) for the mathematical proofs 
behind the methods.  A genetic algorithm (GA) is an iterative computational method 
based on an analogy with Darwinian natural selection and mutation.  As with any 
optimization method, a GA begins with choosing an objective function.  In this 
application, the first objective is to minimize the variance of a hedged portfolio consisting 
RID³VKRUW´SRVLWLRQLQPHGLFDOLQIODWLRQDQGDORQJSRVLWLRQLQDSRUWIROLRRILQYHVWDEOH
assets.  Following the analogy of natural selection, a particular candidate solution is 
knoZQDVDQ³LQGLYLGXDO´ZKLOHWKHH[WHQWWRZKLFKDSDUWLFXODUFDQGLGDWHVROXWLRQPHHWV
WKLVREMHFWLYHLVNQRZQDVWKH³ILWQHVV´RIWKHLQGLYLGXDO7KHPHFKDQLFDOGHWDLOVRIWKLV
SDSHU¶V*$DSSOLFDWLRQDUHJLYHQLQWKH0HWKRGVVHFWLRQ+ROODQGSURYLdes the 
eloquent math demonstrating the efficiency of this problem-solving methodology. 
The contribution of this effort consists of using the GA method to create 
parsimonious economic tracking or risk management portfolios.  The Bauer (1994) 
presentation focuses on using GAs to generate trading strategies based on certain rules, 
but to our knowledge nowhere has anyone (publicly) discussed implementing them to 
generate portfolios that offset the risk posed by uninvestable macroeconomic series.  On 
the other hand, Lamont (2001) describes a model that uses 13 stock and bond 
portfolios²while controlling for other lagged variables²to predict future 
macroeconomic time series.  His method is exclusively regression-based and assumes 
investment in all 13 stock and bond portfolios, or essentially the market, to track each of 
the 7 macroeconomic series he investigates.  While (aggregate) inflation is among the 
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PDFURHFRQRPLFVHULHVKHORRNVDWKHGRHVQRWDVVHVVWKHVHDVVHWV¶DELOLW\WRSUHGLFW
the medical component of inflation.  While medical inflation (CPIMEDSL) has outpaced 
aggregate inflation (CPIAUCSL) since the early-1980s (see Figure 1), we nonetheless 
suspect his main conclusions would hold for medical inflation, too.  For future reference, 
Appendix A includes all figures, and Appendix B includes all tables.  Our contribution 
EH\RQG/DPRQW¶VHIIRUWVLVWRXVHDFRPSOHWHO\GLIIHUHQWWRROWRILQGPRUH
parsimonious, flexible, and perhaps better-performing, set of investable assets to track a 
non-investable (e.g., macroeconomic) series. 
GAs lend themselves to the medical cost hedging problem presented in Jennings, 
Fraser, and Payne (2009) for a variety of reasons, especially when compared to using a 
straightforward multiple regression approach.  First, multiple regressions typically satisfy 
a single objective function: minimize the mean-squared error between the estimated and 
actual data.  While this might be the appropriate objective function for a GA to solve, it is 
flexible enough to solve other objective functions as well.  For instance, perhaps one 
desires a portfolio prohibiting short-selling.  One can implement a rule for positive asset 
weights and then implement a GA to solve this problem.  Additionally, since the GA is 
not a hill-climbing algorithm, it is capable of handling non-linear as well as discontinuous 
objective functions.  In all, as evidenced with the example in this paper, the iterative 
nature of the GA allows for much more flexibility and control over the desired objective 
function than a multiple regression. 
Besides their adaptability, GAs are computationally efficient.  For the purpose of 
this research, there exist literally tens of thousands of possible investable assets 
worldwide that one could use to find the best hedge against medical inflation in this 
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country.  Unfortunately the lack of data and degrees of freedom make it impossible to run 
a multiple regression using all these assets in a single model.  In this instance, since the 
sample includes monthly medical inflation values between January 1967 and August 
2009, there are only 512 data points.  Using too many assets as independent variables 
quickly consumes degrees of freedom.  Further, if one were to explore combinations of 
sub-samples of the assets, an exhaustive search of the combinations could take months or 
years to complete.13  Obviously the hedging strategy in such a case could become 
obsolete by the time it is discovered.  Besides computational considerations, another 
advantage of GAs relates to parsimony and user-defined objectives.  For example, 
transactions costs play a role in any applied investment decisions.  By stipulating the 
number and population of traded assets, users have greater control over these transactions 
costs.  Alternatively, using an exhaustive multiple regression solution could encourage 
the investor to trade every asset in the model depending on the weights assigned to each 
asset. 
As Bauer (1994) highlights, there certainly exists a major caveat to GAs.  Because 
of their iterative nature and the sensitivity to the user-defined inputs (e.g., initial 
population, breeding population, amount of gene crossover, mutation frequency and 
method, etc.), there exists a real probability that a GA will not find the single optimal 
solution.  However, as he demonstrates, it will generally find near-optimal solutions, and 
in some cases the optimal solution.  It is possible the GA will converge too quickly on a 
sub-optimal solution.  As he further articulates, however, in a practical sense achieving 
                                                          
13 As a simple example, if one wanted to select 5 assets from a population of 300 assets, there exist over 
19.6 billion unique combinations.  If a computer processes 1000 multiple regressions per second, then an 
exhaustive analysis would take over 7.5 months to complete.  The processing time further increases with 
portfolio size and the asset population. 
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the time-consuming optimal solution can become less-preferred than the quickly-
developed acceptable one.  Thankfully certain researchers, such as De Jong (1975) have 
quite effectively established appropriate input values and quantified the sensitivity to 
changes in them.  Given the unique problem in this paper, the GA methodology generally 
adheres to convention and uses these recommended input values, but we also provide 
rationale for any deviations. 
 
Data 
Before describing the GA methodology employed, it is useful to outline data 
sources briefly.  Medical inflation comes courtesy of the Federal Reserve Economic 
Database (FRED) hosted online by the Federal Reserve Bank in St. Louis.  The security 
returns as well as the long and short government bonds and Treasury bill rates come from 
the Center for Research in Security Prices (CRSP). 
 
Genetic Algorithm Methodology and Proof of Concept 
Before applying the GA to actual medical inflation values, we test the GA method 
using a set of representative artificial assets to ensure that it works as intended.  Since a 
perfect hedging instrument would track a target series perfectly, the objective in this 
³SURRIRIFRQFHSW´LVWRPLQLPL]HWKHYDULDQFHRIWKHUHWXUQGLIIHUHQFHEHWZHHQDQ
equally-weighted portfolio of five hedging assets and the target according to equation (1) 
below.  Clearly zero variance would mean the hedging portfolio tracks the target 
precisely.  But from a risk management standpoint, it could also prove desirable if the 
hedged portfolio systematically earns higher returns than the target series even if it does 
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not track the target precisely (i.e., ܧݎݎ݋ݎݐ > 0 for most or all periods t).  We discuss this 
auxiliary goal later when using the GA in a real-world application. 
ܯ݅݊݅݉݅ݖ݁ ܸܽݎ݅ܽ݊ܿ݁ሺܧݎݎ݋ݎሻ        ሺ1ሻ  
where  ܧݎݎ݋ݎݐ = ܴ݁ݐܪ݁݀݃݁  ܲ݋ݎݐ݂݋݈݅݋ ,ݐ െ  ܴ݁ݐܶܽݎ݃݁ݐ ,ݐ  
ܴ݁ݐܶܽݎ݃݁ݐ ,ݐ  (ܴ݁ݐܪ݁݀݃݁  ܲ݋ݎݐ݂݋݈݅݋ ,ݐ  ) is the return of the target (hedge portfolio) at 
time t. 
,QWKLV³SURRIRIFRQFHSW´RSWLPL]DWLRQWKHFKRLFHYDULDEOHVWKDWDFFRPSOLVKWKH
objective are a set of five assets chosen from a universe of 3,000 assets.  These 3,000 
assets are a random subsample of over 16,000 stocks from CRSP that have at least 60 
months of returns between 1967 and 2009.  In the vernacular of a GA, the universe of 
assets LVNQRZQDVWKH³SRSXODWLRQ´DQGWKHFKRLFHYDULDEOHVDUHNQRZQDV³JHQHV´$
VHWRIJHQHVWKHQFRPSRVHVWKH³LQGLYLGXDO´,QWKLVFDVHWKHUHH[LVWILYHDVVHWVJHQHV
that compose each portfolio (individual).  The goal of the GA is then to form a hedge 
portfolio by choosing a subset of five assets (i.e., genes) out of the universe of 3,000 
assets (i.e., population) that has the minimum error variance over the investment horizon.  
,Q*$WHUPVWKHJRDOLVWRILQGDQ³LQGLYLGXDO´WKDWKDVDVHWRI³JHQHV´ that generates 
WKHKLJKHVW³ILWQHVV´DPRQJWKH³SRSXODWLRQRILQGLYLGXDOV´ 
 To illustrate the method, we must first define and quantify how well a potential 
solution meets the objective function.   Doing so means choosing 5 assets: i, j, k ,l  and m, 
from 3,000 assets without replacement and equally weighting their returns to form a 
hedge asset with a return series given by equation (2). 
ܴ݁ݐܪ݁݀݃݁ ,ݐ =  0.2 כ ܴ݁ݐሺ݅ሻݐ + 0.2 כ ܴ݁ݐሺ݆ሻݐ + 0.2 כ ܴ݁ݐሺ݇ሻݐ + 0.2 כ ܴ݁ݐሺ݈ሻݐ + 0.2 כ
ܴ݁ݐሺ݉ሻݐ     (2) 
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In this equation, ܴ݁ݐሺݔሻݐ  represents the return on a particular asset at time t, and the 0.2 
coefficients represent the equal-weighting of each asset. 
Next we construct a target portfolio according to equation (3),  
ܴ݁ݐܶܽݎ݃݁ݐ ,ݐ = ܽ1 כ ܯܭܴܶܨݐ + ܽ2 כ ܵܯܤݐ + ܽ3 כ ܪܯܮݐ + ܽ4 כ ܦܧܨݐ + ܽ5 כ ܶܧܴܯݐ   (3) 
where ܯܭܴܶܨݐ  is the monthly value-weighted market return in excess of the risk-free 
rate, ܵܯܤݐ  is Small-minus-Big, calculated by subtracting the return of the decile of the 
largest stocks²by market capitalization²from the decile of smallest stocks, and ܪܯܮݐ  
is High-minus-Low, calculated by subtracting the return of the stock decile having the 
lowest book-to-market equity ratio from the decile with the highest book-to-market 
equity rDWLR7KHVHYDOXHVFRPHVWUDLJKWIURP.HQ)UHQFK¶VGDWDOLEUDU\14  We calculate 
ܦܧܨݐ , the default risk premium, by subtracting the long government bond yield from a 
Baa-and-below portfolio yield of similar duration corporate bonds and ܶܧܴܯݐ , the term 
risk premium, by subtracting the one-month Treasury yield from the long government 
bond yield.  Importantly, ܽ݅  is the median value of the distribution of coefficients 
resulting from 3,000 separate time series regressions of each of our 3,000 assets on these 
five factors, MKTRF, SMB, HML, DEF, and TERM.  Creating a target return series in 
this manner ensures the target is at least reasonably representative of a return series that is 
SDUWRIWKHSRSXODWLRQRIDVVHWV7KDWLVXVLQJWKH³PHGLDQ´DVVHW as the target ensures 
the target is not an outlier we are trying to mimic, or track.  While we subsequently use a 
³UHDO´WLPHVHULHVDVWKHWDUJHWIRUWKLVSURRIRIFRQFHSWZHVLPSO\ZLVKWRHQVXUHWKH*$
tool finds a good solution for a representative target series.  To make sure the solution has 
a reasonable chance at tracking the target series, we deliberately place the target near the 
                                                          
14 http://mba.tuck.dartmouth.edu/pages/faculty/ken.french/data_library.html 
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heart of the joint distribution of all the tracking assets.  If the GA technique works as 
anticipated, we should expect five assets to track the target quite well in this proof of 
concept. 
 Having a target series along with a sample of possible assets to include in a 
KHGJLQJSRUWIROLRZHWKHQFUHDWH³SDUHQW´SRUWIROLRVRUFDQGLGDWHVROXWLRQVZKLFK
are random combinations of five assets.  This set is defined as the initial population (see 
Figure 2).  Each candidate in turn has a quantifiable fitness level according to the 
objective function described in equation (1).  Establishing the initial parent portfolios and 
their respective fitness levels initializes the GA algorithm and leads to subsequent 
iterations, whose goal is to improve the best solution. 
 The GA improves on the population of initial candidate solutions by creating new 
candidates as partial combinations of existing population members.  The production of 
QHZFDQGLGDWHVROXWLRQVLVNQRZQLQWKH*$OLWHUDWXUHDVD³EUHHGLQJ´7KHSURFHVV
begins by first ordering the initial population according to its fitness level as shown in 
Figure 3, Panel A.  The popuODWLRQLVWKHQGLYLGHGLQWRWZRJURXSVFDOOHGWKH³EUHHGLQJ´
SRSXODWLRQDQG³QRQ-EUHHGLQJSRSXODWLRQ´)RUWKLVVWXG\ZHUHWDLQWKHEHVW-fit 10-
percent members as the breeding population and the remaining 90-percent as non-
breeding members.  New candidate solutions come only from the breeding population, 
and a new candidate is formed by randomly pairing two members of this breeding 
population.  For example, using the results in Figure 3, Panel A, the first new candidates 
could be formed from candidates1000 and 2. The next pair considered might be 1 and 
721.  Keeping with the natural selection analogy, the pre-existing or current two 
FDQGLGDWHVROXWLRQVDUHFDOOHG³SDUHQWV´7KHSDUHQWVDUHHDFKGHILQHGE\WKHLUJHQH
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sequence (candidate 1000 by assets 2, 6, 28, 7 and 11 and candidate 2 by assets 23, 9, 7, 
29 and 31).  A breeding produces two new candidate solutions, or offspring, as follows.  
We randomly generate an integer between 1 and 3.  This integer, called the crossover 
number, indicates how many genes (counted from the left) from the two parents to swap 
LQJHQHUDWLQJWZRQHZFDQGLGDWHVROXWLRQVFDOOHG³RIIVSULQJ´)RUH[DPSOHIRUWKHILUVW
pairing, if the crossover number is 2, then the two new offspring would be as shown in 
Figure 3, Panel B.  In the second pairing (see Panel C), if the crossover number is 3, 
Offspring 3 and 4 would be as shown.  This process continues until enough pairings have 
occurred for the breeding population to replace the non-breeding group.  Using our 
parameters, since we have 1,000 members in the population, 100 serve as the breeding 
population, leaving 900 to be replaced through the breeding process.  Thus we perform 
450 pairings to generate the 900 replacement members. 
 The next step is to evaluate the fitness level of each offspring using the process 
described for the initial population (see equation (1)).  Finally, we modify the existing 
population by determining whether the offspring have better fitness levels than their 
parents.  If a particular offspring has a fitness measure better than one of its parents, then 
we replace one member of the non-breeding population with the superior offspring.  
Doing so guarantees that the offspring has higher fitness than the candidate solution it 
replaces because of the original sorting of the population by fitness and division into 
breeding and non-breeding groups.  If an offspring has an inferior fitness level compared 
to its parents, then the offspring does not go into the population but instead becomes 
replaced with a new candidate whose assets are chosen at random.  This scenario 
UHSUHVHQWVUDQGRPPXWDWLRQLQWKHSRSXODWLRQ¶VJHQHSRRO$VZLWKWKHRWKHUPHPEHUV
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we calculate the fitness level of this new candidate and replace one member of the non-
breeding population with this new candidate.  Doing so at worst weakens the non-
breeding population but at best creates a mutation that will move into the breeding 
population for the next generation.  After repeating this process for all the offspring, we 
again sort the population of candidate solutions by fitness level.  This entire series of 
FDOFXODWLRQVLVNQRZQDVFUHDWLQJD³JHQHUDWLRQ´7KHEUHHGLQJSRSXODWLRQWRS-
percent most fit) after each generation will weakly dominate both the initial and prior 
population. 
 The GA approach quickly converges to (near) optimal solutions by two 
PHFKDQLVPV)LUVWWKHDOJRULWKPH[SORLWVWKHIDFWWKDWDJURXSRI³JRRG´VROXWLRQVZLOO
generally contain similar features; in our case this group of assets forms a good hedging 
portfolio for a target series.  By selectively swapping combinations of assets among 
candidates that are by themselves good solutions, better candidates emerge.  The second 
IHDWXUHD*$H[SORLWVLVDFRQFHSWFDOOHG³LPSOLFLWSDUDOOHOSURFHVVLQJ´,QRXU
application, we have 5 assets to choose out of a population of 3,000 assets, or ቀ3,000
5
ቁ 
possible hedges.  If, after several generations, the algorithm determines that asset 20 does 
not contribute to overall fitness, then the algorithm has effectively eliminated all 
candidates that include asset 20.  Doing so means that ቀ2,999
4
ቁ candidates have implicitly 
been eliminated from consideration.15  The combination of these two features allows the 
GA to cover a vast number of candidate solutions very rapidly. 
Running the proof of concept for multiple generations provides encouraging 
results.  Table 1 shows the generation-by-generation results of the GA for 10 generations.  
                                                          
15 There would be 2,999 other assets to choose from once asset 20 was eliminated and 4 assets to choose. 
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The generation-by-generation population minimum, mean, and maximum fitness levels 
vary quite substantially.  Again, we calculate these fitness levels using Equation (1), and 
our goal is to minimize the fitness value.  The final column shows the mean fitness level 
for only the breeding population by generation, or the top 100-performing portfolios in 
this construction.  As expected, the minimum fitness values decrease (Column 2), or 
improve, over generations until a certain point at which convergence likely occurs.  In 
this instance the minimum value appears to converge in the fifth generation.  Notably, the 
mean and maximum (i.e., worst) fit of the population fluctuate over time, which occurs 
because we allow substantial mutation from generation to generation.  We notice two 
things about the mean fit of the breeding population (Column 5).  First, its fitness value 
steadily improves (i.e., decreases) asymptotically over time.  Secondly, the breeding 
population has converged to the minimum value shown in Column 2 by the eighth 
JHQHUDWLRQ7KXVWKH³EHVW´VROXWLRQKDVEUHGRXWDOORWKHUSRVVLELOLWLHVDQGWKHRQO\
possible further improvement would come from mutations in future generations. 
Figure 4, Panel A shows a graphical representation of the monthly returns for the 
hedge portfolio for the best solution (RETURNHEDGE), which is an equally-weighted 
portfolio of assets indexed by numbers 2745, 2432, 2011, 1086, and 2151 (of our 3,000 
original assets), and the target return series (TARGET) between January 1967 and 
August 2009.  Again, equation (2) shows how we calculate the notional target series.  The 
correlation between these two series exceeds 0.96.  Because Panel A makes it difficult to 
discern the difference between the two series, Figure 4, Panel B captures a scatter plot of 
these values.  These results are encouraging, since the corresponding values cluster 
around a line through the origin with slope equal to one. 
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Clearly this proof of concept is artificial²albeit realistic²since all assets are not 
available for investment during the entire period.  This scenario contains look-ahead bias 
since we estimate the coefficients using all information available in the sample.  
Realistically, at any given point in time, we could only estimate the relevant betas using 
past information instead of across the entire time period as shown here.  Additionally, this 
proof of concept does not allow for dynamic factor models that might provide additional 
insight.  We incorporate a form of conditioning factor model where portfolio weights 
FKDQJHZLWKWKH³VWDWH-of-the-ZRUOG´LQWKHIXWXUHUHDO-world applications.  With these 
considerations in mind and with the belief the GA works as intended, we now turn to out-
of-sample testing using an actual target and investable assets. 
 
Applying the GA to Health Care Risk Exposure 
In this more realistic application of the GA, the objective is to minimize the 
variance of a hedged portfolio consisting of a short position in medical inflation and a 
long position in a portfolio of assets.  A zero variance hedged portfolio indicates perfect 
correlation between the target and hedging portfolio.  While such a portfolio would be 
ideal from the hedging standpoint, from a risk management standpoint it is also 
reasonable to allow for a hedging portfolio that allows for superior first and second 
moments of the hedged portfolio even if it does not correlate perfectly with the target.  In 
other words, we contend that if a hedged portfolio of assets provides a higher mean and 
lower variance out-of-sample than simple exposure to the target it intends to hedge, while 
it might not covary perfectly with the target and induce a low hedged portfolio variance, 
such a portfolio nevertheless represents an effective risk management mechanism from a 
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funding standpoint.  We subsequently provide a more tangible explanation of this 
argument. 
In this real-world exploration, the choice variables that accomplish the objective 
are a set of five assets chosen from a universe of 306 assets.  The 306 assets include 303 
stocks pulled from CRSP that have returns as of  January 1967 and December 2008, 
which is the period for which we have relevant medical inflation data.  Additionally, 
these stocks have uninterrupted return data for at least 100 months before 2005, which is 
the earliest out-of-sample period we consider for the macroeconomic series.  We also 
include three government bond monthly return series: the 10-year bond, one-year note, 
and 30-GD\ELOO&OHDUO\DOORIWKHVHDVVHWVDUHWUXO\³LQYHVWDEOH´OHDGLQJXSWRWKHRXW-of-
sample periods in a practical sense, unlike those shown in the proof of concept scenarios.  
Further, the results shown are but a starting point considering the recent work of Brandt 
and Santa-Clara (2006).  These authors show that applying conditioning and timing 
methods to asset returns can expand the asset universe essentially without bound.  While 
we consider conditioned returns for our mutual fund and exchange-traded fund (ETF) 
applications, we do not incorporate timing methods here. 
Broadly speaking, the problem at hand can be characterized as follows.  Starting 
today, you have a known liability (assuming medical prices remain constant) over the 
QH[W\HDUUHVXOWLQJIURPPHGLFDOH[SHQVHV:HDUHDVVXPLQJQR³TXDQWLW\´ULVNLQWKLV
medical expense.  That is, we assume the level of medical services remains constant, and 
the only uncertainty comes from medical price changes.  Given that medical expenses are 
likely to increase in an uncertain fashion (see Figure 1), you need to invest in a set of 
assets that will increase in value at or above the rate of medical inflation, and at the same 
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time result in a combined net asset position that has volatility lower than if the medical 
liability were hedged with risk-IUHHLQYHVWPHQWV6XFK³ULVN-IUHH´LQYHVWPHQWVHJ
JRYHUQPHQWERQGVRU&'VEDVLFDOO\UHSUHVHQWWKH³EDVHOLQH´KHGJLQJVWUDWHJ\VLQFHLWLV
unlikely an exposed entity would let available funds sit idle and bear no interest.   
Panels A through C in Figure 5 depict relevant scenarios.  With return on the y-
axis and time on the x-axis, Short Target represents a short position in the series (e.g., 
medical inflation) you wish to hedge.  In Panel A, the ideal Hedging Portfolio would 
mirror the Short Target series exactly, leading to the ideal Hedged Portfolio, which in this 
example has zero variance.  To the extent this Hedged Portfolio lies above or below the 
zero return line, it is possible to hedge the target using more or less funds than the known 
liability.  Specifically, the Hedged Portfolio in Panel A indicates a hedging portfolio with 
a mean periodic return higher than that of the target series, which means you could invest 
less than the current known liability and still offset the future liability exactly.  Thus 
Panel A is an ideal scenario: a hedged position that is less risky than a natural short 
position along with a fully-funded (in fact over-funded) liability.  Panel B depicts a 
scenario where a constant return asset such as a T-Bill serves as the Hedging Portfolio.  
Clearly the Hedged Portfolio exhibits higher return variance than in Panel A, and in this 
case the variance ratio of the hedged portfolio to the target series equals one since the 
variance of the Hedged Portfolio equals the variance of the Short Target.  Although we 
show a situation where the constant return of the Hedging Portfolio is greater than the 
absolute value of the Short Target return, if this constant return series were less than the 
absolute value of the Short Target return, then we would have a situation where the 
liability would be underfunded over time.  Thus it is important to consider both the 
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variance ratio and return levels when considerLQJWKHKHGJLQJSRUWIROLRV¶HIIHFWLYHQHVV
from a risk management standpoint.  Finally, Panel C depicts a more real-world scenario 
where the Hedging Portfolio correlates with the Target with an absolute value between 
zero and one.  In this case, the Hedging Portfolio relationship with the Short Target series 
creates a Hedged Portfolio with higher variance than the Short Target position.  However, 
the liability is always fully-funded since the returns to the Hedged Portfolio are non-
negative.  It is straightforward to envision the alternative scenario whereby the Hedged 
Portfolio variance is lower than the Short Target with negative returns. 
Returning to our GA, the objective in this case it to choose five assets, (i, j, k , l, 
and m) from 306 assets without replacement and weight them to form a hedging portfolio 
with return ܲ݋ݎݐ݂݋݈݅݋ݐ  according to equation (4), 
ܲ݋ݎݐ݂݋݈݅݋ݐ =  ܽ0 +  ܽ1ܴ݁ݐሺ݅ሻ+ ܽ2ܴ݁ݐሺ݆ሻ+ ܽ3ܴ݁ݐሺ݇ሻ+ ܽ4ܴ݁ݐሺ݈ሻ+ ܽ5ܴ݁ݐሺ݉ሻ  (4) 
where ܴ݁ݐሺݔሻ, represents the return on a particular asset and L«P are the indices that 
indicate one of the 306 assets.  ܽ1. . ܽ5 are hedge ratios determined by OLS regression.  
We next define the hedged position, or hedged portfolio, as ܪݐ  in equation (5). 
ܪݐ = ܲ݋ݎݐ݂݋݈݅݋ݐ െ  ܥܲܫܯܧܦܯܱݐ    (5) 
Here, ܥܲܫܯܧܦܯܱݐ  serves as the medical inflation target we are trying to hedge and 
ܲ݋ݎݐ݂݋݈݅݋ݐ  is the return series of the hedging portfolio which consists of five investable 
assets and is shown fully in equation (4).  Since we are naturally short the medical 
inflation position in that we must pay medical care costs each time period, we take a long 
position in ܲ݋ݎݐ݂݋݈݅݋ݐ  to offset the movements in ܥܲܫܯܧܦܯܱݐ , which will ideally 
stabilize ܪݐ  and minimize the risk of escalating health care costs.  ܪݐ  is analogous to the 
ܧݎݎ݋ݎݐ  series in equation (1).   
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 ,QHYDOXDWLQJWKHKHGJLQJSRUWIROLR¶VILWQHVVZHDJDLQUDQGRPO\JHQHUDWH
candidate hedge portfolios consisting RIILYH³JHQHV´RUDVVHWVDQGGHILQHWKLVVHWDVWKH
initial population.  To evaluate the performance out-of-sample, we divide the data into 
three regions as shown in Figure 6.  For our baseline analysis, these periods include the 
Test period (January 1967 to December 2006), Validation period (January to December 
2007), and the Out-of-Sample period (January to December 2008).  For robustness 
purposes we also explore calendar years 2005-2007 as out-of-sample periods.  We then 
regress medical inflation (ܥܲܫܯܧܦܯܱݐ) on these assets according to Equation (6) using 
only WKHGDWDLQWKH³7HVW´SHULRG(TXDWLRQVKRZVDQH[DPSOHIRUPRIWKLVUHJUHVVLRQ
using assets 1, 7, 25, 36, and 41. 
ܲ݋ݎݐ݂݋݈݅݋ݐ =  ܽ0 +  ܽ1ܴ݁ݐሺ1ሻ+ ܽ2ܴ݁ݐሺ7ሻ + ܽ3ܴ݁ݐሺ25ሻ+ ܽ4ܴ݁ݐሺ36ሻ+ ܽ5ܴ݁ݐሺ41ሻ  (6) 
From this regression come estimates for the hedge ratios ොܽ0 ǥ . ොܽ5 .  Using these 
parameters, it is possible to calculate the time series for ܲ݋ݎݐ݂݋݈݅݋ݐ  RYHUWKH³7HVW´
SHULRGSHUHTXDWLRQDQGFRQWLQXHXVLQJWKHKHGJHUDWLRVWKURXJKWKH³9DOLGDWLRQ´
SHULRG6LQFHWKH³9DOLGDWLRQ´SHULRGLVRXWVLGHWKHUDQJHXVHGWRHVWLPDWHWKH
SDUDPHWHUVLWDFFRXQWVIRUSHUIRUPDQFHRIWKHPRGHOIRUPHGGXULQJWKH³7HVW´SHULRGLQ
a pre-out-of-sample manner and reduces the criticism of overfitting the model based on 
past known information.  Next we calculate the mean and variance of ܪݐ , ܲ݋ݎݐ݂݋݈݅݋ݐ , 
and ܥܲܫܯܧܦܯܱݐ  IRUERWKWKH³7HVW´DQG³9DOLGDWLRQ´SHULRGV7KHILWQHVVOHYHOLQWKLV
application, which we seek to minimize, consists of a weighted measure that accounts for 
these attributes as shown in equation (7),  
ܨ݅ݐ݊݁ݏݏ = ݓ1ߪܪ,ܶ݁ݏݐ2 +ݓ2 ൬
ߪܪ ,ܸ݈ܽ݅݀ܽݐ݅݋݊
2
ߪܪ ,ܶ݁ݏݐ
2 ൰   (7) 
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where  ߪݔ ,ݕ2  is the variance of return series x during period y.  Using the two terms 
incorporates the variance of the hedged portfolio in both the Test and Validation periods.  
Specifically, the first term simply measures the variance of the hedged portfolio, H, 
weighted by factor ݓ1.  The second term expresses the idea that it is desirable for the 
variance of the hedged portfolio in the Validation period to remain consistent with or 
lower that it is in the Test period.  We consider it a stability measure and weight its 
importance by ݓ2.  To emphasize, in this construct lower fitness values are preferred. 
Initially we set (ݓ1,ݓ2) to (1, 1) but also complete sensitivity checks using other 
weight vector values.  We repeat regression (6) and calculate the fitness using equation 
(7) for all 1,000 candidate solutions in the initial population.  Having initialized the 
candidate solution population, we use the iterative GA procedure, or breeding, as 
described in the proof of concept above to evolve an improved solution over multiple 
generations.  The major differences between this real-world application and our earlier 
proof of concept involve the set of possible hedging assets and the fitness level measure.  
The breeding process and its user-defined inputs (e.g., number of genes, number of 
parents, breeding population, mutation procedure, and crossover rate) remain consistent 
with the proof of concept. 
 
Results 
Table 2 shows the generation-by-generation results of a GA run with the fitness 
weights (ݓ1,ݓ2) set to (1, 1).  The generation-by-generation population minimum, mean, 
and maximum fitness measures vary as anticipated.  The minimum decreases over time, 
the maximum fluctuates randomly given our allowance for mutations, and the mean also 
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fluctuates, but to a lesser degree.  Again, we calculate these fitness measures using 
Equation (7).  The final column shows the mean fitness measure for only the breeding 
population, which are the top 100-performing portfolios in each generation.  As expected, 
again the minimum fitness values decrease (Column 2), or improve, over generations 
until convergence in the tenth generation.  In this case, we again notice two things about 
the mean fit of the breeding population (Column 5).  While its fitness value steadily 
improves (i.e., decreases) asymptotically over time, the breeding population has not 
converged to the minimum value shown in Column 2.  Thus it is theoretically possible to 
obtain even better performance if we were to allow for additional generations, and the 
possibility of mutations always makes this possibility hold.  However, improvement 
seems improbable given the best existing solution in most cases is a unique one.  This 
³PRVWILW´PHPEHULVRIWHQMXVWRQHPHPEHULQD-member breeding population, and 
sinFHZHDOORZSDLULQJVWRRFFXUUDQGRPO\DVRSSRVHGWRIRUFLQJWKLV³PRVWILW´VROXWLRQ
WREUHHGHDFKJHQHUDWLRQLVQRPRUHOLNHO\WR³EUHHG´WKDQDQ\RIWKHRWKHUEUHHGLQJ
members. 
Performing a brief sensitivity analysis by varying (ݓ1,ݓ2) leads to Table 3.  
Clearly there are many more possibilities than those shown, but the point is merely to 
demonstrate the potential for the GA to generate nice solutions.  Column 1 shows varying 
weight values, while Column 2 depicts the ratio of the variance of the hedged portfolio to 
the variance of actual medical inflation for the out-of-sample evaluation.  Columns 3 
through 7 depict the assets that compose the best hedge portfolio as determined by the 
GA; the Asset Key table at bottom shows the associated CRSP tickers for these assets.  
Appendix C lists all asset-ticker-industry combinations for the GA-generated portfolios 
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for the rest of this study.  Column 8 shows the generation at which the minimum fitness 
level converges for each respective weight combination.  In the analysis to date, we 
constrain the process to end after 10 generations.  The final column shows the mean out-
of-sample excess monthly return by investing in the hedging portfolio.  For instance, by 
investing in stocks 274, 79, 199, 33, and 214,16 (i.e., weight vector (1,1)) and 
simultaneously remaining naturally short the medical inflation measure, one would earn 
an average return of 0.316 percent per month on hedged portfolio between January and 
December 2008, indicating the liability is fully-funded as described earlier.  And since 
the mean fitness level of the breeding population has not yet converged to the minimum 
value in virtually any of these cases (not shown), again it is theoretically possible that an 
even better solution exists than shown here.  Of course, mutations could always improve 
the population even after convergence. 
For this relatively small sample of weight values, Column 2 of Table 3 (which 
quantifies the variance ratio between the hedge portfolio and medical inflation) indicates 
that the GA-determined hedge portfolio eliminates up to 49 percent (i.e., ratio equals 
0.51) of the variance in medical inflation for the out-of-sample period.  That is, the 
variance of simultaneously having a short position in medical inflation and a long 
position in the five GA-selected stocks and/or bonds generates a portfolio variance less 
than one-half of what it would be simply remaining exposed to the medical inflation 
VHULHV,QWKLV³EHVW´FDVHWKHSRUWIROLRFRQVLVWVRIIRXUVWRFNV17 and the 30-day Treasury 
Bill, which is represented by return series 306.  Figure 7, Panels A through C depict the 
                                                          
16 The major industries of the stocks that correspond to these index numbers are Processed & Packaged 
Goods, Entertainment, Specialty Retail, Security & Protection Services, and Industrial Equipment. 
17 The stock industries include Accident & Health Insurance, Restaurants, Rental & Leasing Services, and 
Domestic Telecommunication. 
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out-of-VDPSOHUHWXUQVHULHVDQGDVVHWV¶UHODWLYHZHLJKWVZLWKLQWKHKHGJLQJSRUWIROLR
respectively.  Clearly for the weight vector (1,0) portfolio, a long position in the T-Bill 
dominates the position, with an investor holding very small positions in the other 4 assets, 
ZKLFKDUHVWRFNV1RWDEO\KRZHYHUHYHQWKHVHVPDOOSRVLWLRQVDIIHFWWKHSRUWIROLR¶V
overall return series non-trivially.  This effect becomes evident by comparing this 
SRUWIROLR¶VYDULDQFHUDWLRRIWRDUDWLRRIZKHQXVLQJRQO\WKH7-bill as a 
hedging portfolio.  We discuss this T-bill situation in more detail below.  The other two 
portfolios consist solely of a set of common stocks.  Clearly the performance is sensitive 
WRWKHZHLJKWYDOXHVDQGHYHQLQWKH³ZRUVW´FDVHGHSLFWHGLHWKHYDULDQFHRI
the hedged portfolio is still below unity at 0.97.  While the variance ratios are appealing, 
perhaps as relevant from a broader risk management perspective is that in each hedged 
portfolio the monthly returns on average dominate the rise in medical inflation, and in 
every case these hedging portfolio returns are greater every month (see Figure 7 and its 
subsequent explanation for the graphical evidence).  Thus while the portfolio might not 
always track the target of medical inflation precisely, investing in a GA-selected portfolio 
of five common stocks and government bonds appears to offset the rise in health care 
costs in the out-of-sample period studied here, while simultaneously lowering the liable 
HQWLW\¶VULVNH[SRVXUH 
Knowing the sensitivity to the weights, we must select a set of weights for further 
DQDO\VLVDQGDSSOLFDWLRQ:KLOHDSSHDUVWREHWKH³EHVW´UHVXOWIrom Table 3, we are 
concerned this set of weights fails to account for the Validation period results and the 
associated performance stability we desire and described earlier.  The weight vector (1,1) 
is also appealing, since its hedged portfolio reduces the risk of exposure to medical care 
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costs by approximately 14 percent.  However, since the weight vector (0,1) also provides 
convincing results (i.e., variance ratio is less than one and the mean monthly return of the 
hedged portfolio is positive), it seems to present the most conservative yet still effective 
case.   Therefore we select the vector (0,1) for analysis from here forward.  We label this 
ZHLJKWYHFWRUWKH³JRRG´FDVH²DVRSSRVHGWRWKH³EHWWHU´RU³EHVW´FDVH²going 
forward.  Making this selection provides us with an effective hedge for medical inflation 
since the variance ratio is less than one, allows us to account for both the Test and 
9DOLGDWLRQSHULRGGDWDDQGKRSHIXOO\IRUHVWDOOVDOOHJDWLRQVWKDWZHDUH³FKHUU\-SLFNLQJ´
for the best subsequent results.   
To expand a bit on this weight set using Figure 7, it is visually difficult to discern 
that the hedge portfolio, H, has lower variance than medical inflation, since the ratio is 
close to unity.  However, it is clear the monthly returns for the hedging portfolio for the 
³JRRG´FDVH5(7+('*(3257RXWSDFHPHGLFDOLQIODWLRQ,QRWKHUZRUGVLQYHVWLQJLQ
this hedging portfolio of assets 81, 76, 84, 229, and 11718 FRYHUVDILUP¶VPHGLFDO
inflation exposure and on average provides a mean monthly excess return of 0.328 
percent (or roughly 4 percent annually) during the out-of-sample period over medical 
inflation.   
While we introduce the significance of excess mean return in the discussion 
surrounding Figure 5, Table 4 quantifies what this excess return means for the entity 
seeking to fund a future liability for the year 2008.  Assuming an entity is setting aside $1 
million to fund the anticipated medical care expense it will incur sometime during 2008, 
Column 2 shows monthly medical inflation, with Column 3 showing what the $1 million 
                                                          
18 The stock industries include Chemicals, Business Equipment, Electric Utilities, Manufacturing, and Steel 
& Iron.  Appendix A lists the stock index numbers, tickers, and industries. 
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liability would cost if incurred at the end of the associated month.  Column 4 shows the 
monthly hedging portfolio return using assets 81, 76, 84, 229, and 117 (see Figure 7, 
Panel B), and Column 5 translates these returns into dollar values if the $1 million set-
aside is invested in the hedging portfolio.  Column 6 shows how much of the original $1 
million would have been needed to offset the liability exactly, with Column 7 (8) 
showing the excess initial funds (as a percentage) at the beginning of the year if the 
whole liability were to occur at the end of the associated month.  The ranJHRI³H[FHVV´
funds at the outset is between 0.09 percent and 3.93 percent in this example.  Again, this 
overfunding occurs due to the hedging portfolio returns outpacing medical inflation every 
month of 2008, and the GA finds an investment portfolio that creates less risk for the 
exposed entity than doing nothing and remaining exposed to medical inflation.  And 
while a portfolio of all stocks like the one with weight vector (0,1) perhaps creates more 
risk than simply investing in T-bills, using T-bills requires investing all of the liable 
funds in this single asset.  A shock to the one-to-one relationship between medical 
inflation and T-bills could be devastating for the liable entity, whereas a portfolio of 
multiple (e.g., five) assets could more easily absorb a shock to the relationship between 
one of its assets and the medical inflation target, not to mention the inferior performance 
of the T-bill as a lone hedging asset discussed in the subsequent paragraph.  Additionally, 
while the all-stock portfolio with weight (0,1) is inferior from a volatility standpoint, it is 
possible that the excess mean return compensates for this loss. 
Figure 8, Panel A, depicts the potential portfolios in mean-standard deviation 
space.  Clearly all three of the hedged positions dominate a short position in medical 
LQIODWLRQ³0HG,QI´ZLWKERWKDKLJKHUPHDQDQGORZHUVWDQGDUGGHYLDWLRQLQWKHLURXW-
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of-sample returns, and it appears the hedging portfolio with weights (0,1) is slightly 
inferior to (1,1), again confirming it as the conservative choice going forward.  Finally, 
since the question naturally occurs, untabulated analysis shows simply taking a long 
position in T-bills provides a slightly inferior variance ratio of 0.995 but also means an 
average return deficit of 0.22 percent per month in 2008.  In other words, simply 
investing in T-bills is (slightly) more risky than the GA-generated hedging portfolio 
while also leaving the entity underfunded for the year. 
Another natural question that arises concerns the effectiveness of the S&P 500 as 
a hedge for medical inflation.  Intuitively, since medical inflation has generally been 
positive since the 1970s (Figure 1) and the S&P 500 index has also tended to grow over 
time, one might think these two trends might correlate well.  Contrary to this intuition, 
investing in the S&P 500 would serve as a relatively poor hedge for medical inflation 
when considering the GA-generated portfolios.  Taking a long position in the S&P 500 
does not serve as an effective hedge for medical inflation in terms of its variance ratio.  
Respectively, for calendar years 2005, 2006, 2007, and 2008, the variance ratios of the 
hedged portfolio (i.e. long S&P 500; short medical inflation) to the medical inflation 
target series are 271.04 , 232.25, 380.67, and 4,203.12.  The respective correlations 
between the S&P 500 monthly return series and monthly medical inflation of 0.21, -0.40, 
-0.13, and -0.19 for 2005 to 2008 also provide weak support for using the S&P 500 to 
hedge medical inflation.  Finally, using the S&P 500 not only makes the hedged portfolio 
more risky but also fails to manage risk from the standpoint of funding the medical 
liability.  In 2005, 2007, and 2008, the average monthly returns of a hedged portfolio 
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consisting of a long position in the S&P 500 are negative (-0.11, -0.13, and -4.27 percent, 
respectively). 
5HWXUQLQJWRWKH³JRRG´SRUWIROLRUHVXOWLQJIURPWKH*$LWLVIXUWKHUSRVVLEOHWR
generate the parameters in equation (4) to see the out-of-sample hedge ratios for assets 
that form the hedging portfolio.  Table 4 shows these results for the Test period according 
to equation (7).  As an aside, the relative weights in Figure 7, Panel B come from 
normalizing these regression parameters (i.e., dividing each individual parameter by the 
sum). 
ܥܲܫܯܧܦܯܱݐ = ߚ1 + ߚ2 ή ܴ݁ݐሺ81ሻݐ + ߚ3 ή ܴ݁ݐሺ76ሻݐ + ߚ4 ή ܴ݁ݐሺ84ሻݐ + ߚ5 ή ܴ݁ݐሺ229ሻݐ + ߚ6 ή
ܴ݁ݐሺ117ሻݐ + ݒݐ       (7) 
In this model, the ܴ݁ݐሺݔሻ labels refer to the monthly security returns for stock x as 
described earlier.  Table 4 indicates hedge ratios on the individual assets are statistically 
insignificant at conventional levels.  However, this statistical insignificance during the Test 
Period becomes less relevant when we consider that our ultimate concern is the out-of-
sample performance. 
 Two natural concerns with implementing this method are transactions costs and 
the ability to take short positions in the required assets.  Since in this application the 
hedging portfolio is formed at the beginning of the out-of-sample calendar year and 
frozen for the rest of the year, transactions costs occur once.  Therefore, since portfolio 
turnover is almost nonexistent, we do not account for transactions costs in our 
macroeconomic examples.  However, in foreshadowing, the mutual fund and ETF 
extensions in this paper exhibit greater turnover and do account for such transaction 
costs.  Regarding short sale constraints, for this version of the paper, we proceed in the 
spirit of Brandt and Santa-Clara (2006), who also exhibit optimal portfolios consisting of 
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short positions in both stocks and bonds.  At an applied level, clearly short sales must be 
dealt with by the practitioner on an asset-by-asset basis.  Potential future work involves 
altering the fitness function to avoid any short positions. 
Finally, to put these findings into graphical perspective and relate them to past 
work, Figure 8, Panel B compares the possible medical inflation hedging scenarios in the 
mean/standard deviation space.  Knowing the hedged position for the all GA-generated 
cases dominates the natural short position in both the first and second moments from 
3DQHO$3DQHO%SUHVHQWVDUHODWLYHFRPSDULVRQRIWKH*$KHGJLQJSRUWIROLRV¶
performance to the health care mutual funds in the spirit of Jennings, Fraser, and Payne 
(2009).  Clearly the GA hedging portfolio performs superior to the intuitive natural 
hedges represented by the health care-related mutual funds offered by Eaton Vance, 
Vanguard, and Fidelity (ETHSX, VGHCX, and FSPHX, respectively).   
 
Extended Applications: Out-of-Sample Robustness Analysis, Other Macroeconomic 
Series, and Investable Assets 
Out-of-Sample Robustness and Other Macroeconomic Series 
 +DYLQJGHPRQVWUDWHGWKH*$¶VDELOLW\WRILQGDQHIIHFWLYHLQYHVWDEOHKHGJLQJ
portfolio for medical inflation that is also a better hedge than health care-related mutual 
funds using calendar year 2008 as the out-of-sample period, the natural follow-up 
question is its ability to provide good solutions for a more robust set of timeframes as 
well as for other uninvestable macroeconomic series, such as some of the 17 series 
analyzed in Flannery and Protopapadakis (2002).  Additionally, one wonders whether this 
GA technique could perhaps find a parsimonious or better-performing portfolio relative 
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to investable assets such as stock indexes, mutual funds, or exchange-traded funds 
(ETFs).  As the following results show, while the GA performance does not universally 
reduce the risk as measured by portfolio variance, it gains appeal when considering the 
mean return provided to offset this (sometimes very slight) additional risk.  Finally, the 
GA-developed portfolios perform quite well out-of-VDPSOHZKHQ³PLPLFNLQJ´RWKHr 
investable assets such as mutual funds and ETFs. 
 The prior results surrounding medical inflation invite the criticism of look-ahead 
bias.  While up to this point we have chosen a fitness measure weight vector 
retrospectively based on out-of-sample performance that has already occurred, to 
strengthen the argument for applying this GA procedure requires selecting a fitness 
measure a priori without the foresight of which (ݓ1,ݓ2) weight vector is best.  As 
discussed and decided upon earlier, we run all future results with and only with (ݓ1,ݓ2) 
HTXDOWRZKLFKZHFDOOWKH³JRRG´FDVHDQGRQHFRXOGDUJXHLVFRQVHUYDWLYHVLQFHLW
GRHVQRWSURYLGHWKH³EHVW´RXW-of-sample hedging portfolio for medical inflation.  
Making this decision in advance represents the situation we would face in a real-world 
application. 
We select macroeconomic series based on practical relevance as well as data 
availability.  Not all target series are available beginning in January 1967; we note the 
available dates for each series parenthetically in future descriptions.  Additionally, we 
think the results presented could be conservative for a reason beyond the fitness weight 
vector.  While some target series begin in, say, the mid-1980s, we do not expand the 
investable stocks available to hedge the particular series to those that have returns 
beginning in the mid-1980s and continuing until the present. So while we constrain the 
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number of available assets in the hedging portfolios at one level, on another level we 
allow them to expand.  As Brandt and Santa-Clara (2006) highlight, we could include 
conditional assets to expand the set available almost infinitely.  To foreshadow, we do 
increase the available assets in the mutual fund and ETF analyses by incorporating a 
conditioning variable (see Cochrane (1996)), but doing so comes with a price, as altering 
the portfolio more often than annually increases transaction costs.  We account for these 
costs in this analysis.    
One rationale for using this GA technique to hedge other macroeconomic series 
could be for insurers to hedge the payouts to claimants, particularly for homeowners 
policies.  Since various macroeconomic series might best capture these liabilities, we 
look at a host of possibilities, including the housing component of inflation (January 1967 
to December 2008), the Case-Shiller 10-City Composite Housing Price Index (January 
1987 to December 2008), and the Producer Price Index for Residential Construction 
(June 1986 to December 2008).  The first and last series come from FRED, and the Case-
6KLOOHU,QGH[GDWDFRPHVIURPWKH6WDQGDUGDQG3RRU¶VZHEVLWH19 
From a transportation and energy perspective, there could be multiple uses for an 
investment portfolio to hedge associated liabilities such as fuel prices.  For this reason, 
we apply the GA to the energy component of inflation (January 1967 to December 2008), 
transportation inflation (January 1967 to December 2008), spot oil price for a barrel of 
West Texas Intermediate (January 1967 to December 2008), spot price for a gallon of 
New York Harbor kerosene-type jet fuel (April 1990 to December 2008), and monthly 
price per gallon for diesel fuel (March 1994 to December 2008).  FRED provides data on 
                                                          
19 http://www.standardandpoors.com/indices/sp-case-shiller-home-price-indices/en/us/?indexId=spusa-
cashpidff--p-us---- 
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the inflation measures, Dow Jones provides information on the spot oil prices, and the 
Department of Energy is the source for both jet and diesel fuel prices. 
Last, but certainly not least, two macroeconomic series of general interest include 
aggregate inflation and changes in the S&P 500 index.  Bodie (1976) investigated the 
question of hedging aggregate inflation, so this question is not new, and our GA-
generated results support his conclusion that shorting common stocks is an effective 
hedge for inflation.  However, the GA in this paper tells us exactly which five stocks do 
an effective job.  While we anticipate the GA will find a set of five stocks that will 
generally track the S&P 500 index, we do not believe it will be easy for such a portfolio 
to have lower variance given the Statman (1987) finding that well-diversified portfolios 
require 30 to 40 stocks as opposed to the five we select using this GA.  Finally, from a 
time series econometrics standpoint, since all of these data series mentioned are captured 
in levels, we difference the natural log values between periods to convert them into 
returns to correspond with the return values for the hedge portfolios as well as move from 
non-stationary to stationary time series. 
7KHUHVXOWVRIWKH*$¶VSHUIRUPDQFHIRUWKHVHYDULRXVPDFURHFRQRPLFVHULHVDUH
VKRZQLQ7DEOH3DQHOV$WKURXJK'RI7DEOHGHSLFWFDOHQGDU\HDUV¶ZRUWKRIRXW-
of-sample results.  The Panels are in reverse chronological order so we can view more 
recent out-of-sample results first.  We use the calendar years 2005 to 2008 to capture 
recent results across a range of economic climates, with the earliest 2 years (2005-2006) 
showing evidence of economic growth as measured by the S&P 500, followed by a 
UHODWLYHO\³IODW´\HDULQDQGHQGLQJZLWKWKHREYLRXVO\FKDOOHQJLQJHFRQRP\LQ the 
year 2008. 
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Overall, these results show that selecting a set of five investable assets to hedge 
various macroeconomic phenomena is imperfect, which supports the Chen, Roll, and 
Ross (1986) finding that the first-pass Fama-MacBeth (1973) regressions of 
macroeconomic factors on stock portfolios do not perform very well, but it is not 
impossible.  The best variance ratios occur with the S&P 500, the only series having 
ratios of less than unity across all time periods.  It has variance ratios ranging from 0.62 
to 0.87, which indicates the GA-identified hedged positions reduce variance by 13 to 38 
percent.  Additionally, the S&P hedged portfolio provides positive mean monthly returns 
for the most recent two years studied, 2007 and 2008, indicating that perhaps the GA 
technique is most effective in flat or downward-moving markets.  Globally, the worst 
variance ratio is the 2008 Case-Shiller 10-City Composite Index, where the GA-
generated hedged portfolio is 29 percent more volatile than the Case-Shiller Index. 
Looking at medical inflation, the GA portfolios perform well in our estimation.  
In both 2007 and 2008, the variance ratios of the hedged portfolio is lower than 1.0, and 
the worst variance ratio occurs in 2006 at 1.07.  Nevertheless, in every case the entity 
embracing the hedging portfolio is fully funded out-of-sample, with monthly (annual) 
excess returns ranging from 0.13 (1.58) percent in 2007 to 0.33 (4.01) percent in 2008.  
From a mean-standard deviation perspective, the hedging portfolios in 2007 and 2008 
provide an unambiguously better position for the exposed entity.  The Pearson 
correlations between medical inflation and the hedging portfolio presented in Column 5 
provide mixed results; the positive values in 2007 and 2008 are desirable, but the 
negative correlations in 2005 and 2006 are concerning.  The 2005 and 2006 results 
indicate at worst the entity must seriously consider the tradeoff between risk and return, 
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since with slightly more risk it can clearly fund the health care liability.  In no case is the 
GA-generated hedging portfolio unambiguously worse (i.e., higher variance and lower 
return).   
The housing-related series tend to provide mixed results over time.  As a whole, 
the variance ratios are better during the economic growth years of 2005 and 2006 with 2 
of the 3 series having ratios below 1.0 in each year (housing inflation and Case-Shiller in 
2005; Case-Shiller and PPI residential construction in 2006).  However, from the 
perspective of fully-funding the liability, the latter years of 2007 and 2008 provide better 
risk management portfolios with positive mean monthly returns to the hedge portfolios 
for both housing inflation and the Case-Shiller Index.  The target-hedging portfolio 
correlations are positive for PPI residential construction in all years except 2008, but no 
clearly apparent trends emerge for the other series over time or based on the economic 
environment. 
The energy and transportation area includes five series that provide mixed results 
in terms of hedging effectiveness.  Approximately one-half of the series-year 
combinations show reduced risk from taking the hedged position, since 11 of the 20 
combinations exhibit variance ratios under 1.0, and exactly 10 of the 20 series-year 
combinations indicate the hedged portfolio fully funds the liability.  While in the difficult 
economic environment of 2008 all hedged portfolios are slightly more volatile than the 
target with variance ratios ranging from 1.01 (energy inflation, transportation inflation, 
and diesel fuel PPG) to 1.13 (jet fuel spot price), all of the liabilities are overfunded based 
on the positive mean monthly returns to the hedged portfolios.  At the opposite extreme, 
in 2005, all variance ratios are less than one, ranging from 0.86 (jet fuel spot price) to 
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0.99 (energy inflation and diesel fuel PPG), but the hedged portfolios exhibit negative 
mean monthly returns in all but one case (transportation inflation).  Additionally, as a 
group the positive correlations between the target and hedging portfolios are more 
appealing for the year 2005 than for 2008.  In the more flat economic period of 2007, a 
hedged position would reduce risk in four of five cases, with transportation inflation 
representing the exception, but the hedging portfolio would underfund the liability in 
every case.  During the economic growth year of 2006, hedging performance is 
noteworthy for both the oil spot price and transportation inflation, as both exhibit risk-
reducing hedged portfolios that would fully fund the associated liability.  All things 
conVLGHUHGLWDSSHDUVWKH*$KHGJLQJSRUWIROLRV¶HIIHFWLYHQHVVLQDGGUHVVLQJ
energy/transportation-related risk is sensitive to the economic environment, with the 
slightly more effective results appearing to come during difficult economic environments 
like the one that occurred in calendar year 2008. 
Finally, with the other two series of interest, aggregate inflation and the S&P 500 
return series, hedging performance generally appears solid across all periods.  For 
aggregate inflation, the hedged portfolio fully funds the liability in every year studied.  
Both 2008 and 2005 are years where the benefit of the hedging portfolio is unambiguous, 
since besides having mean excess returns, in these years taking the long position in the 
hedging portfolio reduces the volatility of the return series.  While the correlations could 
certainly be higher, with the maximum (minimum) correlation of 0.23 (0.02) occurring in 
2005 (2006), it is encouraging they are non-negative for all out-of-sample years.  For the 
S&P 500, as previously mentioned, it is the only macroeconomic series studied where the 
hedged portfolio exhibits less volatility than the target in every year.  Again, the concern 
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is certainly the underfunding that occurs out-of-sample during the economic growth years 
of 2005 and 2006.  This concern is somewhat mitigated by the correlations between the 
target and the five-stock hedging portfolio, which range from 0.38 in 2007 to 0.70 in 
2008.  Oddly enough, of all the macroeconomic series investigated here, the only two 
containing a bond in the GA-generated hedging portfolio are the energy inflation in 2006 
and the S&P 500 in 2005.  Untabulated results show this short (one-year) bond composes 
over 99 percent of these portfolios, with the energy inflation hedge consisting of a short 
position in the bond and the S&P 500 consisting of a long position.   
 
Other Investable Assets: Mutual Funds and Exchange Traded Funds (ETFs) 
The recent S&P 500 results encourage us to expand our analysis further regarding 
the GA performance for investable assets.  In 2008, the five stocks found by the GA 
create a hedged portfolio that is approximately 40 percent less risky than the S&P 500 
while exhibiting a mean out-of-sample monthly (annual) return of 3.38 percent (49.10 
percent).  While one might be concerned this performance occurs in 2008, a notoriously 
poor market, we are encouraged the GA finds good solutions exactly when investors need 
them.  Again, these GA-generated hedging portfolios consist of stocks listed on the major 
US exchanges, not more speculative assets such as derivatives, which would surely have 
higher expected returns but also likely higher risk.  If an industry such as insurance were 
to invest according to these results, regulators would more likely raise issues if the 
hedging assets for medical inflation consist of corn or soybean futures than common 
stocks. 
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From an investment standpoint, the S&P results indicate the potential for the GA 
to find appealing investment tracking portfolios.  Specifically, the S&P results force us to 
investigate whether the GA can find a portfolio of five stocks that track a mutual fund or 
ETF with perhaps either less return variance and/or higher mean returns out-of-sample.  
To perform an initial exploration of this question, we randomly select ten mutual fund 
series with varying return history lengths and run the GA using these funds as respective 
targets.  As with the macroeconomic series, we keep the weight vector (ݓ1,ݓ2) equal to 
(0,1) to avoid any look-ahead bias.  These funds include those with ticker symbols 
ACMVX (April 2004 to December 2008), BRGIX (December 1998 to December 2008), 
EXOSX (July 2002 to December 2008), EXTAX (April 1998 to December 2008), 
FBALX (January 1987 to December 2008), FCNTX (May 1989 to December 2008), 
FDVLX (July 1989 to December 2008), JMCVX (September 1998 to December 2008), 
SPHIX (November 1994 to December 2008), and WAGTX (January 2001 to December 
2008).  We list the funds and their associated Morningstar style boxes in Figure 9.20   
The major difference between the mutual fund and prior macroeconomic series 
analysis involves the use of conditional weighting on our hedging assets.  Cochrane 
(1996) demonstrates the relevance of using returns that are conditioned on some state 
variable, and Brandt and Santa-Clara (2006) discuss how doing so greatly increases the 
effective assets under consideration.  As we discuss later, doing so comes with the 
transactions costs imposed by frequent rebalancing. 
In this case we condition the hedging asset weights on the predicted value of the 
mutual fund under consideration.  To summarize the problem, the objective in this case is 
                                                          
20 Collected from http://finance.yahoo.com/ 
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to choose five assets, (i, j, k, l, and m) from 306 assets without replacement and weight 
them to form a hedging portfolio according to equation (8). 
ܲ݋ݎݐ݂݋݈݅݋ݐ =  ܽ0 +  ܽ1ܴ݁ݐሺ݅ሻ+ ܽ2ܴ݁ݐሺ݆ሻ+ ܽ3ܴ݁ݐሺ݇ሻ+ ܽ4ܴ݁ݐሺ݈ሻ+ ܽ5ܴ݁ݐሺ݉ሻ
+ܾ1ܴ݁ݐሺ݅ሻܥ݋݊݀ݐ + ܾ2ܴ݁ݐሺ݆ሻܥ݋݊݀ݐ + ܾ3ܴ݁ݐሺ݇ሻܥ݋݊݀ݐ + ܾ4ܴ݁ݐሺ݈ሻܥ݋݊݀ݐ + ܾ5ܴ݁ݐሺ݉ሻܥ݋݊݀ݐ
  
(8) 
where ܴ݁ݐሺݔሻ, represents the return on a particular asset and L«P are the indices that 
indicate one of the 306 assets.  ܽ1. . ܽ5 and ܾ1ǥܾ5 are hedge ratios determined by OLS 
regression.   ܥ݋݊݀ݐ  is a conditioning variable, which is the best predicted mutual fund 
UHWXUQZHFDQJHWIURPDVWHSZLVHUHJUHVVLRQDFURVVWKH³7HVW´SHULRGWKDWLQFOXGHV
PRQWKV¶ODJJHGYDOXHVRIWKHPXWXDOIXQGWKHPDUNHWUHWXUQQHWRIWKHULVN-free rate, the 
S&P 500 return, inflation, the long government bond return, short government bond 
return, and 30-day Treasury Bill returns.  In other words, the conditioning variable is 
formed only using past information that is readily available to predict the future fund 
return.  Notationally, the stepwise regressions include the aforementioned variables at 
time t-NZKHUHN:KLOHGDWDPLQLQJLVFOHDUO\DFULWLFLVPRIWKLVVSHFLILF
technique, the practical goal of this step is to generate the best forecast for the respective 
mutual fund using all relevant information available.  The resulting conditioning variable 
and estimation equation varies by fund, but for example, the conditioning variable for 
fund ACMVX looks like equation (9),   
ܥ݋݊݀ݐ =  ܣܥܯܸܺ෣ ݐ =  ߙො0 + ߙො1ܣܥܯܸ ܺݐെ3 + ߙො2ܯܭܴܶܨݐെ3  + ߙො3ܤ10ܴ݁ݐݐെ2   (9) 
where ܣܥܯܸܺݐ  represents the fund return for month t, ܯܭܴܶܨ is the market return 
minus the risk-free rate, and ܤ10ܴ݁ݐݐ  is the 10-year government bond return for month t.  
This conditioning variable allows the hedge ratios on the individual assets to change with 
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the state-of-the-world as suggested in Cochrane (1996).  As before, we next define the 
hedged position, or hedged portfolio, as ܪݐ  in equation (10). 
ܪݐ = ܲ݋ݎݐ݂݋݈݅݋ݐ െ  ܣܥܯܸ ܺݐ    (10) 
 In evaluating the hedge fitness, we again randomly generate 1,000 candidate 
KHGJHSRUWIROLRVFRQVLVWLQJRIILYH³JHQHV´HDFKDQGGHILQHWKLVVHWDVWKHLQLWLDO
population.  We use the same Test, Validation, and Out-of-Sample periods discussed 
previously.  We regress the mutual fund target series (ܣܥܯܸܺݐ) on these assets and their 
conditioned variables according to Equation (8) using only WKHGDWDLQWKH³7HVW´SHULRG 
Results for these mutual fund targets are found in Table 7 for the out-of-sample 
period calendar year 2008.  From the top-level, the GA finds hedged portfolios (i.e., short 
position in mutual fund and long position in hedging portfolio of five stocks) that reduce 
the variance of simple exposure to the mutual fund in 7 of 10 cases (i.e., EXOSX, 
)'9/;DQG:$*7;DUHWKHH[FHSWLRQV,QWKH³VXFFHVVIXO´FDVHVWDNLQJSRVLWLRQV
in the hedged portfolios reduces risk exposure (i.e., variance) by anywhere from about 5 
to 57 percent.  In the three cases where hedged positions exacerbate the risk, the increase 
in risk ranges from 6 to 47 percent.  Notably, however, for these three funds, the excess 
return of holding the hedged position is non-trivial, ranging from 4.61 (71.77) to 8.94 
(179.32) percent monthly (annually).  Thus the higher risk begets higher returns in these 
FDVHV,QWKHRWKHUFDVHVWKHKHGJLQJSRUWIROLRXQDPELJXRXVO\LPSURYHVWKHLQYHVWRU¶V
situation in that it creates a scenario with less risk and higher returns, ranging from on 
average 2.23 (30.31) to 3.64 (53.49) percent monthly (annually).  For all cases the 
correlation between the target fund and hedging portfolio is above zero (see Column 9).  
As we note in Table 7, in the cases of BRGIX and EXTAX the stepwise prediction 
regression finds no variables that performed well in predicting future returns to these 
129 
 
 
 
funds.  Thus the out-of-sample investments in the hedging portfolios for these two funds 
are fixed for the entire out-of-sample period, just as they are for the prior macroeconomic 
target series.   
To emphasize the point that the GA-generated solutions are unambiguously 
better, we look at adjusting the hedging portfolios for risk using both the Sharpe ratio and 
-HQVHQ¶VDOSKD  Because it is practically difficult to take a short position in a mutual fund 
per se without simply shorting each stock in the fund, our risk-adjusted comparisons 
juxtapose the GA-generated hedging portfolio with the target mutual fund.  Columns 5 
and 6 of Table 7 quantify the Sharpe ratios for both the hedging portfolio and the target.  
The shaded values indicate which series has the higher Sharpe ratio, and in every case the 
GA-generated portfolios offer greater returns out-of-sample for each unit of risk (as 
measured by standard deviation).  We emphasize this point using Figure 9, Panel A, 
which depicts the out-of-sample alternatives for an investor: (1) either invest in ACMVX 
or one of the other 9 funds or (2) invest in the GA-generated five-stock portfolio 
DOWHUQDWLYHRUFRXQWHUSDUWODEHOHG³$$&09;´RU³$[[[[[´ZKHUH[[[[[
represents the ticker for one of the other nine funds.  The arrows on this plot originate at 
the target fund and proceed to the GA-generated five-asset portfolio.  For example, the 
circled points indicate alternative (1) above, which is to invest in ACMVX, connected 
with alternative (2), which is to invest in the GA-JHQHUDWHG³PLPLFNLQJ´ILYH-asset 
portfolio, or (A) ACMVX.  Since most investors with typical mean-variance preferences 
would desire higher return and lower risk, it is clear (A) ACMVX presents both for this 
out-of-VDPSOHSHULRG%H\RQGWKLVVSHFLILFH[DPSOHLQDOOEXWRQHFDVHWKH³QRUWKZHVW´
direction of the arrows unambiguously indicates the GA-generated portfolio provides 
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GRPLQDQWILUVWDQGVHFRQGPRPHQWV7KHORQH³QRUWKHDVW´DUURZLHIXQG:$*7;
presents a scenario where an investor must make a judgment call based on risk 
preferences over the mean and standard deviation of returns.  Notably, if one were able to 
short the fund and go long the GA-generated portfolio, the results would become stronger 
than depicted. 
As mentioned before, one clear consideration when opting for the GA-generated 
five-asset portfolio is transaction costs.  While the investing policy (possibly) changes 
annually, the conditional nature of the hedging portfolio means its composition likely 
changes monthly based on updated predictions about the target series according to 
equation (11), which is simply equation (8) re-arranged to group terms associated with 
each asset i, j, k, l, and m. 
ܲ݋ݎݐ݂݋݈݅݋ݐ =  ܽ0 +  ሺܽ1 + ܾ1ܥ݋݊݀ݐሻܴ݁ݐሺ݅ሻ+ (ܽ2 + ܾ2ܥ݋݊݀ݐ)ܴ݁ݐሺ݆ሻ+ (ܽ3
+ ܾ3ܥ݋݊݀ݐ)ܴ݁ݐሺ݇ሻ+ ሺܽ4 + ܾ4ܥ݋݊݀ݐሻܴ݁ݐሺ݈ሻ + (ܽ5 + ܾ5ܥ݋݊݀ݐ)ܴ݁ݐሺ݉ሻ 
 
The weight placed on each asset varies with the state-of-the-world, ܥ݋݊݀ݐ , or the 
predicted value of the fund described with equation (9).  As a result, each of the five 
securities in the hedging portfolio is likely traded monthly to establish the optimal 
position going forward.  Thus the transactions costs will impact the return to the hedging 
portfolio.  Assuming that each stock is traded once per month, each year will see 60 
WUDGHV,QWKH³ZRUVW´FDVHRI)&17;ZKLFKVKRZVDQDYHUDJHH[FHVVUHWXUQWRWKH
hedged portfolio of 2.48 percent per month without transaction costs, the effective annual 
return is 34.17 percent.  Roughly calculated, dividing this excess annual return by the 60 
trades indicates the hedging portfolio still proves more appealing than the actual fund (in 
the second moment) if trades cost less than 0.57 percent on average.   
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5HVHDUFKRQWUDQVDFWLRQFRVWLQGLFDWHVWKDWODUJHWUDGHUVVXFKDVLQ)LGHOLW\¶V
agreement with Lehman Brothers costs can be as low as approximately 2 to 2.5 cents per 
share.21  This same book excerpt indicates an overall rate for sales traders, block traders, 
program traders, and algorithm trading for transaction costs are approximately 3.3 cents 
per share.  According to another source, in fourth quarter 2004, NYSE (NASDAQ) 
transactions cost the average investment manager 0.26% (0.35%) per trade.22  To remain 
conservative in our analysis, we assume the GA identifies only NASDAQ stocks and that 
each of the five stocks identified are traded every month.  Thus we assume a monthly loss 
of approximately 1.75% due to transaction costs.  Continuing the ACMVX example 
shown above, the circled points in Table 10, Panel B show the monthly effect in the 
return-risk space of monthly transactions costs of 1.75 percent.  The return to the GA-
generated portfolio, (A) ACMVX, decreases by 1.75 percent compared to the return 
shown in Panel A.  Even though (A) ACMVX exhibits a negative mean monthly return, 
an investor with typical mean-variance preferences would still prefer this GA-generated 
portfolio to the ACMVX fund return-risk combination.  Overall, Figure 9, Panel B 
demonstrates that even with this conservative assumption toward transaction costs, the 
GA hedging portfolios remain unambiguously better out-of-sample than the target funds 
in 9 of 10 cases for the calendar year 2008. 
%HVLGHVWKH6KDUSH5DWLR&ROXPQVDQGVKRZWKHFRPSDULVRQRI-HQVHQ¶V
DOSKDXVLQJDVLQJOHIDFWRULH&$30PRGHO,QRIWKHIXQGVWKH-HQVHQ¶VDOSKD
is absolutely higher for the GA-generated portfolio than for the target fund out-of-sample.  
                                                          
21 http://www.automatedtrader.net/online-exclusive/631/transaction-cost-research 
22 
http://www.capco.com/files/pdf/71/02_SERVICES/06_Market%20impact%20Transaction%20cost%20ana
lysis%20and%20the%20financial%20markets%20%28Opinion%29.pdf 
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However, in only 2 of these cases (i.e., ACMVX and FBALX) is the alpha significantly 
different than zero.  Our caveat with this measure is that we do not set up the fitness 
IXQFWLRQWRPD[LPL]HWKLV-HQVHQ¶VDOSKDPHDVXUHVRWKHVHUHVXOWVDUe but a positive 
externality of the fitness function we define in equation (7).  Certainly altering the fitness 
function to incorporate alpha is a possibility when applying the GA technique, and we 
leave it for future research.  Overall, it appears from this sample of mutual funds that 
using the GA allows one to mimic various mutual funds quite well and possibly 
outperform them out-of-sample in the first two statistical moments. 
Finally, since mutual funds exhibit a short-selling constraint, we move to 
Exchange-Traded Funds, or ETFs, which do allow short positions.  This time we use 5 
randomly-selected ETFs as the target series for this GA technique.  Table 8 and its Panels 
A through E, along with Figure 10 Panels A and B, depict the results for these ETFs that 
are analogous to the mutual fund results provided earlier.  The ETFs sampled are EWC 
(April 1996 to December 2008), DIA (January 1998 to December 2008), IWD (May 
2000 to December 2008), IXN (November 2001 to December 2008), and IJT (August 
2000 to December 2008).  As with the mutual funds results, the GA finds quite effective 
mimicking, or hedging, portfolios for these random ETFs.  In every case the hedged 
portfolio of going long the five-asset portfolio and shorting the ETF reduces the out-of-
sample variance relative to simply going short the ETF.  This reduction ranges from 
approximately 17 (EWC) to 85 percent (IXN).  Additionally, in every case shown there 
exists an average positive excess return to holding the hedged portfolio.  This monthly 
(annual) return premium ranges from 1.74 (22.92) to 4.39 (67.51) percent in our out-of-
sample period.  The correlations are again positive in all ETF cases.  The Sharpe ratios 
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for the hedging portfolios outpace those for the target ETFs in every case, and the 
JenVHQ¶VDOSKDPHDVXUHVDUHDJDLQPL[HG)LJXUH3DQHO$3DQHO%VKRZVWKH
performance of the ETF and GA-generated hedging portfolio in mean/standard deviation 
space without (with) transaction costs as conservatively quantified earlier.  In all five 
cases the GA set of assets is preferred, even when we include the assumed transaction 
costs as discussed with mutual funds.  In summary, the GA again generates effective out-
of-sample hedging portfolios. 
To reiterate the caveat discussed earlier, while the results shown so far appear to 
support the GA as a viable technique to create hedging portfolios, we have started the 
Test Period in the case of each target, whether macroeconomic series, mutual fund, or 
ETF, to maximize the amount of time series information possible.  There is certainly 
merit to using a shorter time horizon for estimating asset weights than beginning in 1967 
since using data from four decades ago inherently assumes relationship stability that has 
existed over that timeframe will continue for another 12 months.  It is almost a certainty 
that using a shorter Test Period will change the results, but we cannot currently speculate 
as to the direction.  Therefore, we leave this data collection and incorporation effort to a 
future generation of this research. 
 
Conclusions 
Historically it seems the effort to tie asset pricing theory and empirical 
phenomena has focused on using macroeconomic data to explain asset returns (e.g., 
Chen, Roll, and Ross (1986)).  However, there exist important risk-reduction reasons for 
using inveVWDEOHDVVHWVWR³H[SODLQ´RUPRUHDSSURSULDWHO\KHGJHQRQ-investable 
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macroeconomic series.  In just one example, as Jennings, Fraser, and Payne (2009) 
highlight, many large entities could benefit from reducing their future exposure to 
medical care costs.  From an insurance standpoint, there exist an almost boundless 
number of non-investable risky phenomena that one might wish to protect against by 
investing in particular assets.  For example, property insurers might wish to manage the 
risk imposed by construction costs, or mass carriers might wish to offset their 
transportation or energy consumption risk.  The Genetic Algorithm (GA) technique 
presented in this paper provides a viable alternative for addressing such problems. 
The purpose of this paper is to demonstrate that the Holland (1975) Genetic 
Algorithm (GA) process can find such hedging portfolios based on user-defined 
parameters in a relatively efficient manner.  In the case of medical inflation, across the 
out-of-sample time period from 2005 to 2008, these five-asset GA-generated portfolios 
appear to perform much better than the current investable mutual funds at managing the 
risk of escalating health care expenses.  Using these GA-generated hedging portfolios at 
worst approximates the same risk (i.e., variance) level as exposure to medical inflation 
itself, but they also provide superior returns in the out-of-sample months investigated, 
UHVXOWLQJLQDQHQWLW\¶VDELOLW\WRIXOO\IXQGWKHDVVRFLDWHGOLDELOLWLHVE\LQYHVWLQJLQWKHVH
portfolios. 
The results for nine other macroeconomic series presented here, while mixed 
overall, generally show a weakly-preferred situation.  The GA-generated portfolios at 
least provide an opportunity for entities to tradeoff their desired levels of risk and return.  
It is rare that the hedged position formed by holding a long position in the GA portfolio 
against a natural short position in the macroeconomic series presents an unambiguously 
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worse scenario for the hedging entity.  In only 4 of the 40 series-year combinations (PPI 
residential construction in 2008, transportation inflation in 2007, diesel fuel in 2006, and 
Case-Shiller 10-City Composite Index in 2005) are the hedged portfolio variance higher 
than the target series and the entity underfunded in the out-of-sample year.  On the other 
hand, for almost three times as many (11) of the series-year combinations, the GA-
recommended hedged position unambiguously improves a hedging entities situation by 
fully funding the liability with less out-of-sample risk.  The remaining 25 series-year 
combinations allow the liable party to tradeoff risk and return when deciding whether to 
manage its risk using the GA portfolio.  
The GA technique described in this paper provides a mechanism to find 
commonly-traded asset combinations to address exposure to non-traded risk.  One 
extension of this research could involve including additional assets in the hedging 
portfolios (e.g., 10 stocks) with the hope of decreasing the inherent unsystematic risk in 
the existing portfolios.  And the results for tracking investable assets, while less robust in 
this presentation, are encouraging and present another avenue for future research. 
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Figure 1 
Monthly Consumer Price Index (CPI) Measures 
January 1967-August 2009 
 
CPIAUCSL: Aggregate CPI 
CPIMEDSL: Medical Component of CPI 
CPIHOSSL: Housing Component of CPI 
CPIUFDSL: Food Component of CPI 
CPITRNSL: Transportation Component of CPI 
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Figure 2 
Initial Population for Genetic Algorithm (GA) 
 
Assets included in the Candidate Solution 
Candidate Solution # Ret(i) Ret(j) Ret(k) Ret(l) Ret(m) Fitness Level 
1 1 7 25 36 41 1.02 
2 23 9 7 29 31 0.8 
3 7 3 2 19 15 2 
* * * * * * * 
* * * * * * * 
* * * * * * * 
721 22 15 14 9 38 1.05 
* * * * * * * 
* * * * * * * 
1000 2 6 28 7 11 0.25 
 
We choose 1,000 possible asset combinations to form hedge portfolios. These are referred to as 
parents or candidate solutions.  Each candidate solution includes the return series from 5 assets 
out of a universe of 3,000 assets.  For example, candidate 1 forms a hedge portfolio using assets 
1,7, 25, 36, and 41.  The hedge is estimated by equally-weighting these assets into a portfolio 
according to the equation below, 
 
ܴ݁ݐܪ݁݀݃݁ ,ݐ =  0.2 כ ܴ݁ݐሺ݅ሻݐ + 0.2 כ ܴ݁ݐሺ݆ሻݐ + 0.2 כ ܴ݁ݐሺ݇ሻݐ + 0.2 כ ܴ݁ݐሺ݈ሻݐ + 0.2 כ ܴ݁ݐሺ݉ሻݐ  
 
where i = 1, j = 7, k = 25, l = 36, and m = 41. 
 
The degree of hedging effectiveness is then calculated and UHFRUGHGDVWKHFDQGLGDWH¶VILWQHVV 
level.  Fitness levels indicate the extent to which the objective function (see equation (1)) is 
optimized. 
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Figure 3 
GA Pairing Example 
 
Panel A 
Ranking by Fitness 
 
Candidate Solution # Ret(i) Ret(j) Ret(k) Ret(l) Ret(m) Fitness Level 
1000 2 6 28 7 11 0.25 
2 23 9 7 29 31 0.8 
1 1 7 25 36 41 1.02 
721 22 15 14 9 38 1.05 
3 7 3 2 19 15 2 
* * * * * * * 
 
The initial candidate population is ranked according to fitness.  The most fit candidates 
are called the breeding population. 
 
Panel B  
Pairing 1: Crossover Equal to 2 
 
Candidate Solution # Ret(i) Ret(j) Ret(k) Ret(l) Ret(m) Fitness Level 
1000 2 6 28 7 11 0.25 
2 23 9 7 29 31 0.8 
Offspring 1 23 9 28 7 11 
Offspring 2 2 6 7 29 31 
 
Candidate 1000 and 2 constitute the first pairing based on their best fitness.  They produce two 
offspring or alternative solutions by the process of crossover.  With a crossover of 2, Ret(i) and 
Ret(j) from candidate 1000 and 2 are swapped while the remaining three assets remain the same.  
 
Panel C 
Pairing 2: Crossover Equal to 3 
 
Candidate Solution # Ret(i) Ret(j) Ret(k) Ret(l) Ret(m) Fitness Level 
1 1 7 25 36 41 1.02 
721 22 15 14 9 38 1.05 
Offspring 3 22 15 14 36 41 
Offspring 4 1 7 25 9 38 
 
Candidate 1 and 721 constitute the second pairing based on their fitness.  They produce two 
offspring or alternative solutions by the process of crossover.  With a crossover of 3, Ret(i) , 
Ret(j) and Ret(k) from candidate 1 and 721 are swapped while the remaining two assets remain 
the same. 
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Figure 4 
GA Proof of Concept Performance 
 
Panel A 
0RQWKO\5HWXUQRI7DUJHW6HULHV³7DUJHW´YHUVXV%HVW+HGJLQJ3RUWIROLR³5HWXUQKHGJH´
Chosen by the GA 
January 1967-August 2009 
 
 
 
Panel B 
6FDWWHU3ORWRI7DUJHW6HULHV³7DUJHW´YHUVXV+HGJLQJ3RUWIROLR³5HWXUQKHGJH´ 
January 1967-August 2009 
  
 
 
Correlation = 0.96 
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Figure 5 
Hedging Portfolio Examples 
 
Panel A: Ideal Hedging Portfolio 
 
 
 
Panel B: Uncorrelated (Constant Return) Hedging Portfolio Example 
 
 
 
 
Panel B: Correlated (Varying Return) Hedging Portfolio Example 
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Figure 6 
Division of the Data and Evaluation of Fitness 
 
 
 
7KH³7HVW´SHULRG-DQXDU\-December 2006) is used to estimate the hedge ratio 
parameters for ොܽ0 ǥ . ොܽ5  and ෠ܾ0 ǥ . ෠ܾ5 using OLS regression.  The hedging effectiveness is 
PHDVXUHGRYHUERWKWKH³7HVWLQJ´SHULRGDQGWKH³9DOLGDWLRQ´SHULRG-DQXDU\2007-December 
20071RWHWKDW³9DOLGDWLRQ´SHULod is outside the range used to estimate the parameters.  The 
³2XW-of-6DPSOH´SHULRGLVWKHPRQWKVVSDQQLQJ-DQXDU\-December 2008.  The variance 
of ܪݐ  IRUWKH³7HVW´DQG³9DOLGDWLRQ´SHULRGVLVXVHGWRPHDVXUHWKHH[WHQWWRZKLFKWKHKHGJH
candidDWHRSWLPL]HVWKHREMHFWLYHIXQFWLRQFDOOHGWKHILWQHVV:HGHILQHDVRXU³ILWQHVV´D
weighted average of the two variance measures: 
ܨ݅ݐ݊݁ݏݏ = ݓ1ߪܪ,ܶ݁ݏݐ2 +ݓ2 ቆ
ߪܪ,ܸ݈ܽ݅݀ܽݐ݅݋݊2
ߪܪ,ܶ݁ݏݐ2
ቇ 
ߪݔ ,ݕ2  is the variance of series x  during period y.  x consists of the hedging portfolio consisting of 
five assets, the target series (i.e., medical inflation in this case), or the hedged portfolio, H, which 
represents a long position in the hedging portfolio and short position in the target series (i.e., 
medical inflation).  y consists of the Test, Validation, or Out-of-Sample period as shown and 
described above.  (ݓ1,ݓ2) represent the subjectively-assigned weights for each respective term. 
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Figure 7 
Genetic Algorithm Portfolio Performance for Out-of-Sample Period 
January 2008-December 2008 
 
 
Panel A: Weight Vector (1,1) 
 
Monthly Returns for Hedged Portfolio (H), Genetic Algorithm Hedging Portfolio 
(RETHEDGEPORT), and Medical Inflation (TARGET) for Out-of-Sample Period 
 
 
 
 
GA Hedging Portfolio Assets and Weights 
 
Stock Number Industry Membership Relative Weight 
274 Processed & Packaged Goods -1.12 
79 Entertainment -0.38 
199 Specialty Retail 0.39 
33 Security & Protection Services -0.11 
214 Industrial Equipment 0.21 
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Panel B: Weight Vector (0,1) 
 
 
GA Hedging Portfolio Assets and Weights 
 
Stock Number Industry Membership Relative Weight 
81 Chemicals -0.11 
76 Business Equipment -0.02 
84 Electric Utilities -0.53 
229 Manufacturing 0.02 
117 Steel & Iron -0.36 
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Panel C: Weight Vector (1,0) 
 
 
 
GA Hedging Portfolio Assets and Weights 
 
Stock Number Industry Membership Relative Weight 
306 T-Bill 1.00 
297 Accident & Health Insurance 0.00 
288 Restaurants 0.00 
225 Rental & Leasing Services 0.00 
32 Telecommunications 0.00 
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Figure 8 
Medical Inflation and Potential Hedging Portfolio Return Characteristics in Mean-
Standard Deviation Space for Out-of-Sample Period 
January 2008-December 2008 
 
Panel A: GA Portfolios Relative to Each Other 
 
 
 
Panel B: GA Portfolios Relative to Other Health-Care Related Mutual Funds 
 
 
 
Definitions: 
Med Inf: medical inflation series 
(H) Med Inf (x,y): hedged portfolio (RetPortfolio ± Medical Inflation) using (w1,w2) = (x,y) 
ETHSX: Eaton Vance Worldwide Health Science A 
VGHCX: Vanguard Health Care 
FSPHX: Fidelity Select Health Care   
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Figure 9 
Mutual Fund and Potential Hedging Portfolio Return Characteristics  
Mean-Standard Deviation Space 
Out-of-Sample Period 
January 2008-December 2008 
 
Panel A: No Transaction Costs 
 
 
 
Panel B: 1.75% per month Transaction Costs 
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ACMVX: American Century Mid Cap 
Value Inv 
 FCNTX: Fidelity Contrafund 
 
 
 
 
BRGIX: Bridges Investment 
  
FDVLX: Fidelity Value 
 
 
 
 
EXOSX: Manning & Napier Overseas 
  
JMCVX: Janus Perkins Mid Cap Value 
T 
 
 
 
 
EXTAX: Manning & Napier Tax 
Managed A 
  
SPHIX: Fidelity High Income 
 
  
Unavailable 
 
FBALX: Fidelity Balanced 
  
WAGTX: Wasatch Global Science & 
Technology 
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Figure 10 
Exchange-Traded Fund (ETF) and Potential Hedging Portfolio Return Characteristics  
Mean-Standard Deviation Space  
Out-of-Sample Period 
January 2008-December 2008 
 
Panel A: No Transaction Costs 
 
 
 
Panel B: 1.75% per month Transaction Costs 
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EWC: iShares MSCI Canada Index 
 
 
DIA: SPDR Dow Jones Industrial Average  
 
Unavailable 
 
 
IWD: iShares Russell 1000 Value Index 
 
 
IXN: iShares S&P Global Technology 
 
 
IJT: iShares S&P SmallCap 600 Growth 
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Table 1 
Fitness Level for Asset Portfolios across Generations using Proof of Concept Returns 
January 1967-August 2009 
 
Population Breeding Sample 
Generation 
Minimum 
Fitness Level 
Mean  
Fitness Level 
Maximum 
Fitness Level Mean Fitness Level 
1 7.61 40.34 309.31 21.12 
2 7.00 36.09 379.93 13.43 
3 5.29 37.36 302.12 9.30 
4 4.68 38.27 358.80 7.44 
5 4.28 36.60 480.70 5.83 
6 4.28 37.98 423.33 4.86 
7 4.28 41.47 234.77 4.46 
8 4.28 56.43 359.41 4.28 
9 4.28 54.81 338.54 4.28 
10 4.28 56.56 349.44 4.28 
 
This table shows how the GA population evolves over many generations.  Fitness level is 
the quantified measure for the variance of a time series called ܧݎݎ݋ݎ, which is the difference 
between a target series and portfolio of five assets seeking to hedge the target series.  The 
objective function is shown below. 
 
ܯ݅݊݅݉݅ݖ݁ ܸܽݎ݅ܽ݊ܿ݁ሺܧݎݎ݋ݎሻ 
where  ܧݎݎ݋ݎݐ = ܴ݁ݐܪ݁݀݃݁  ܲ݋ݎݐ݂݋݈݅݋ ,ݐ െ  ܴ݁ݐܶܽݎ݃݁ݐ ,ݐ  
 
ܴ݁ݐܶܽݎ݃݁ݐ ,ݐ  (ܴ݁ݐܪ݁݀݃݁  ܲ݋ݎݐ݂݋݈݅݋ ,ݐ  ) is the return of the target series (hedge portfolio series) at time 
t. 
In this proof of concept example, the hedging assets are simulated investable assets, with 
representative factor loadings.  To generate the simulated assets, we estimate betas of a five-
factor model for each asset from a random sample of 3,000 assets from CRSP, pulled from the 
DVVHWVZLWKDWOHDVWPRQWKV¶UHWXUQVEHWZHHQ-DQXDU\DQG'HFHPEHU7KH
five factors include the market risk premium, SMB, HML, default risk premium (DEF), and term 
risk premium (TERM).  The target series is a simulated asset composed of the median factor beta 
values from the 3,000 sampled assets. 
In the table, minimum fitness level is for the portfolio of five assets among the entire 
breeding population, which has 1,000 members, that has the lowest, or best, fitness measure.  The 
mean (maximum) fitness level is the population mean (maximum).  In this example, the breeding 
population consists of 10 percent of the population, or 100 members, and the final column shows 
the mean fitness level for this breeding sub-population. 
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Table 2 
Fitness Level for Asset Portfolios over Generations using Actual Target (Medical Inflation) 
and Investable Assets (303 Stocks from CRSP, Long Government Bond, Short Government 
Bond, and Treasury Bill) During the Test and Validation Periods 
January 1967-December 2007 
 
Weight = 
(1,1) Population Breeding Sample 
Generation 
Minimum 
Fitness Level 
Mean  
Fitness Level 
Maximum 
Fitness Level Mean Fitness Level 
1 0.271 0.339 0.504 0.301 
2 0.250 0.338 0.504 0.282 
3 0.246 0.332 0.536 0.268 
4 0.242 0.333 0.506 0.258 
5 0.242 0.339 0.575 0.254 
6 0.240 0.343 0.609 0.251 
7 0.233 0.339 0.533 0.248 
8 0.233 0.339 0.521 0.245 
9 0.233 0.337 0.500 0.242 
10 0.233 0.347 0.516 0.242 
 
This table shows how the GA population evolves over many generations.  Fitness 
level is the quantified by the following. 
 
ܨ݅ݐ݊݁ݏݏ = ݓ1ߪܪ,ܶ݁ݏݐ2 +ݓ2 ቆ
ߪܪ,ܸ݈ܽ݅݀ܽݐ݅݋݊2
ߪܪ,ܶ݁ݏݐ2
ቇ 
 
ߪݔ ,ݕ2  is the variance (mean) of series x  during period y.  x consists of the hedging portfolio 
consisting of five assets, the target series (i.e., medical inflation in this case), or the hedged 
portfolio, H, which represents a long position in the hedging portfolio and short position in the 
target series (i.e., medical inflation).  y consists of the Test, Validation, or Out-of-Sample period 
as shown and described above.  (ݓ1,ݓ2) represent the subjectively-assigned weights for each 
respective term and equal to (1,1) here. 
 The investable assets in this example consist of 303 stocks from CRSP that have returns 
from January 1967 to December 2008 and three government bond/bill return series (i.e., 10-year 
bond, one-year bond, and 30-day bill). 
In the table, minimum fitness level is for the portfolio of five assets among the entire 
breeding population, which has 1,000 members, that has the lowest, or best, fitness measure.  The 
mean (maximum) fitness level is the population mean (maximum).  In this example, the breeding 
population consists of 10 percent of the population, or 100 members, and the final column shows 
the mean fitness level for this breeding sub-population. 
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Table 3 
Portfolio Hedging Effectiveness against Medical Inflation  
Out-of-Sample Period 
January 2008-December 2008 
 
Weights 
(w1, w2) 
Variance Ratio 
ቆ
࣌ࡴ,ࡻ࢛࢚࢕ࢌࡿࢇ࢓࢖࢒ࢋ૛
࣌ࢀࢇ࢘ࢍࢋ࢚,ࡻ࢛࢚࢕ࢌࡿࢇ࢓࢖࢒ࢋ
૛ ቇ Assets  (Return Series Stock Number) 
Generation 
Converged 
Mean Excess 
Monthly Return 
of Hedging 
Portfolio vs. 
Medical 
Inflation 
(1,1) 0.866 274 79 199 33 214 9 0.316 
(0,1) 0.971 81 76 84 229 117 7 0.328 
(1,0) 0.513 306 297 288 225 32 3 0.105 
 
Column 1 shows the weights implemented in the fitness measure shown in equation (7).  Column 
2 depicts the ratio of the variance of the hedged portfolio, H, to the variance of medical inflation 
for the Out-of-Sample period (January 2008-December 2008).  Column 3 shows the assets that 
compose the hedging portfolio.  Each number, 1 to 306, represents an index referring to a return 
series of an traded stock or government bond who has returns in CRSP from January 1967 to 
'HFHPEHU³*HQHUDWLRQ&RQYHUJHG´VKRZVWKHJHQHUDWLRQRIWKHJHQHWLFDOJRULWKPZKHUH
the best solution appears to have stabilized.  The final Column quantifies the mean monthly 
excess return to the hedging portfolio over the mean monthly medical inflation, or Ret(Hedge) ± 
CPIMEDMO, for the Out-of-Sample period. 
 
Assets 
Stock Number Industry Membership 
274 Processed & Packaged Goods 
79 Entertainment 
199 Specialty Retail 
33 Security & Protection Services 
214 Industrial Equipment 
81 Chemicals 
76 Business Equipment 
84 Electric Utilities 
229 Manufacturing 
117 Steel & Iron 
306 T-Bill 
297 Accident & Health Insurance 
288 Restaurants 
225 Rental & Leasing Services 
32 Telecommunications 
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Table 4 
Hedging Portfolio Performance in Funding $1M Health Care Liability 
January 2008-December 2008 
 
Medical 
Inflation 
(%) 
Health Care 
Costs 
($M) 
Portfolio 
Return 
(%) 
Portfolio 
Assets 
($M) 
Initial Investment 
Required to Offset Cost 
($M) 
Excess at 
Time 0 
(%) 
Jan 0.48 1.005 0.57 1.006 0.999 0.09 
Feb 0.12 1.006 0.53 1.011 0.995 0.50 
Mar 0.22 1.008 0.53 1.016 0.992 0.81 
Apr 0.15 1.010 0.53 1.022 0.988 1.19 
May 0.14 1.011 0.45 1.026 0.985 1.50 
Jun 0.26 1.014 0.56 1.032 0.982 1.80 
Jul 0.10 1.015 0.54 1.038 0.978 2.23 
Aug 0.21 1.017 0.51 1.043 0.975 2.51 
Sep 0.27 1.019 0.60 1.049 0.972 2.84 
Oct 0.15 1.021 0.66 1.056 0.967 3.32 
Nov 0.24 1.024 0.57 1.062 0.964 3.64 
Dec 0.27 1.026 0.58 1.068 0.961 3.93 
 
This table presents the funding performance of an investment in the medical inflation hedging 
portfolio consisting of assets 81, 76, 84, 229, and 117.  Assuming an entity is setting aside $1 
million to fund the anticipated medical care expense it will incur sometime during 2008, Column 
2 shows monthly medical inflation, with Column 3 showing what the $1 million liability would 
cost if incurred at the end of the associated month.  Column 4 shows the monthly hedging 
portfolio return, and Column 5 translates these returns into dollar values if the $1 million set-
aside is invested in the hedging portfolio.  Column 6 shows how much of the original $1 million 
would have been needed to offset the liability exactly, with Column 7 showing the excess initial 
funds as a percentage at the beginning of the year if the whole liability were to occur at the end of 
the associated month. 
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Table 5 
Hedge Ratios for ³*RRG´ Genetic Algorithm Portfolio for Test Period 
January 1967-December 2006 
 
Parameter P-Value 
Constant 0.537 0.000 
Ret(81) -0.00037 0.850 
Ret(76) -0.00006 0.970 
Ret(84) -0.00171 0.453 
Ret(229) 0.00007 0.938 
Ret(117) -0.00118 0.556 
R-Squared 0.003 
N  420 
 
 
OLS regression results for the following specification, 
 
ܥܲܫܯܧܦܯܱݐ =  ܽ0 + ܽ1ܴ݁ݐሺ81ሻ+ ܽ2ܴ݁ݐሺ76ሻ+ ܽ3ܴ݁ݐሺ84ሻ+ ܽ4ܴ݁ݐሺ229ሻ+ ܽ5ܴ݁ݐሺ117ሻ 
 
for the Test Period, January 1967 to December 2006, where is monthly medical inflation and is 
the return series for a stock bond with index x.  The estimated parameters represent the hedge 
ratios for each respective asset x.  The weight vector (ݓ1,ݓ2) equals (0,1) for the fitness function 
(see equation (6)) used to generate this hedging portfolio. 
 
Assets 
Stock Number Industry Membership 
81 Chemicals 
76 Business Equipment 
84 Electric Utilities 
229 Manufacturing 
117 Steel & Iron 
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Appendix C 
Stock Numbers, Tickers, and Industries 
 
Number Ticker Industry  Number Ticker Industry 
1 SUN Oil & Gas  81 DOW Chemicals 
3 ABL Rubber & Plastics  82 DPL Diversified Utilities 
4 ABT Pharmaceuticals  83 DTE Electric Utilities 
8 AEE Diversified Utilities  84 DUK Electric Utilities 
10 AIP Paper Products  86 EDE Electric Utilities 
11 AIT Industrial Equipment  87 EGN Gas Utilities 
13 ALK Airlines  88 EIX Electric Utilities 
15 AMR Airlines  89 EK Photo Equipment 
16 AP Industrial Machinery  90 EML Tools 
20 ASA Financial  93 ESP Electronics 
21 ASH Chemicals  97 F Auto Manufacturing 
24 AVP Personal Products  102 FMC Chemicals 
25 AVT Electronics  103 FO Home Furnishings 
30 BAX Medical Supplies  104 FOE Chemicals 
32 BCE Telecommunications  105 FPL Electric Utilities 
34 BDK Machine Tools & Equip  108 GAM Financial 
36 BFA Beverage  111 GD Aerospace/Defense 
37 BFB Beverage  113 GIS Food 
38 BGG Industrial Machinery  114 GLW Communication Equip 
40 BMY Pharmaceuticals  117 GNI Steel & Iron 
41 BP Oil & Gas  118 GR Aerospace/Defense 
42 BRN Oil & Gas  120 GV Heavy Construction 
43 BWS Textiles  122 GY Conglomerate 
44 CAS Materials Wholesale  123 HAL Oil & Gas 
45 CAT Heavy Equipment  124 HE Electric Utilities 
46 CBE Conglomerate  127 HL Silver Mining 
48 CEG Electric Utilities  128 HNZ Food 
49 CEM Chemicals  132 HPQ Computer Systems 
51 CFS Management Services  135 HSC Steel & Iron 
53 CHG Diversified Utilities  137 HUBA Electronic Equpiment 
56 CMC Steel & Iron  138 HUBB Electronic Equpiment 
64 CR Conglomerate  139 IBM Computer Systems 
66 CSC IT Services  140 IDA Electric Utilities 
70 CUB Science Instruments  143 IMO Oil & Gas 
71 CUO Building Materials  145 IR Industrial Equipment 
72 CVR Auto Manufacturing  146 IRF Semiconductors 
76 DBD Business Equipment  149 JCP Department Store 
77 DD Chemicals  151 K Food 
168 
 
 
 
Number Ticker Industry  Number Ticker Industry 
153 KO Beverage  228 ROL Business Services 
154 KR Grocery  229 RONC Manufacturing 
156 L Property/Casualty Ins  230 RRD Business Services 
157 LDR Research Services  231 RSH Electronics Retail 
158 LG Gas Utilities  233 S Wireless Comm 
160 LMT Aerospace/Defense  234 SCG Utilities 
161 LUK Lumber Production  236 SCX Manufacturing 
162 LZ Chemicals  237 SEB Meat Products 
168 MDP Publishing  238 SGP Healthcare 
171 MHP Publishing  241 SJM Food 
172 MMM Conglomerate  243 SLB Oil & Gas 
174 MOGB Aerospace/Defense  245 SLI Electronics 
175 MOT Telecommunications  247 SNR Electronics 
176 MRK Pharmaceuticals  249 SO Electric Utilities 
177 MRO Oil & Gas  250 SPA Electronics 
178 MSB Financial-Land  251 STL Banking 
179 MUR Oil & Gas  253 SWK Machine Tools & Equip 
184 NEM Mining  254 SXI Industrial Equipment 
185 NEU Chemicals  255 SYNL Steel & Iron 
186 NFG Gas Utilities  256 TE Electric Utilities 
187 NGA Industrial Equipment  257 TEG Diversified Utilities 
188 NI Diversified Utilities  258 TJX Department Store 
190 NOC Aerospace/Defense  263 TPL Financial-Land 
192 NR Oil & Gas  266 TSTY Food 
194 NVE Diversified Utilities  269 TXT Conglomerate 
195 NXY Oil & Gas  272 UIS IT Services 
196 OGE Electric Utilities  273 UL Food 
197 OKE Gas Utilities  275 UST Tobacco 
198 OLN Synthetics  277 UVV Tobacco 
199 OMX Business Equipment  287 WEDC Semiconductors 
200 OXM Textiles  288 WEN Fast Food 
202 PAS Food  289 WEYS Textiles 
203 PBI Business Equipment  291 WGL Gas Utilities 
204 PBY Auto Parts  297 WSC Accident & Health Ins 
212 PG Personal Products  301 XEL Electric Utilities 
215 PKE Circuit Boards  303 ZAP Holding Company 
216 PKI Medical Supplies  304 Long Bond Long Bond 
219 POM Electric Utilities  305 Short Bond Short Bond 
226 ROG Rubber & Plastics  306 T-Bill T-Bill 
227 ROH Chemicals     
